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Abstract 
 
The poly(ADP-ribose) polymerase (PARP) family consists of 17 proteins, some of 
which are involved in DNA repair, regulation of transcription and mediation of  
telomere length.  PARP-14 is the largest molecule in this family and has already been 
shown to play a nuclear role in regulating Stat6-activated transcription, TH2 
differentiation, and preventing apoptosis in B cells. This thesis describes work that 
has explored the hypothesis that PARP-14 also has a role in the cytoplasm.  Based on 
observations that GFP-tagged full length PARP-14 and a GFP-tagged fragment of 
PARP-14 consisting of the region from the third macro domain (M3) to the WWE 
domain (M3-WWE) both localise to granules in the cytoplasm of Hela cells, we 
initially used  M3-WWE as bait in a yeast two-hybrid screen to search potential 
binding partners. This failed to identify any definite and relevant hits for follow-up. 
Using PHYRE (a web-based protein fold recognition programme established at 
Imperial College), we subsequently discovered three previously unrecognized 
degenerate KH domains in PARP-14, with one (KH3) situated between the third 
macro domain and WWE domains. Using a panel of GFP-fusion proteins and 
confocal microscopy, we found that KH3-GFP localises to cytoplasmic granules in 
Hela cells in a similar manner to full length PARP-14, which in turn showed a similar 
distribution to that of antibody-detected endogenous PARP-14 in mouse macrophages.  
Using a panel of antibodies against protein components of stress granules, exosomes 
and lysosomes, we found that PARP-14 colocalises with stress granules in cells 
stressed by sodium arsenite, but with exosome complex proteins in cells activated by 
LPS. Co-immunoprecipitation experiments confirmed that KH3-GFP associates with 
eIF3η and TTP and that these associations were RNA-dependent manner. These 
observations support a role for PARP-14 in regulating RNA processing in stress 
granules and exosomes, and suggest that the KH3 domain is critical for PARP-14 
cytoplasmic granule localisation. 
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PHYRE: Protein Homology/analogy Recognition Engine 
PMR1: polysome-associated RNAse 1 
PMSF: phenylmethanesulfonyl fluoride 
PPC: baculovirus particles per cell 
PPI: protein-protein interaction 
PRKAR1A: protein kinase, cAMP-dependent, regulatory, type I, alpha 
PTB: Polypyrimdine tract binding protein 
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QDO: quadri-drop-out 
Rap55: RNA-associated protein 55 
RBD: RNA binding domain 
RFP: red fluorescent protein 
RIG-1: retinoic acid-inducible gene 1 
RNA-BP: RNA-binding proteins 
RNAi: RNA interference 
RNP: ribonucleoprotein 
ROS: reactive oxygen species 
RRM: RNA recognition motif 
Rrp: 3’-to-5’ exoribonucleases rRNA-processing 
rRRS: reverse Ras recruitment 
RT: room temperature 
SA1: stromal antigen 1 
SC: sensitized and challenged 
SDO: single drop-out 
SGs: stress granules 
SH2: Src Homology 
SIRT1: sirtuin 1 
SKI: superkiller 
SMG: suppressor with a morphogenetic effect on genitalia 
SRC3: steroid coactivator 3 
SSB: single strand breaks 
STAR: Signal Transduction and Activation of RNA 
Stat6: signal transducer and activator of transcription 6 
T.cruzi: Trypanosoma cruzi 
TADs: transcription activation domains 
TCDD: 2,3,7,8-tetrachlorodibenzo-p-dioxin 
TIA-1: T cell internal antigen-1 
TIAR: TIA-1 related 
TIN2: TRF1-interacting protein 2 
tiPARP: 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-inducible PARP 
TMED7: transmembrane emp24 protein transport domain containing 7 
TNF-α: tumor necrosis factor alpha 
Treg cell: regulatory T cell 
TRF: telomeric repeat-binding factor 
TSA: trichostatin A 
TTP: tristetraprolin 
TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling 
U2AF: U2 snRNP auxiliary factor 
U2B’: U2 small nuclear ribonucleoprotein B’ 
UIM: ubiquitin interaction motifs 
UPF: up-frameshift 
USP10: ubiquitin-specific processing protease 10 
UTR: untranslated region 
V-SGs: virus-induced SGs 
VEEV: venezuelan equine encephalitis virus 
vPARP: vault PARP 
VSV:  vesicular stomatitis virus 
VZV: varicella-Zoster-Virus 
W: tryptophan 
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WT: wild type 
X-α-Gal: 5-Bromo-4-chloro-3-indolyl-α-D-galactopyranoside 
XRCC1: X-ray repair cross complementing 1 
XRN1: 5’-to-3’ exonuclease 
Y: tyrosine 
Y2H: yeast two hybrid 
ZAPS: zinc-finger antiviral protein shorter isoform 
ZBP1: zipcode binding protein 1 
ZnF: Zinc finger 
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Chapter 1    Background 
 
1.1.   PARP superfamily 
There are at least 17 genes encoding proteins with a conserved poly(ADP-ribose) 
polymerase (PARP) domain, with four subfamilies categorized by the functional 
domain architectures of their members (Gibson and Kraus, 2012). These are the 
DNA-dependent PARPs, the tankyrases, the CCCH PARPs, and the macro-PARPs. 
The DNA-dependent PARPs include PARP-1, PARP-2, and PARP-3; the tankyrases 
include tankyrase 1 (also known as PARP-5a) and tankyrase 2 (also known as PARP-
5b); the CCCH-type zinc-finger PARPs include 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD)-inducible PARP (tiPARP, also known as PARP-7), PARP-12, PARP-13.1, 
and PARP-13.2; the macro-PARPs include B-aggressive lymphoma protein 1 (BAL1; 
also known as PARP-9), BAL2 (also known as PARP-14 or CoaSt6), and BAL3 (also 
known as PARP-15) (Amé et al., 2004; Gibson and Kraus, 2012; Schreiber et al., 
2006). Of note, vault PARP (vPARP; also known as PARP-4), PARP-6, PARP-8, 
PARP-10, PARP-11, and PARP-16 do not fit into these four subfamilies and, apart 
from vPARP, are all mono-ADP-ribosyltransferases (Kleine et al., 2008). 
1.1.1.   Poly(ADP-ribosyl)ation  
Poly(ADP-ribosyl)ation (PARylation) is a post-translational protein modification 
mediated by PARPs (Hakmé et al., 2008b). During this protein modification (Figure 
1-1), nicotinamide adenine dinucleotide (NAD+) is hydrolysed by the PARP catalytic 
domain to produce ADP-ribose (ADPr) and nicotinamide (Nam).  ADPr is then 
transferred and polymerized, with covalent linkage mainly to glutamic residues of 
acceptor proteins, including the PARP protein itself (D'Amours et al., 1999; Hakmé et 
al., 2008b; Kalisch et al., 2012). Poly(ADP-ribosyl)ation, as the name implies, 
indicates that multiple ADPrs are transferred to acceptor proteins and are linked 
through 2’,1’’-O-glycosidic ribose-ribose bonds or 2’’, 1’’’-glycosidic bonds, which 
lead to a long linear poly(ADP-ribose) (PAR) polymer structure or a complex 
branched structure, respectively (Kalisch et al., 2012). PARylation is involved in 
many cellular processes: for example, maintenance of genomic stability, 
transcriptional regulation, chromatin structure, telomere homeostasis, chromosome 
segregation, energy metabolism, DNA methylation, cell differentiation, cell 
proliferation as well as cell death (Kalisch et al., 2012; Krietsch et al., 2013). From a 
molecular biology point of view, PARylation alters the biochemical and functional 
properties of target proteins, and, as such, mediates protein-protein or protein-nucleic 
acid (both DNA and RNA) interactions, thus promoting the formation of scaffolds 
which direct proteins to a precise site, and regulating other protein modifications (e.g., 
ubiquitylation).           
 
Some PARP members such as PARP-6, tiPARP, PARP-8, PARP-10, PARP-11, 
PARP-12, PARP-14, PARP-15, and PARP-16 only catalyze mono-ADP-ribosylation, 
whereas PARP-9 and PARP-13 are inert (Kleine et al., 2008). The term “Polymerase” 
is commonly used for template-dependent DNA or RNA synthesizing enzymes but 
not to proteins that modify other proteins at a defined amino acid. Based on this 
consideration, “transferase” is more suitable to accurately describe the PARP 
enzymatic reaction. Moreover, the currently assigned numbers of PARP superfamily 
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members do not reflect the fact that some of them belong to the same phylogenetic 
subgroup, whereas PARP-5a and PARP-5b are two distinct proteins rather than splice 
variants (Hottiger et al., 2010). Since these deficiencies in the current PARP 
nomenclature do not accurately represent the nature of the PARP family members’ 
structure and their enzymatic reactions, Hottiger et al., have proposed a new 
nomenclature based on their post-translational modification of amino acid residues 
and on the structural similarity between the PARP family and diphtheria toxin. Thus, 
the mammalian PARPs may be renamed ADP-ribosyltransferase diphtheria toxin-like 
(ARTD) (Hottiger et al., 2010). 
 
Poly(ADP-ribose) glycohydrolase (PARG) is an enzyme with both exo- and 
endoglycosidase activities, which hydrolyses the glycosidic bond between ADPr units 
to generate free ADPr (Schreiber et al., 2006). Several PARG isoforms encoded by 
the same gene localise in different cellular compartments in mammalian cells: for 
example, active nuclear PARG proteins (full-length 110-128kDa and a shorter 
107kDa variant) and a mitochondrial isoform (60-65kDa) reside in the nucleus and 
mitochondria, respectively (Shirai et al., 2013). Besides these two predominant 
isoforms, another two cytoplasmic splice variants (lacking exon 1 (102kDa) and 
lacking exon1 and 2 (99kDa)) that might be involved in stress granule nucleation have 
also been described (Leung et al., 2012).       
 
The putative PARP domains that are homologous to the residues 859-908 of PARP-1 
are the common denominator of the PARP superfamily. In the following sections, I 
will further discuss the functions of these PARPs and the therapeutic potential of 
inhibiting them. 
1.1.2.   Known functions of PARPs 
1.1.2.1.   The DNA-dependent PARPs 
PARP-1 is the PARP protein that has been most studied (Kotz, 2012). It has been 
shown to be involved in DNA damage repair (De Vos et al., 2012) and 
immune/inflammatory responses (Laudisi, 2011). Following DNA damage (single 
strand breaks (SSB) and/or double strand breaks (DSB)), two zinc finger motifs of 
PARP-1 act as a molecular sensor of DNA damage and mediate the recruitment of 
PARP-1 to DNA. This is followed by activation of PARP-1/PARP-2, poly(ADP-
ribose) PAR chain synthesis, and then PARylation of PARP-1/PARP-2, histone H1, 
and H2B. PARylation of these target proteins is thought to relax the structure of 
chromosomes and facilitate the formation/association of DNA repair complexes (for 
example, X-ray repair cross complementing 1 (XRCC1) (in the base-excision 
repair/single-strand break repair (BER/SSBR process)), Ku70/80 heterodimer and 
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) (in the Non-
homologous end joining (NHEJ) pathway), and MRE11/ATM (in the homologous 
recombination (HR) pathway)) at SSB or DSB (De Vos et al., 2012; Wang et al., 
2012a; Ciccia and Elledge, 2010). Under conditions of mild DNA damage, SSB 
and/or DSB can be repaired via these complexes, whilst PARP over-activation in 
severe DNA damage leads to NAD+/ATP depletion and subsequently to a cell death 
process (necrosis) (Koh et al., 2005). Notably, because of structural differences of 
DNA-binding domains in PARP-1, PARP-2, and PARP-3, PARP-1 responds to SSB, 
DSB, DNA crosslinks, and stalled replication forks, whereas PARP-2 has been 
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reported to have higher affinity for gaps and flap structures in damaged DNA and 
PARP-3 selectively recruits to DSB (De Vos et al., 2012). 
 
Apart from its role in DNA damage repair, PARP-1 has been shown to be critical for 
the control of NFκB transcription factor activation (positively regulating production 
of cytokines/chemokines), to have a permissive role in telomere duplication during S-
phase and to influence regulatory T cell differentiation (Welsby et al., 2012; Orlando 
et al., 2012). In PARP-1 knockout (KO) mice, NFκB activation is defective due to 
reduced binding of p65/p50 to DNA, leading to almost complete abolition of TNF-α 
accumulation and the down-regulation of inducible nitric oxide synthase (iNOS) 
expression and free radical generation. This results in protection of the PARP-1 KO 
mice from LPS-induced septic shock (Oliver et al., 1999). Ba et al., have reported that 
reactive oxygen species (ROS)-mediated PARP-1 activation induces the PARylation 
of p65-binding nuclear proteins, leading to NFκB activation, followed by the increase 
mRNA level for interleukin-1β (IL-1β) and tumor necrosis factor alpha (TNF-α) in 
Trypanosoma cruzi (T.cruzi)-infected cardiomyocytes (Ba et al., 2010). The 
cooperative roles of PARP-1 and PARP-2 are shown by the further attenuation of 
nitric oxide (NO), IL-1β, TNF-α, and Chemokine (C-C motif) ligand 2 (CCL2) when 
PARP-2 is knocked down in PARP-1 KO astrocytes (Phulwani and Kielian, 2008). In 
addition to these proinflammatory mediators, chemoattractant chemokines such as 
interleukin-8 (IL-8), monocyte chemotactic protein-1 (MCP-1), Macrophage 
inflammatory protein (MIP)-1, and MIP-2 have also been found to be down-regulated 
in PARP-1 KO mouse models or animals treated with a PARP inhibitor (Bai and 
Virág, 2012).  
 
A recent study also indicates that PARP-1 interacts with telomeric repeat-binding 
factor (TRF) 2 and that PARP-1 knockdown leads to reversible telomere shortening. 
In this study, Beneke et al., have further proposed a tempting model of the role of 
PARP-1 for telomere regulation: PARP-1 interacts with TRF2 at the telomere during 
S-phase; the basal activity of PARP-1 leads to TRF2 PARylation, followed by t-loop 
opening and replication fork passage (Beneke et al., 2008).  
 
Regulatory T (Treg) cells from PARP-1 KO mice are functionally and phenotypically 
similar to wild type (WT) Treg cells. However, in PARP-1 KO mice, more induced 
regulatory T (iTreg) cell are converted from native CD4 cells in comparison with the 
conversion in WT mice. Thus, PARP-1 might be involved in Treg differentiation 
rather than in the regulation of their function (Nasta et al., 2010).  
 
In addition to the functions of PARP-1 and PARP-2 described above, recent studies 
have indicated that PARP-3 not only orchestrates the repair of DNA DSB with PARP-
1, but is also involved in mitotic spindle stabilization as well as telomere integrity by 
associating and regulating nuclear mitotic apparatus (NuMA) protein (Boehler et al., 
2011). The details will be described in the next section on tankyrases. 
1.1.2.2.   Tankyrases 
Tankyrase-1 (PARP-5a) has been demonstrated to be involved in mediating telomere 
length, the separation of sister telomeres as well as mitotic progression, and glucose 
transporter (GLUT) 4 vesicle trafficking (Hsiao and Smith, 2008). Tankyrase-1 
interacts with TRF1 and the tankyrase-1/TRF1 complex redirects to telomeres. 
Tankyrase-1 PARylates TRF1 in vitro, abolishing the ability of TRF1 binding to 
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telomeric DNA. This is followed by TRF1 ubiquitination and degradation, enabling 
telomere elongation by telomerase (Smogorzewska and de Lange, 2004). In addition 
to regulating telomere length, Dynek and Smith have demonstrated that knockdown 
of tankyrase-1 results in the failing to separate sister telomeres, followed by mitotic 
arrest. They have further shown that this phenotype can be rescued by PARP-active 
tankyrase-1 (Dynek and Smith, 2004). In 2007, Canudas et al., showed that depletion 
of a telomeric repeat-binding factor 1/TRF1-interacting protein 2/stromal antigen 1 
(TRF1/TIN2/SA1) cohesin complex restored the normal resolution of sister telomeres 
in Hela cells following tankyrase-1 knockdown. They also proposed that tankyrase-1-
mediated PARylation of TRF1 would be crucial for sister telomere resolution and 
mitotic progression (Canudas et al., 2007). Of note, cells in which tankyrase-1 is 
knocked down have also been shown to have defects in assembly of bipolar spindles 
as well as to generate supernumerary spindle poles and microtubules with abnormal 
bending angles at spindle poles (Chang et al., 2005). Chang et al., proposed a model 
in which PARylation of NuMA and tankyrase-1 ensures that PAR covalently attaches 
to spindle poles as well as positioning these poles at the correct distance from each 
other. Without PAR, the distance between each pole may be too far, resulting in 
supernumerary pole generation.  
 
Boehler et al., have shown that depletion of human PARP-3 induced supernumerary 
pole generation and delay bipolar spindle assembly, which is similar to the tankyrase-
1 knockdown model observed by Chang et al., in 2005 (Boehler et al., 2011); 
furthermore, Boehler et al., have demonstrated that active PARP-3 can either 
stimulate auto-ADP ribosylation of tankyrase-1 and, in turn, enhance its ability to 
PARylate NuMA, or can directly PARylate NuMA in a DNA-dependent manner. 
Together, these studies have indicated that the protein network of PARP-3/tankyrase-
1/NuMA is essential for the assembly of the bipolar spindle and/or sister telomeres 
separation for exit from anaphase and that PARP-3 acts as the positive regulator of 
tankyrase-1-mediated NuMA PARylation.  
 
In addition to telomere integrity and mitotic progression, tankyrase-1 has also been 
shown to be involved in GLUT4 storage vesicles (GSVs) trafficking. Yeh et al., have 
shown that knockdown of tankyrase-1 attenuated insulin-stimulated GSV 
translocation and glucose uptake and also altered the intracellular distribution of 
GLUT4 and insulin-responsive aminopeptidase (IRAP). They have also indicated that 
the translocation process may be regulated by active tankyrase-1 as IRAP PARylation 
may generate a reversible tag on GSVs which guides their sorting. This is rather 
similar to phosphorylation- and ubiquitin-directed sorting of other cargo proteins 
(Yeh et al., 2007). The roles of tankyrase-2 (PARP-5b) in mediating telomere length, 
mitotic progression and GSV trafficking remain to be determined (Hsiao and Smith, 
2008). 
1.1.2.3.   CCCH-type zinc-finger PARPs 
As shown in Figure 1-2, the domain structures of CCCH-type zinc finger PARPs 
including tiPARP (PARP-7), PARP-12 and PARP-13 are rather similar, comprising 
CX8CX5CX3 like zinc fingers, a WWE domain, and a PARP catalytic domain 
(Schreiber et al., 2006; Hakmé et al., 2008b).  
 
PARP-7 has been shown to be involved in suppression of hepatic gluconeogenesis by 
an environmental toxin, TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin, dioxin). Diani-
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Moore et al. have reported that PARP-7 silencing resulted in the rescue of the 
suppression of glucose output and NAD+ by TCDD. They further proposed that 
activation of aryl hydrocarbon receptor (AHR) by TCDD induced PARP-7, which 
decreases the level of NAD+, leading to a decrease in sirtuin 1 (SIRT1) activity and 
the stability of peroxisome proliferator-activated receptor γ coactivator 1α (PGC1α). 
Decreasing the stability of PGC1α causes reduction in the expression of 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), 
followed by diminishing hepatic gluconeogenesis (Diani-Moore et al., 2010).  
 
Two isoforms of PARP-13 have been identified, with one lacking the catalytic PARP 
domain (zinc-finger antiviral protein shorter isoform (ZAPS)). ZAPS has been 
identified as a regulator of retinoic acid-inducible gene 1 (RIG-1)-mediated innate 
immune responses, directly associating with RIG-1 and strengthening the induction of 
type I interferon as well as other inflammatory cytokines. ZAPS has also been 
reported to bind p72 DEAD box RNA helicase and to lead to the degradation of viral 
RNA, leading to suppression of viral replication after infection with RNA viruses 
(influenza virus, Newcastle disease virus (NDV)) (Hayakawa et al., 2011). This dual 
antiviral function of ZAPS offers the potential for therapeutic application (Hayakawa 
et al., 2011). By contrast, the viral immunity function of the PARP-13 isoform 
expressing the catalytic PARP domain still needs to be determined. A recent study has 
also shown that PARP-13 is one of the components of G3BP-mediated stress granules 
but the function of PARP-13 in these granules remains to be discovered (Isabelle et al., 
2012).  
 
So far, not many papers have reported on the function of PARP-12. Recent studies 
have found that PARP-12, an interferon-stimulated gene, has moderate inhibitory 
effects on vesicular stomatitis virus (VSV), murine gammaherpes virus 68 (MHV-68), 
venezuelan equine encephalitis virus (VEEV) replication (Liu et al., 2012; Atasheva 
et al., 2012). However, Atasheva et al., have also found that individual interferon-
stimulated genes, for example, PARP12, exhibit a low but detectable antiviral effect 
within in a highly cooperative/complementary anti-viral network. As a result, it may 
be difficult to dissect the particular antiviral function of each individual gene.  
1.1.2.4.   Macro-PARPs 
The Macro-PARPs comprise PARP-9/BAL1 (B-aggressive lymphoma 1), PARP-
14/BAL2/CoaSt6 and PARP-15/BAL3, and are so named because they contain 2-3 
Macro domains. This domain has a globular mixed α-helix and β-sheet structure of 
approx. 130-190 amino acids, and a potential ligand-binding pocket.  The Macro 
domain was originally named A1pp after being found in yeast YBR022W associated 
with ADP-ribose 1-phosphate (Appr-1-P)-processing activity (A1pp) (Martzen et al., 
1999). It is conserved during evolution in viruses (coronaviruses, alphaviruses), 
archaea (Archaeoglobus fulgidus), bacteria (Escherichia coli), invertebrates 
(drosophila melanogaster), amphibians (xenopus laevis) mammals (human, mice), 
and plants (Arabidopsis thaliana, oryza sativa). At least 7 other human proteins 
contain a Macro domain, including macro-histone 2A, LRP16/MDO1, and 
GDAP2/MDO3, etc (Martzen et al., 1999; Aravind, 2001; Allen et al., 2003; Han et 
al., 2011). 
 
The main function of Macro domains appears to be to bind NAD metabolites such as 
mono-ADP-ribose, poly-ADP-ribose or O-acetyl-ADP-ribose and nucleic acids, 
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resulting in molecular bridges that bring together diverse target proteins via 
interactions with ADP-ribose (Han et al., 2011; Amé et al., 2004). In the case of the 
macro-PARPs, the Macro domain(s) may be involved in transcriptional regulation. 
For example, the Macro domains in PARP-14 is involved in the co-activation of Stat6 
to increase IL-4-induced gene expression (Goenka and Boothby, 2006), whereas the 
Macro domains in PARP-9 and PARP-15 repress TK-driven transcription (Aguiar et 
al., 2005). Han et al., have proposed that the conformation of the Macro domain 
and/or its interactions with other proteins determine its effect upon transcription (Han 
et al., 2011).  
 
PARP-9/BAL1, which lacks PARP catalytic activity, was identified due to its 
abundant expression in high-risk diffuse large B cell lymphomas (DL-BCL) and 
overexpression of PARP-9 increased the migration rate of B-cell lymphoma cells, 
indicating its potential role in promoting tumour dissemination (Aguiar et al., 2000). 
In the mouse embryonic development model, PARP-9 has been shown to be 
developmentally regulated, prominently expressed in the thymus, in specific regions 
of the central nervous system and gut, suggesting that PARP-9 could have a function 
in lymphogenesis, neurogenesis, and development of the intestine. In the adult mouse, 
the highest levels of PARP-9 transcripts were detected in the medulla of the thymus, 
suggesting a role for PARP-9 in thymocyte maturation (Hakmé et al., 2008a). In 
addition to its roles aforementioned, PARP-9, which is itself an interferon-γ (IFN-γ) 
inducible gene, has also been shown to increase the expression of IFN-γ-stimulated 
genes, indicating that PARP-9 may play a role in antiviral activities (Juszczynski et al., 
2006).        
 
PARP-14/BAL2/CoaSt6 was identified by yeast two hybrid (Y2H) screening as a 
binding partner of signal transducer and activator of transcription 6 (Stat6) and 
subsequently found to act as a coactivator with Stat6 (Goenka and Boothby, 2006). In 
the mouse embryonic development model, PARP-14 was mainly detected in thymus 
from embryonic day 14.5 to 18.5 at a low but significant level. In adult mouse, 
thymus is also a major organ where PARP-14 expression can be detected, suggesting 
that PARP-14 may play a role in thymic development and function (Hakmé et al., 
2008a). A more detailed description of PARP-14 functions will be in the next section. 
 
So far, little is known about PARP-15/BAL3. As all the macroPARPs are localised 
within 200kbp in the 3q21 human chromosomal region and they are all over-
expressed in B aggressive lymphoma, they may have similar functions and PARP-15 
may play a role in malignant B cell migration (Papeo et al., 2009). Besides this, a 
recent study that was published during the work on this thesis has indicated that 
PARP-14 and PARP-15 are localised in stress granules (Leung et al., 2012). 
1.1.2.5.   The other PARPs 
At 193 kDa, PARP-4/vault PARP (vPARP) is the second largest member of the 
PARP superfamily. vPARP has several protein-protein interaction domains which are 
likely to be involved in interacting with other vault components, contributing to the 
structural stability of the vault complex (Elmageed et al., 2012; van Zon et al., 2002). 
Elmageed et al., further indicated a direct dynamic relationship between vaults and 
vPARP, suggesting that vPARP may be involved in intracellular transport with the 
vault complex. In addition to its role in intracellular transport, vPARP has also been 
thought to have a role in DNA repair (Davar et al., 2012).  
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PARP-10 has been identified as a c-Myc-associated protein and is a ubiquitously 
expressed gene with preference for spleen and thymus. PARP-10 predominantly 
localises normally in cytoplasm. In the presence of leptomycin B (LMB), PARP-10 
localises in the nucleus, suggesting that the localisation in cytoplasm is controlled by 
a nuclear export sequence (NES) (Yu et al., 2005). In addition, Yu et al., have further 
indicated that PARP-10 inhibits Myc/Ha-Ras- and E1a/Ha-Ras-dependent 
transformation of primary rat embryo fibroblast as well as of immortalized fibroblasts. 
Furthermore, it has been observed that PARP-10 localises in discrete bodies in the 
cytoplasm, which exchange subunits rapidly and associate with poly-ubiquitin 
receptor p62 (Kleine et al., 2012). Kleine et al., proposed that PARP-10/p62 
association may result in PARP-10 bodies being targeted to autophagosomes. 
However, whether PARP-10 has any role in autophagosomal machinery remains to be 
determined. Recent studies have also indicated another role for PARP-10 in antiviral 
activities. Thus, Yu et al., have found that the C-terminal of PARP-10 (glutamate rich 
region and PARP domain) interacts with non-structural protein 1 (NS1) protein of 
avian influenza virus (AIV), which might block NES and ubiquitin interaction motifs 
(UIM) of PARP-10, resulting in NS1/PARP-10 complex migration form the 
cytoplasm to the nucleus via NES of NS1. High expression of NS1 led to endogenous 
decreased PARP-10 transcription and protein level, followed by cell arrest in G2-M 
stage and promotion of AIV replication. On the other hand, overexpression of PARP-
10 in BKH21 cells decreased AIV proliferation (Yu et al., 2011). Of note, knockdown 
of PARP-10 by shRNA led to loss of cell viability, and phosphorylation of PARP-10 
by CDK2-cyclin E enhanced the PARP activity of PARP-10 and was associated with 
cell proliferation (Chou, 2006).  
 
So far, apart from the WWE domain of PARP-11, no other functional domain has 
been found in PARP-6, PARP-8, PARP-11 and PARP-16. In the absence of published 
data, it is therefore difficult to speculate on their possible functions (Papeo et al., 
2009). 
1.1.3.   PARP inhibitors and their therapeutic potential 
The therapeutic potential of PARP inhibitors has offered a new therapeutic strategy in 
oncology over the last decade. PARP-1 was first discovered in 1963 (Chambon et al., 
1963). Since then, PARP-1 has been found to be involved in many DNA repair 
mechanisms (e.g., BER, HR, NHEJ). Moreover, PARP-1 is overexpressed in one 
third of ductal carcinoma in situ and in poor prognosis infiltrating breast carcinomas 
(Rojo et al., 2012). The concept of using a PARP inhibitor to enhance the DNA 
damage caused by chemotherapy through prevention of DNA repair was introduced in 
1980 (Durkacz et al., 1980). PARP inhibitors (e.g., NU1025 and AG14361) were used 
to increase the number of SSBs and these persistent SSBs were converted into DSBs 
at fork replication. Cancer cells are unable to maintain the integrity of their genome 
and die (Underhill et al., 2011). Of note, this strategy is only feasible when cancer 
cells are deficient of genes (e.g., RAD51, RAD54, DSS1, and RPA1) involved in the 
complex HR pathway (McCabe et al., 2006; Underhill et al., 2011).  
 
The first identified inhibitor of PARP catalytic activity was the product of NAD+ 
hydrolysis, nicotinamide (Clark et al., 1971). First generation of synthetic PARP 
inhibitors (e.g., 3-aminobenzamide (3-AB)) are neither potent enough nor selective 
enough by the current standard. The second generation of inhibitors was based on the 
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study of structure-activity relationship and crystal structure-based drug design, which 
led to enhanced potency. After medical chemistry study and preclinical development, 
third generation PARP inhibitors have been evaluated clinically. These inhibitors are 
designed to compete with NAD+ at the enzyme active site. Thus, the inhibitors 
mimicking the Nam moiety of NAD+ bind to the catalytic domain of PARPs, 
inhibiting automodification and subsequent release of enzyme from the site of DNA 
damage (Zaremba and Curtin, 2007; Rouleau et al., 2010; Pandya et al., 2010; 
Kummar et al., 2012). Clinically, PARP inhibition can be used either in combination 
with different cytotoxic reagents as chemosensitisers or as a single reagent after the 
standard chemotherapy fails. Notably, most clinically evaluated PARP inhibitors do 
not discriminate the PARP-1 activity from the others. Underhill et al., mentioned that 
clonogenic survival of normal cells is better when only PARP-1 or PARP-2 is 
silenced than when both PARP-1 and PARP-2 are silenced. Ongoing clinical trials 
will answer the risks involved in non-specific PARP inhibition (Underhill et al., 2011). 
Table 1-1 shows the current PARP inhibitors in clinical trials. 
 
Whilst most PARP inhibitors to date are non-selective, there are active drug discovery 
programmes developing mono-specific inhibitors for each of the different PARP 
proteins (Wahlberg et al., 2012; Andersson et al., 2012; Ekblad et al., 2013).  
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Figure 1-1 Metabolism of poly(ADP-ribose) during DNA damage and repair. In 
response to DNA-strand breaks, DNA damage-dependent poly(ADP-ribose) 
polymerases (PARPs; specifically PARP-1 and PARP-2) hydrolyse NAD+, releasing 
nicotinamide (Nam) and one proton (H+), and catalyse the successive transfer of the 
ADP-ribose moiety to nuclear protein acceptors that might be transiently inactivated. 
The reaction is initiated by the formation of an ester bond between the amino-acid 
acceptor (Glu, Asp or COOH-Lys) and the first ADP-ribose; polymer elongation 
involves the catalysis of a 2′–1′′ glycosidic bond; polymer branching occurs on 
average after 20 ADP-ribose units and branching points are located at regular 
distances (every 40–50 ADP-ribose units). The same chemistry is used during the 
elongation and branching reactions because of the equivalent orientation of the 2′ OH 
of the riboses relative to the Ade (in the elongation mode) or to the Nam (in the 
branching mode) of NAD+. The degradative nuclear enzyme poly(ADP-ribose) 
glycohydrolase (PARG) has endo- and exoglycolytic activities that cleave glycosidic 
bonds between ADP-ribose units. The concurrent actions of DNA-dependent PARPs, 
PARG and NAD+-recycling enzymes contribute to NAD+ consumption in heavily 
damaged cells. The stimuli that activate PARP-3–16 are not known. P, phosphate; Rib, 
ribose. This figure is from Schreiber et al. Nature Reviews Molecular Cell Biology 7, 
517–528 (July 2006). 
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Figure 1-2 Domain architecture of human PARP superfamily members. Domain 
architecture of human poly(ADP-ribose) polymerase family members. Within each 
putative PARP domain, the region that is homologous to residues 859–908 of 
PARP1—the PARP signature—is indicated by a darker colour. BRCT, SAM, UIM, 
MVP-BD, VWA and ANK are protein-interaction modules. ANK, ankyrin; BRCT, 
BRCA1-carboxy-terminus; HPS, homopolymeric runs of His, Pro and Ser; macro, 
domain involved in ADP-ribose and poly(ADP-ribose) binding; MVP-BD, MVP-
binding; NES, nuclear export signal; N(o)LS, nuclear (nucleolar) localization signal; 
PARP, poly(ADP-ribose) polymerase; PARP_Reg, putative regulatory domain; RRM, 
RNA-binding motif; SAM, sterile α-motif; TiPARP, 2,3,7,8-tetrachlorodibenzo-p-
dioxin-inducible poly(ADP-ribose) polymerase; UIM, ubiquitin-interacting motif; 
VIT, vault inter-α-trypsin; vPARP, vault poly(ADP-ribose) polymerase; vWA, von 
Willebrand factor type A; WGR, conserved W, G and R residues; WWE, conserved 
W, W and E residues; ZnF, DNA or RNA binding zinc fingers (except PARP1 ZnFIII, 
which coordinates DNA-dependent enzyme activation). Of note, three K homology 
(KH) domains have been reported in this thesis. The domain structures of PARP-14 
can be found in Figure 4-1.  The figure was taken directly from Hakmé et al. EMBO 
reports, 9, 1094-1100 (Oct 2008). 
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Table 1-1 Clinical cancer studies involving PARP inhibitors 
 
 
 
 
 
This table was taken directly from Rouleau et al. Nature review cancer, 10, 293-301 
(Apr 2010). 
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1.2.   PARP-14 
Poly (ADP-ribose) polymerase 14 (PARP-14) is the largest member (202.8 kDa) of 
the PARP superfamily. In the National Center for Biotechnology Information (NCBI) 
protein database, PARP-14 has also been named collaborator of Stat6 (CoaSt6), B-
aggressive lymphoma 2 (BAL2), and ADP-ribosyltransferase diphtheria toxin-like 8 
(ARTD8). 
1.2.1.   The functional domains and motifs in PARP-14 
In the NCBI protein database, the PARP-14 protein is made up of a number of 
domains. 
1.2.1.1.   RRM (RNA recognition motif) 
In the NCBI structure database, a RRM, spanning the region from 8th amino acid to 
91th amino acid of PARP-14, has been crystallised by Dang and co-workers. The 
RRM, also known as RNA-binding domain or ribonucleoprotein (RNP) domain is one 
of the most common domains in eukaryotes (Maris et al., 2005). The details of this 
RNA recognition motif will be introduced in 1.4.2. 
1.2.1.2.   Macro domain  
PARP-14 has three macro domains. Macro domains have already been introduced in 
section 1.1.2.4. 
1.2.1.3.   WWE domain 
The WWE domain is named after its three conserved residues, two conserved 
tryptophan (W) residues and a glutamate (E) residue. A WWE domain can be found 
in two functional classes of proteins: namely, those involved in ubiquitination and 
those associated with PARylation (Aravind, 2001). WWE domains mediate specific 
protein-protein interactions (PPI) and recognise PAR but not ADPr via interacting 
with iso-ADP-ribose (iso-ADPr) (Wang et al., 2012b). Many WWE domain-
containing proteins are known to be ubiquitin E3 ubiquitin ligases and the WWE 
domains in those proteins recognise PAR, suggesting the WWE domain may be a key 
bridge linking PARylation and ubiquitination as well as PARylation. In the case of 
PARP-14, the function of WWE domain is unclear because some critical PAR 
recognition residues are not conserved (Kalisch et al., 2012). 
1.2.1.4.   PARP domain  
The PARP-like catalytic domain of PARP-14 has been shown to be enzymatically 
active (Kleine et al., 2008). The core secondary structure elements of the canonical 
PARP-1 catalytic domain are histidine (H), tyrosine (Y), and glutamate (E), with the 
first two residues of this highly conserved “HYE” triad being found in the PARP-14 
catalytic core motif, HYL. Thus a leucine has replaced the catalytic glutamate found 
in PARP-1. In addition to this, the loop length between β sheets 4 and 5 of PARP-1 
catalytic domain is 37 residues, whereas that of PARP-14 catalytic domain is only six 
residues. Because HYE motif is replaced by HYL and the loop is considerably shorter, 
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Kleine and the co-workers suggested that PARP-14 functions as a mono-ADP-
ribosyltransferase (mART) (Kleine et al., 2008).         
1.2.2.   PARP-14 as a binding partner of Stat6  
Inerleukin-4 (IL-4) has been shown to be involved in Th cell differentiation, 
alternative macrophage activation, isotype class switching of B cells to IgE synthesis, 
B cell and T cell proliferation, and mast cell recruitment (Maes et al., 2012; Luzina et 
al., 2012; Wurster et al., 2002). IL-4 utilizes the Jak-Stat pathway to activate Stat6 for 
mediating these functions. Engagement of IL-4 receptor (IL-4R) leads to cytoplasmic 
Stat6 being phosphorylated via the activation of Jak1 and Jak3. Phosphorylation of 
three tyrosine residues of IL-4Rα provides docking sites for Stat6 monomers, 
followed by Stat6 dimerization through their Src Homology (SH2) domain, and 
translocation to the nucleus. Active Stat6 dimers then bind to specific sequences 
(TTC(X2-4)GAA) to regulate IL-4-dependent genes (Goenka and Boothby, 2006; 
Hebenstreit et al., 2006). Recent studies have found that Stat1, Stat5, and Stat6 recruit 
a shared set of histone-modifying cofactors, p300, CREB binding protein (CBP), and 
a p160 family co-activator, as the co-activators. However, when fused to a Gal4 DNA 
binding domain, the C-terminal transcription activation domains (TADs) of Stat6 
were found to be stronger than the TAD of Stat1 or Stat5 (Goenka and Boothby, 
2006). Using yeast two hybrid screening (see Section 1.3 below) with full-length 
Stat6 as a bait, Goenka et al., discovered a novel protein, which they originally 
designated CoaSt6 but which will be subsequently referred to as PARP-14 (Goenka 
and Boothby, 2006). This binds to Stat6 but not Stat1 and contributes to the enhanced 
transcriptional potency of Stat6 over Stat1. They confirmed this result in 293 cells, 
M12 B lymphoma cells, and primary mice splenocytes via co-immunoprecipitation 
(Co-IP) with/without IL-4 stimulation. They have further confirmed that PARP-14 
acts as a cofactor and increases IL-4-induced, Stat6–mediated transcriptional 
activation in HepG2 cells and Jurkat T cells, whereas this is abrogated when pcDNA3 
encoding a Stat6 binding-site mutant is used in the luciferase assay. In Stat6 knock-
out B cells, overexpressing Stat6 and partial PARP-14 (amino acids 1216-1817) led to 
several fold greater expression of IL-4-induced CD23 compared to the expression in 
cells expressing either Stat6 or partial alone. Furthermore, in M12 B cells, PARP-14 
selectively enhanced the induction of endogenous CD23 by IL-4, whereas there was 
no significant change of Stat1-dependent IFN regulatory factor (IRF)-1 following 
overexpression or knockdown the PARP-14. Taken together, PARP-14 therefore 
exhibits specificity as a coactivator for Stat6 rather than Stat1. 
 
Goenka et al., also showed a salient feature of the triple macro domains. They 
demonstrated that macro domains can enhance the levels of Stat6 induced gene 
expression and Stat6/PARP-14 association (Goenka and Boothby, 2006). In 2007, 
Goenka et al., further discovered that the active PARP-like catalytic domain in the C-
terminal region of PARP-14 positively regulates IL-4-induced, Stat6-dependent gene 
transcription. They showed that PARP-14 exhibits enhanced auto-PARylation activity 
with IL-4-activated Stat6 in 293T cells and, in M12 B cells, p100, a Stat6-associated 
transcriptional co-factor, associates with PARP-14 as well as is the target for 
PARylation by CoaSt6/PARP-14. Moreover, when M12 B cells were incubated with 
2.5mM of cell-permeable PARP inhibitor 3-AB, the induction of IL-4 induced CD23 
mRNA was almost abrogated. In HepG2 cells, E1810K point mutant of PARP-14, 
which dramatically reduced the PARP catalytic activity, was cotransfected with 
CD23b-(N3)3-luc reporter and Stat6 expression plasmid, showing that, in comparison 
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with the wild type PARP-14, the PARP-14 mutant decrease IL-4-induced, Stat6-
dependent trans-activation of CD23 reporter (Goenka et al., 2007). 
1.2.3.   The functions of PARP-14 in IL-4 treated B cells 
Cho et al., generated PARP-14 KO mice to investigate the role of PARP-14 in B cells 
(Cho et al., 2009). The KO mice exhibit no significant difference in overall numbers 
of cells in thymus, spleen, and lymph nodes, compared with the control littermates. 
Regarding T cell lineage subsets and B lymphoid lineage of the PARP-14 deficient 
mice, there was an increase in the frequency of thymocytes showing ongoing 
generation of T lymphocytes, especially for mature CD8 T cells in the periphery, 
whereas analysis of the splenic B cells showed that PARP-14 KO mice had fewer 
marginal zone B and more follicular B cells. There were lower IgA anti-Keyhole 
limpet hemocyanin (anti-KLH) responses in PARP-14 KO mice and no significant 
difference in the other isotypes. Taken together, PARP-14 influences B- and T-cell 
subset differentiation and contributes to IgA generation and response to antigen (Cho 
et al., 2009). Cho et al., further used PARP-14-null B cells to investigate the role of 
PARP-14 in B cell proliferation. They demonstrated that the PARP-14 null B cells, in 
comparison with the control WT B cells, exhibited lower response to anti-IgM + IL-4 
treatment, decreased IL-4 protection against apoptosis in a Terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) assay, and attenuated IL-4 rescue from 
B cell apoptosis induced by γ-irradiation or “death by neglect”. These observations 
suggest that PARP-14 deficient B cells show impaired IL-4-induced survival 
signaling.  
 
As PARP-14 acts as a cofactor for Stat6, Cho et al. also investigated whether Stat6 is 
involved in IL-4-induced B cell protection (Cho et al., 2009). IL-4-induced rescue 
was almost abrogated in Stat6-null B cells. In comparison with PARP-14 KO B cells, 
the contribution of Stat6 to IL-4-induced B cell protection was greater than that of 
PARP-14 to the B cell protection, suggesting that not all the protective molecular 
mechanisms of Stat6 require PARP-14. Cho et al. have further demonstrated that 
PARP-14 does not affect the levels of phospho-Stat6 and Stat6 in B cells. Blocking 
ADP-ribosylation non-specifically led to abrogation of the IL-4-induced protection 
against apoptosis, consistent with a role for the PARP-14 PARP domain catalytic 
activity. Moreover, IL-4 treatment decreased the level of activated caspase-3 caused 
by “death by neglect” or death after irradiation in the littermate WT B cells, whereas 
the caspase-inhibitory effect of IL-4 was abrogated in the PARP-14 KO B cells, 
suggesting that PARP-14 is involved in mediating IL-4 suppression of caspase-3 
activation in IL-4-treated B cells. Of note, in the “death by neglect” assay, PARP-14 
had more influence on the caspase-inhibitory effect of IL-4 in comparison with Stat6, 
suggesting that PARP-14 may exert some Stat-6 independent function in preventing 
apoptosis. Because of the anti-apoptotic nature of PARP-14 in B cells, Cho et al. also 
adopted microarrays on B-cell mRNAs and discovered that PARP-14 positively 
regulates IL-4 induced Pim-1 and Mcl-1, which promote B cell survival. Altogether, 
PARP-14 mediates the IL-4 protection against apoptosis, possibly via ADP-
ribosylation. It also mediates IL-4 effects on the levels of gene products that regulate 
cell survival, proliferation as well as lymphomagenesis. 
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1.2.4.   Mechanism of PARP-14-regulated Stat6-activated transcription 
With respect to the molecular mechanism by which PARP-14 mediates IL-4-induced, 
Stat6-dependent gene transcription, Mehrotra et al., have proposed that PARP-14 acts 
as a transcriptional switch (Mehrotra et al., 2011). Firstly, they observed that, 
following treatment of M12 B cells with IL-4, Stat6 binding to cognate promoters, 
namely the germline epsilon (Iε, precursor for IgE) promoter and the gene for low 
affinity IgE Fc receptor (Fcer2a), was promoted by PARP-14 and the catalytic 
activity associated with it, whereas this was attenuated in PARP-14 deficient B cells.  
Further, it has also been observed that PARP-14 specifically binds to Stat6-responsive 
promoters but not Stat1 or Stat4 responsive promoters in the absence of IL-4. 
However, in the presence of IL-4, PARP-14 is no longer required at the promoter 
before transcription initiates. Of note, PARP-14 exits the promoter regions under the 
influence of IL-4 and this requires PARP-14 catalytic activity. These findings suggest 
that PARP-14 acts as a repressor or recruits repressors to prevent IL-4-induced, Stat6 
mediated genes from transcription under non-stimulating condition.  
 
To evaluate the possibility that histone deacetylases (HDACs) are involved in 
repressing transcription, Mehrotra et al., adopted Co-IP and pull-down assays 
(Mehrotra et al., 2011). These showed that PARP-14 associates with HDAC 2 and 
HDAC 3 by its N (aa 1-813) and middle (aa 800-1395) portions.  Moreover, they 
further used a Stat6-responsive reporter assay and an HDAC inhibitor, trichostatin A 
(TSA), in M12 B cells to show that HDAC 2 and 3 decrease IL-4-mediated induction 
by at least 50% and that, in the presence of TSA, the expression of Iε and Fcer2a 
transcripts are significantly increased, respectively. If HDAC 2 and 3 repress IL-4-
induced, Stat6 dependent gene transcription, it should be possible to detect them at the 
promoter of these genes. Using chromatin immunoprecipitation (ChIP), the binding of 
HDAC 2 and 3 to the Iε and Fcer2a promoters in M12 B cells was found in the 
absence of IL-4 signal and the associations between HDAC 3 and Stat6-responsive 
promoters were via its interaction with PARP-14. In contrast, these associations were 
lost under the influence of IL-4 stimulation.  
 
In previous research, Goenka et al., had demonstrated that the active PARP-like 
catalytic domain of PARP-14 positively mediates Stat6-dependent gene transcriptions 
(Goenka et al., 2007). Therefore, Mehrotra et al., further investigated whether HDAC 
2 and 3 can be ADP-ribosylated by PARP-14 upon IL-4 stimulation. They found that 
PARP-14 auto-ADP-ribosylates at its N (aa 1-813) and C (aa 1389-1817) portions and 
also ADP-ribosylates HDAC 2 and 3 upon IL-4 stimulation; once HDAC 2 and 3 are 
ADP-ribosylated, they are no longer able to associate with PARP-14, leading to 
HDACs uncoupling from the promoter region (Mehrotra et al., 2011). Taken together, 
Mehrotra et al., proposed a conceptual model of how PARP-14 may mediate IL-4-
induced, Stat6-dependent gene transcription illustrated in Figure 1-3. In the absence 
of stimulation, PARP-14 associates with HDAC 2 and 3 and Stat6 cognate promoters, 
and acts as a repressor. Once IL-4 activates Stat6 phosphorylation and induces PARP-
14 enzymatic activity, PARP-14 ADP-ribosylates itself and HDAC 2 and 3, followed 
by PARP-14/HDACs complex dissociating from the promoter, enabling Stat6 and 
histone acetyl transferases (HATs) such as CBP/p300, NcoA-1, and NcoA-3 to bind 
to the promoters and to promote Stat6-dependent transcription. By dissociating from 
the promoter, PARP-14 “switches on” Stat6-dependent transcription. Mehrota et al., 
further proposed that this model may be similar to the heat shock model of PARP-1 
and mH2A at the Hsp70.1 and Hsp70.2 promoters (Ouararhni et al., 2006). 
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1.2.5.   Role of PARP-14 in T cells 
IL-4 induced Stat6 activation has been reported to be involved in TH2 development, 
TH2 cytokine expression and immunoglobulin class-switching to IgE in B cells, which 
play key roles in pathogenesis of asthma (Broide et al., 2011; Goenka and Kaplan, 
2011). Moreover, PARP-14 has been reported to be involved in regulating Stat6-
dependent gene transcription, which is critical to TH2 differentiation. However the 
role of PARP-14 in asthma is unclear. Therefore, Mehrotra et al., investigated the 
therapeutic potential of PARP-14 in asthma or Allergic Airway Disease (AAD). 
Firstly, it was shown that TH2 cytokine (e.g., IL-4, IL-5 and IL-13) generation was 
significantly reduced in PARP-14 KO mouse naïve T cells from the spleen in 
comparison with the WT naïve T cells. Furthermore, by using PJ34 (an inhibitor of 
PARPs) in WT-naïve CD4+ T cells under TH2 condition, the levels of TH2 cytokines 
decreased in a dose-dependent manner in comparison with untreated cells, whereas 
there was no distinguishable effect on the secreted IFN-γ levels of TH1-skewed cells 
treated with or without PJ34. It was also shown that knocking down PARP-14 mRNA 
leads to lower TH2 cytokine expression in vitro. All of these data suggest that PARP-
14 and the enzymatic activity associated with it participate in TH2 differentiation 
(Mehrotra et al., 2012). When the mice were sensitized and challenged (SC) with 
ovalbumin (OVA), lung resistance, inflammatory cells (e.g., eosinophils, T cells, 
neutrophils, and macrophages), TH2 cytokines, chemokines (CCCL11/eotaxin-1 and 
CCCL24/eotaxin-2), and the levels of IgE in bronchoalveolar lavage (BAL) fluid 
were reduced in PARP-14 KO mice, suggesting a proallergic role of PARP-14. 
Mehrotra et al., have further demonstrated that the inhibition of PARP-14 activity 
with PJ34 attenuated AAD manifestations in WT mice to a degree similar to that seen 
with deficiency of PARP-14, consistent with a critical role for PARP-14 enzymatic 
activity.  
 
By using ChIP-Seq analysis with an antibody directed against the active form of RNA 
polymerase II, Mehrotra et al., also found that the peak profile and average peak value 
of Gata3 (Trans-acting T-cell-specific transcription factor) in TH2 from the PARP-14 
KO mice were reduced in comparison with those of Gata3 in TH2 from WT mice, 
indicating that PARP-14 may affect TH2 differentiation by mediating the expression 
of Gata3 (Mehrotra et al., 2012).   
1.2.6.   Role of PARP-14 in myeloma  
PARP-14 also appears to play a role in multiple myeloma (MM) pathogenesis. 
Regulation of MM survival is crucial for its pathogenesis and reducing survival may 
provide a remedy for this incurable cancer. Among the mitogen-activated protein 
kinase (MAPK) involved in mediating MM survival, the role of Jun N-terminal kinase 
(JNK) in the pathogenesis of MM is unclear. Firstly, nuclear staining for phospho-
active JNK2 (p-JNK) and JNK2 activity were significantly higher in myeloma plasma 
cells in comparison with normal plasma cells in which p-JNK and JNK activity can 
hardly be detected. Moreover, the quantity of p-JNK2 (phospho-p54, which is the 
prominent spliced form of JNK2) was significantly greater than that of p-JNK1 (p-
p46, which is the prominent spliced form of JNK1) in myeloma plasma cells. 
Secondly, 89.8% RPMI-8226, a human MM cell line, died of apoptosis after 8 days of 
JNK2 knock down, which inhibits basal JNK1-mediating apoptosis. Of note, the 
apoptosis caused by JNK2 depletion can be rescued by co-silencing both JNK1 and 
JNK2. These data indicated that JNK2 is constitutively active in myeloma cells and is 
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required for myeloma cell survival (Barbarulo et al., 2012). Barbarulo et al., found 
that knockdown of JNK2 significantly reduced the level of PARP-14 and, as with p-
JNK2, the expression of PARP-14, mainly in nucleus, is higher in MM cell lines as 
well as in primary myeloma plasma cells in comparison with normal B cells. 
Knocking down PARP-14 or inhibiting PARP-14 enzymatic activity, as with JNK2 
knock down, markedly increased JNK1 activity, suggesting that JNK2 may promote 
MM cell survival by mediating the level of PARP-14. Notably, PARP-14 
overexpression in RPMI-8226 cell line was able to completely rescue the apoptosis 
induced by JNK2 depletion. Clinically, high expression of PARP-14 transcripts 
correlated with a markedly shorter survival in patients, whereas depletion of PARP-14 
significantly enhanced cytotoxicity of dexamethasone (an anti-myeloma agent) to 
MM cells. Conversely, the overexpressing of truncated PARP-14 (from the macro 
domain to PARP domain) in MM cells caused resistance of dexamethasone-induced 
apoptosis. Moreover, PJ34 addition to MM cells overexpressing truncated PARP-14 
neutralized the resistance of apoptosis, indicating that PARP-14 and the enzymatic 
activity associated with it contribute to the survival of myeloma cells.  
 
Increased secretion of phosphoglucose isomerase/autocrine motility factor (PGI/AMF) 
has been shown to foster pancreatic cancer progression and metastasis by stimulating 
cell motility via binding to gp78/AMF receptor (AMFR) (Silletti et al., 1991; 
Tsutsumi et al., 2004). Thus, finding a binding partner of the complex of PGI/AMF-
AMFR could be useful to discover the new therapeutic targets for cancer therapy. 
Using CytoTrap yeast two hybrid screening with PGI/AMF as a bait, Yanagawa et al., 
cloned a truncated PARP-14 containing the WWE and PARP domain. They 
confirmed the screening result by showing endogenous PGI/AMF-PARP-14 
association as well as endogenous colocalization of PGI/AMF-PARP-14 in HT-1080 
cells with Co-IP and confocal immunofluorescence microscopy, respectively 
(Yanagawa et al., 2007). They have further reported that PARP-14 inhibits PGI/AMF 
ubiquitination, leading to stabilization the secretion of PGI/AMF. These data suggest 
that PARP-14 inhibits the ubiquitination of PGI/AMF and promotes its secretion.  
1.2.7.   The possible roles of PARP-14 in RNA metabolism 
A recent paper that was published during the course of this study unveiled two novel 
functions for poly-ADPr (pADPr) in the cytoplasm, both of which relate to RNA 
metabolism. These are the assembly of cytoplasmic stress granules (SG) and the 
modulation of microRNA activities (Leung et al., 2012).  
1.2.7.1.   Stress Granules (SGs) 
Mammalian stress granules are aggregates of stalled or abortive preinitiation 
complexes and associated RNA-binding proteins (RNA-BP) and they can be induced 
by oxidative stress, heat shock, and viral infection, etc (Stoecklin and Kedersha, 
2012). The purpose of SGs is proposed to serve as temporary repositories for these 
complexes and RNA-BP. Once the cellular stresses are attenuated, the preinitiation 
complexes can be rapidly released to resume gene expression (Reineke and Lloyd, 
2013).  
 
Sodium arsenite induced SGs have been studied extensively. The exposure of human 
cell lines to sodium arsenite increases the production of ROS, and leads to an 
elevation of intracellular oxidative stress level, oxidative DNA damage and apoptosis 
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(Chen et al., 2013). Leung et al., have indicated that sodium arsenite-induced SGs 
contain pADPr, two PARG isoforms (PARG99 and PARG102) and five PARPs, 
including PARP-5a, PARP-12, PARP-13.1, PARP-13.2, PARP-15, and possibly also 
PARP-14 (Leung et al., 2012). Moreover, overexpression of PARG isoforms or 
knockdown of PARGs resulted in inhibition of SG assembly or delay of disassembly 
of SG, respectively. These data suggest that PARPs are amongst the core components 
of SG and contribute to their assembly.  
 
Leung et al., have proposed a possible mechanism by which pADPr and PARG 
mediates the assembly and disassembly of SG (Leung et al., 2012). In their working 
model (Figure 1-4), SGs are dynamically balanced by the reciprocal activities of 
PARP and PARG. During stress, pADPr acts as a nucleator of SGs via PARylation of 
RNA-binding proteins (e.g., Ago1-4, TIA-1, G3BP1, and PARP-13.1/2) followed by 
cross-linking to pADPr-binding proteins (e.g., poly(A)-binding protein). pADPr 
chains emanating from PARylated RNA-binding proteins recruit additional RNA-
binding proteins through non-covalent pADPr-protein interactions to form intensive 
networks of stalled translation initiation complexes, multiple RNA-binding proteins 
and poly(A)+ mRNAs. Of note, those PARPs localised in SGs may initiate part of the 
formation of SGs via their various binding domains (e.g., macro domain, CCCH-Zinc 
finger domain, WWE domain, and Ankyrin-repeat domain, etc) for RNA, protein, and 
pADPr. When the stress condition has been alleviated, PARG could rapidly 
disassemble SGs, while keeping RNA/protein complexes and their function intact. 
More details of SG will be introduced in 1.5.1. 
1.2.7.2.   MicroRNA 
In addition to SG assembly, Leung et al., also indicated that pADPr and PARPs are 
involved in mediating microRNA silencing. Upon stress, multiple PARPs (PARP-5a, 
PARP-13, and PARP-12) bind to argonaute family (Ago1-4) and PARylate the family 
members in a sequential manner. This occurs first by mono(ADP-ribosyl)ating PARP-
12, followed by PARylating PARP-5a, or directly via PARP-5a alone. Notably, 
increased argonaute PARylation parallels reduced microRNA silencing. The possible 
mechanism of this phenomenon is that PARylated argonaute could alter the 
argonaute/microRNA complex structure, leading to steric hindrances and/or 
disrupting electrostatic interactions between the complex and target mRNA. 
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Figure 1-3 PARP-14 acts as a transcriptional switch for Stat6-dependent gene 
transcriptions. Conceptual model of how PARP-14 may regulate Stat6-mediated 
transcription. Under non-stimulating conditions PARP-14 is bound to Stat6-
responsive promoters and recruits HDAC 2 and 3 and keeps the gene silent. Upon IL-
4 stimulation, Stat6 is activated and binds to its promoter element and induces the 
PARP-14 enzymatic activity indicated by the star symbol. PARP-14 then modifies 
itself on the N terminus and HDAC 2 and 3 in the complex, again represented as stars. 
This results in the disassociation of PARP-14 and the HDACs from the promoter, 
which allows for p300, NCoA-1, and NCoA-3 to be recruited to the promoter and 
acetylation of the histones. This figure was taken directly from Mehrotra P et al. J. 
Biol. Chem., 286,1767-1776 (Jan 2011). 
 
 
 
 
 37 
 
(A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-4 Proposed model of SG assembly (A) and disassembly (B).  Upon stress, 
active PARPs PARylate pADPr acceptor/RNA binding proteins (e.g., Ago2), 
following by pADPr binding proteins (e.g., PABP) association with PARylated 
pADPr acceptor with mRNAs. This nucleates SG core components. On the other hand, 
PARG hydrolyses the glycosidic bonds between ADPr units, which leads to rapid 
disassembly SG and keeps individual RNA/protein complexes and their functions 
intact. SG assembly and disassembly is balanced by the activities of PARP and PARG. 
These figures were taken directly from Leung A.K.L et al. RNA Biology, 9, 542-548 
(May 2012). 
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1.3.   Yeast two-hybrid (Y2H) screening 
The yeast two hybrid screening system is the most widely used genetic tool to 
discover novel protein functions (Lentze and Auerbach, 2008). Since 2001, there have 
been approximately one thousand research papers published every year using the Y2H 
system as a tool to screen the potential binding partners of a protein of interest (bait) 
and to further interpret the novel functions of a bait (Koegl and Uetz, 2007). 
Moreover, approximately 50% of the protein interaction data on the databases have 
been acquired with Y2H (Brückner et al., 2009). Besides finding PPIs and the 
interpretation of novel protein functions, Y2H can also be used in the area of new 
drug discovery (Lentze and Auerbach, 2008) and zinc finger protein selection (Chen 
and Olsen, 2007). 
1.3.1.   The concept and history of the inception of Y2H 
In 1986, Ptashne et al., demonstrated some specific characteristics of Gal4, a 
transcriptional activator in yeast Saccharomyces cerrevisiae. They found that the first 
74 amino acids of Gal4 (N terminus) are responsible for DNA-binding and the C-
terminus is responsible for transcriptional activation (Keegan et al., 1986). In 1989, 
Fields and Song used the findings of Ptashne et al., to develop a new genetic tool for 
monitoring PPIs (Fields and Song, 1989). Basically, they showed that the 
transcription activating capacity of the separated N-terminus and C-terminus could be 
restored if each was fused to a different member of a pair of proteins that bound each 
other. A reconstituted functional Gal4 then recruited RNA polymerase II, leading to 
transcription of a Gal1-lacz fusion gene that encodes the enzyme β-galactosidase, 
which produced sufficient β-galactosidase activity to grow dark-blue colonies on a 
plate containing the β-galactosidase substrate X-gal (Brückner et al., 2009). They 
used SNF-1 and SNF-4 yeast proteins to test this novel system and successfully 
demonstrated that the Gal4 transcription ability was reconstituted. Of note, the 
requirements of this Y2H developed by Fields et al., are that the PPI can occur within 
the yeast nucleus, that the Gal4-activation region is accessible to the transcription 
machinery, and that the N-terminal Gal4 fusion protein is itself not a potent activator.   
 
The concept of Y2H is illustrated in Figure 1-5. The basic idea of the classic Y2H 
system is to split the Gal4 transcription activator cDNA into two halves, with the 
binding domain fused to cDNA encoding the bait protein and the activation domain 
fused with a cDNA library (prey proteins). A prey protein interacting with the bait 
forms a bridge which links the two halves of Gal4, and thereby restore Gal4 
transcriptional ability (Koegl and Uetz, 2007; Brückner et al., 2009). When Gal4 
transcription is activated, the transformed yeast can grow on selective media or show 
a colorimetric readout. On the other hand, if the binding and activation domain of the 
split Gal4 transcription activator fail to be brought to proximity, the transformed yeast 
cannot survive on selection media. Therefore, the blue yeast colonies growing on the 
selection medium can be regarded as potentially harboring cDNA which encode 
potential candidate proteins that interact with the bait. Notably, Y2H-based data 
should only be published once the interaction has been confirmed by another 
independent method, such as Co-IP or mammalian two hybrid confirmation (Koegl 
and Uetz, 2007).   
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1.3.2.   The validation of Y2H hits 
Major concerns on the quality of the data produced from high-throughput Y2H are the 
limited overlaps among different independent studies, indicating that lack of 
reproducibility is one of the limitation of Y2H (Auerbach and Stagljar, 2005; Hamdi 
and Colas, 2011). Due to the high false positive screening results generated from Y2H, 
any specific “interesting and novel” PPI obtained from Y2H should be viewed with 
caution until validated by another discrete method, for example, Co-IP, mass 
spectrometry, and mammalian two hybrid assays (Cusick et al., 2005). Here, we 
discuss these three most common validations for the screening results from Y2H. 
1.3.2.1.   Co-Immunoprecipitation (Co-IP) 
In a canonical Co-IP validation, a specific bait protein is expressed endogenously or 
overexpressed by a plasmid encoding a tagged bait protein in mammalian cells, 
followed by it being extracted with a cell lysis reagent. The bait complex is captured 
with a specific antibody that is immobilized using protein A or protein G covalently 
attached to sepharose beads or magnetic beads. Having washed the beads several 
times, the bait, the antibody, and the proteins associated to the bait were eluted by 
boiling. The bound proteins can then be identified by immuno-blotting. If there is a 
significant signal, in comparison with isotype control, produced by the antibody 
targeting the binding partner of the bait, the result of Y2H can be verified (Berggård 
et al., 2007). Of note, a highly specific antibody is required when the endogenous bait 
protein is detected with a Co-IP validation. The beauty of studying endogenous 
proteins with Co-IP is that the artificial effect of tag protein overexpression is avoided.  
 
There are two main concerns of the Co-IP validation: namely, availability and 
specificity of the antibody used in Co-IP validation for endogenous bait protein 
(Bauer and Kuster, 2003). It is often not easy to obtain a commercially available 
“good” monoclonal antibody (e.g., high specificity and affinity) for the Co-IP 
validation and, in some cases, antibodies need to be custom made (Miernyk and 
Thelen, 2008). Moreover, the quality of the custom made antibodies is not guaranteed 
to meet the requirement of Co-IP. Another potential problem of the Co-IP antibodies 
is cross-reactivity with proteins other than the target bait or the specific binding 
partner of the bait. This situation even exits in some mouse monoclonal antibody for 
Co-IP (Bauer and Kuster, 2003). In this case, a protein complex would be recognised 
as the binding partner of the bait but, in reality, the complex does not directly 
associate with the bait. Although these downsides of antibodies are hard to avoid, Co-
IP is still the most commonly used validation method for Y2H. 
1.3.2.2.   Mass spectrometry 
Tandem mass spectrometry (MS) is commonly used in most proteomic studies and is 
regarding as the core technology in this field (Bensimon and Heck, 2012). In general, 
endogenous or overexpression protein complex is extracted from cells or tissues, 
followed by trypsin or Lys-C digesting into peptides. The peptides are then separated 
by liquid chromatography (LC), ionized, and transferred into MS, where the peptide 
fragment ion spectra are recorded. These spectra can then be paired with protein or 
nucleotide sequence database to identify the contents of the protein complex. Notably, 
1D gels can also be used to separate the protein complex before it is digested into 
peptides. In this case, a specific molecular weight of protein complex is analyzed 
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rather than the whole complex and LC separation can be omitted (Bauer and Kuster, 
2003; Bensimon and Heck, 2012). Figure 1-6 shows the procedure of protein 
identification by tandem MS adopting 1D gel separation. In general, the protein 
identification of MS-based method is a very challenging task and the current protein 
identification method can only identify fewer than 50% of the proteins in a protein 
complex (Wang and Wilson, 2013). There are several reasons contributing to the low 
protein identification in a MS-based method. For example, protein of interest can only 
be identified by database search approach if it is one of the known proteins in the 
adopted protein database. Furthermore, the protein of interest can only be identified 
by de novo sequencing approach if the longest possible peptide sequence that best 
matches the experimental spectrum can be found. The facts that proteins in a protein 
complex are often modified proteins during biological process and tandem mass 
spectra are inherently deficient directly contribute to the low protein identification 
coverage. 
1.3.2.3.   Mammalian two-hybrid (M2H) validation 
After PPI demonstrated by Y2H, the best environment to verify the interactions is in 
an intact mammalian cell which offers the native physiological context to ensure the 
proper conformational alternation that is necessary for the interaction to occur and to 
provide the relevant cofactors and regulatory proteins that are essential for any post-
translational modifications, for example, phosphorylation, acetylation or 
ubiquitination (Lievens et al., 2012). In comparison with MS-based method, two-
hybrid validation can discover the protein interactions within a protein complex and 
can further map the interaction, which is not an easy task for MS-based validation 
(Uetz, 2002). M2H not only can be used to verify the PPIs identified by Y2H but can 
also be used to screen PPIs by itself. Figure 1-7 shows the basic procedure of M2H 
used by Suzuki et al., to screen the protein-protein interactions in Chinese hamster 
ovary (CHO) cells. Approximately 3500 mouse cDNAs were amplified by PCR to 
generate open reading frame (ORF) X and ORF Y, followed by mixing with another 
PCR product carrying a cytomegalovirus (CMV) promoter with either a Gal4 DNA-
binding domain (DBD) or a VP16 transcriptional activation domain (AD). 
Overlapping sequences were fused into one DNA fragment by a second PCR reaction. 
The final PCR fragments (CMV-DBD-ORF X and CMV-AD-ORF Y) were 
transfected into CHO-K1 together with a luciferase reporter plasmid. When the 
encoded proteins interact, the luciferase reporter gene is transcribed and its activity 
can be measured (Suzuki et al., 2001). 
 
There are several different M2H kits that can be purchased from different companies: 
for example, M2H assay kit from Agilent Technologies, Matchmaker M2H System 
from TaKaRa, or Tango Open Enabling Model from Invitrogen. 
1.3.3.   Possible reasons for false positive and negative results 
Although Y2H is widely used, it may give false positive and false negative screening 
results. A false positive result in Y2H is an interaction between a bait and a prey 
which cannot be repeated by another independent assay such as Co-IP. Basically, 
there are five reasons that can lead to false positive results: high expression level of a 
bait and a prey in the same compartment of a cell, an interaction between a prey and 
reporter genes, the binding of membrane anchors to a bait protein, unspecific bindings 
caused by some “sticky” proteins, and proteins which allow yeast to overcome 
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nutritional selection (Brückner et al., 2009). In some reports, false positives have 
ranged from 25% to 45% of hits (Suter et al., 2008). In order to address the problems 
caused by false positives, an independent assay should be used to confirm the results 
(Lentze and Auerbach, 2008). On the other hand, false negatives are more difficult to 
eliminate in comparison with false positives (Lentze and Auerbach, 2008). Reasons 
for false negatives include requirement for post-translational modification (e.g., 
glycosylation and phosphorylation) and steric hindrance (Brückner et al., 2009), etc. 
1.3.3.1.   Methods to tackle false positive and negative results 
The five aforementioned reasons of false positive screening can be further divided 
into biological artifacts and technical artifacts (Stynen et al., 2012). Biological 
artifacts are caused by binding of the bait to prey that should normally be separated in 
space (i.e. different subcellular compartments) or time. Although such proteins may 
be able to interact with each other, the interactions are without any biological 
relevance. Technical artifacts include nutritional selection failure, reporter gene 
activation by the prey alone, unspecific binding caused by “stickiness” or incorrectly 
folded preys to the bait, plasmid rearrangements or copy number changes that 
generate autoactivators, or mutation at reporter genes that cause constitutive 
expression, etc. To reduce these artifacts, especially the technical ones, a two-hybrid 
dual bait system can be used (Serebriiskii, 1999; Kotova and Coleman, 2009). Briefly, 
one protein of interest (bait 1) is expressed as a fusion protein carrying a DNA-
binding domain LexA which binds to LexA operator (lexop) that transcriptionally 
induces LacZ and LEU2 reporter genes, while the other protein of interest (bait 2) is 
expressed as a fusion protein carrying a DNA-binding domain cI which binds to cI 
operator (cIop) that transcriptionally induces GusA and LYS2 reporter genes. A 
plasmid encoding the activation domain-fusion protein (the prey) that can be either a 
cDNA library or specific binding partner of the bait1 is expressed in yeast ready for 
mating with the yeast containing dual baits. After the mating, replica plating selection 
selects potential clones which LacZ and LEU2 but not GusA and LYS2 are transcribed. 
With the dual bait system, the nonspecific capture of binding partner for a given bait 
can be reduced (Kotova and Coleman, 2009).  
 
Autoactivation caused by the bait can be solved by deletion of the domain that causes 
the autoactivation or by increasing 3-aminotriazole (3-AT) levels when using the 
HIS3 as the selection maker because 3-AT enhances the requirement of His3 for 
survival on histidine-deficient medium. There are another two alternative methods to 
address this issue. One is to adopt nuclear two-hybrid system (e.g., RNA Pol III 
system (M et al., 2001) or a repressed transactivator system (Hirst et al., 2001)) and 
the other is to fuse the AD rather than the DBD to the autoactivating bait protein, 
followed by screening with the library in fusion with the DBD (Du et al., 1996). 
 
The problem caused by false negatives is a decrease to the reproducibility of Y2H 
screens. The overlap of PPIs discovered by two large-scale independent Y2H screens 
with the same method is less than 30% and the known PPIs can be found in both Y2H 
screens are only 12.5% (Ito et al., 2001). Therefore, the false negatives represent the 
real limitation of Y2H (Brückner et al., 2009). To manage the false negatives caused 
by the canonical Y2H, another suitable Y2H can be considered. Figure 1-8 shows the 
suitable Y2H that can be used to screen potential PPIs in different cellular 
compartment. For example, G-protein fusion system, membrane split-ubiquitin 
system (MbY2H), reverse Ras recruitment system (rRRS), or split-trp system can be 
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used to detect PPIs of membrane proteins (Stagljar et al., 1998; Ehrhard et al., 2000; 
Hubsman, 2001; Tafelmeyer et al., 2004). A split-trp system or split-ubiquitin system 
can be considered if PPIs occur in the cytosol of a cell (Johnsson and Varshavsky, 
1994; Tafelmeyer et al., 2004). When the suitable type of Y2H to detect unknown 
PPIs is decided according to the cellular compartment where PPIs occur, permutated 
fusion vectors with the bait and the prey library in a specific Y2H can be adopted to 
further decrease the false negatives (Stellberger et al., 2010). Stellberger et al., have 
constructed two new Y2H vectors (pGBKCg and pGADCg), allowing them to make 
new C-terminal fusion proteins of DBD and AD and to combine with the existing N-
terminal Y2H vectors. The permutation of C- and N-terminal Y2H vectors thus allow 
four different bait-prey combinations: NN, CC, NC, and CN. They have tested 
approximately 4,900 pairwise combinations of 70 varicella-Zoster-Virus (VZV) 
proteins for discovering potential PPIs and have found 182 PPIs with NN, 89 PPIs 
with NC, 149 PPIs with CN, and 144 PPIs with CC. They found that permutated four 
screens rather than a classical one screen resulted in about twice as many PPIs and 
thereby decreased false negatives. With the use of a suitable type of Y2H and the 
permutated screens, the false negatives would be decreased significantly and the 
maximum coverage can be achieved (Rajagopala et al., 2012). 
1.3.4.   The application of Y2H 
Since Y2H was first described in 1989, it has been adapted to promote the progress of 
proteomics, the discovery of new drug targets, and the development of systems 
biology. Y2H screens have been routinely used to detect novel PPIs among proteins 
in a protein complex (Rajagopala et al., 2012), to discover new potential therapeutic 
targets for future anti-infective drugs (Hamdi and Colas, 2011), to map protein 
binding domains (Rajagopala and Uetz, 2011; Dagkessamanskaia et al., 2010), and to 
explicit protein functions in a specific signal pathway or an interaction (Duarte et al., 
2011; Li et al., 2012; Park et al., 2009). In the following sections, we will discuss 
these applications in details. 
1.3.4.1.   Drug and protein interaction networks discovery 
Few disease-associated proteins offer a tractable therapeutic target. Thus, most 
disease-associated proteins are classified as intractable disease-associated proteins 
without druggable sites or with druggable sites that are not useful as they are 
substantially conserved in other related proteins (Hamdi and Colas, 2012). In this 
situation, targeting the binding partner of the associated proteins discovered by 
proteome-wide (exhaustive) or sub-proteome-wide (partial) Y2H screens can lead to 
novel therapeutic targets. For example, the interaction of activated Ras with Raf 
initiates MEK/ERK signaling pathway that contributes to tumorigenesis and agents 
which specifically interrupt the interaction may have therapeutic benefits (Maurer et 
al., 2011; Kato-Stankiewicz et al., 2002). Ki et al., showed that Ras/Raf-1 interaction 
in the Y2H has been disrupted by radicicol, a macrocyclic antifungal antibiotic 
isolated from the fungus Monosporium bonorden (Ki et al., 1998). Later, Kato-
Stankiewicz et al., have identified small molecule compounds (MCP1 and its 
derivatives, 53 and 110) block Ras/Raf interaction with Y2H approach (Kato-
Stankiewicz et al., 2002), followed by González-Pérez et al., using pull-down assays 
in NIH 3T3 cells to confirm that MCP110 inhibits the physical interaction between 
Ras and Raf in a dose-dependent manner (González-Pérez et al., 2010). Yin et al., 
also used Y2H approach to search potential agents inhibiting c-Myc function and 
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found that seven small molecule compounds, in the low micromolar range, to inhibit 
the association between c-Myc and Max, followed by increasing G0/G1 cell 
population and disrupting in vivo tumor growth (Yin et al., 2003). They further 
indicated that these seven small molecule compounds might inhibit the association of 
c-Myc/Max via different domains and it is plausible that better antitumor efficacy 
might be achieved with combinations of compounds. Since the Y2H candidates with 
which c-Myc function was inhibited in mammalian cells are all real c-Myc inhibitors, 
Yin et al., suggested that Y2H-based approaches would be of more general utility in 
finding potential useful small molecule compounds for antitumor. Thus far, Y2H 
screens have been the most widely used approach to discover PPI inhibitors or small 
molecule compounds for the treatments of cancers, epilepsy, and neurodegenerative 
disease (Table 1-2) (Hamdi and Colas, 2012).  
 
In addition to the novel small molecule compound discovery from Y2H, PPI map 
compiling is another application of Y2H. PPI networks generated by Y2H provide 
valuable information for understanding not only functional organization of the 
proteome and individual protein functions but also disease mechanisms and signaling 
pathways (Stelzl et al., 2005). In the next section, we will discuss another application 
of Y2H, discovering novel protein functions from PPI networks. 
1.3.4.2.   Determination of protein functions 
PPIs are essential for all physiological and cellular processes and compiling PPI 
networks provides a better platform to understand the functional arrangements 
between these proteins under specific circumstances as well as shedding light on new 
insights into protein functions. Stelzl et al., used a Y2H matrix approach to identify 
3186 novel human PPIs, connecting 1705 human proteins (Stelzl et al., 2005). In this 
human PPI network, 195 disease proteins and 342 uncharacterized proteins were 
discovered, which directly or indirectly interact with other proteins, allowing them to 
be given new functional roles. Wong et al., also adopted high-throughput Y2H screen 
to identify more than 100 new binding partners for two mammalian intersectin (ITSN) 
proteins (ITSN1 and ITSN2), and found that ITSNs regulate Rab and Arf GTPase 
pathway and that there are links between ITSNs and the regulators of signal 
transduction pathway (Wong et al., 2012). This research used Y2H to expand the role 
of ITSNs that were originally regarded as regulators of endocytosis. Recent 
developments of high-throughput screening technologies, for example, Y2H have 
enabled a large amount of PPI data to be generated and analyzed by many different 
computational algorithms to predict the missing links in original experimental PPI 
networks for understanding important connections between protein topologies and 
functions (Lei and Ruan, 2013). From the systems biology point of view, the 
contribution of Y2H for discovering novel protein functions relies on the large 
amount of PPI data generated by high-throughput Y2H, followed by systematic 
analysis by using bioinformatic databases. 
1.3.4.3.   Determining the crucial sequences for protein-protein 
interaction 
By using truncation mutants of a specific protein with DBD as a bait, crucial 
sequence/domain in a specific protein for PPIs can be determined with several 
different Y2H screens. For example, Sato et al., identified that the N-terminal domain 
of Bcl-2 is required to interact with the C-terminal of Bcl-2 in the head-to-tail fashion 
 44 
of Bcl-2 homodimerization by using Y2H approach (Sato et al., 1994). Fordham-
Skelton et al., also used Y2H to test the possibility of the interaction between KIS 
domain in AtPTPKIS1 and SNF1-related kinase AKIN11. They demonstrated the PPI 
between AtPTPKIS1 and SNF1-related kinase AKIN11 and the PPI between KIS 
domain in AtPTPKIS1 and SNF1-related kinase AKIN11 with Y2H approach, 
followed by confirming the latter interaction with GST pull-down assay (Fordham-
Skelton et al., 2002). In these two studies, Y2H approach was a useful tool to map the 
crucial domain/region in a specific protein for the specific PPIs. 
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Figure 1-5 The classical yeast two-hybrid system. The classical yeast two-hybrid 
system. (A) The protein of interest X, is fused to the DNA binding domain (DBD), a 
construct called bait. The potential interacting protein Y is fused to the activation 
domain (AD) and is called prey. (B) The bait, i.e. the DBD-X fusion protein, binds 
the upstream activator sequence (UAS) of the promoter. The interaction of bait with 
prey, i.e. the AD-Y fusion protein, recruits the AD and thus reconstitutes a functional 
transcription factor, leading to further recruitment of RNA polymerase II and 
subsequent transcription of a reporter gene. Figure was taken directly from Brückner 
A. et al. Int J Mol Sci., 10, 2763-2788 (June 2009). 
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Figure 1-6 The procedure of protein identification by tandem mass spectrometry. 
A protein complex is separated by 1D PAGE and bands of interest are cut from the 
gel, digested with trypsin and the generated peptides are partially sequenced by 
tandem mass spectrometry. Series of signals marked with Y¢¢n allow the 
corresponding peptide sequence to be determined from the tandem mass spectrum. 
Mass and partial amino-acid sequence data are simultaneously searched against 
protein or nucleotide sequence databases for protein identification. Figure was taken 
directly from Bauer A. et al. Eur. J. Biochem., 270, 570-578 (Jan 2003). 
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Figure 1-7 Mammalian two-hybrid system used by Suzuki and the co-workers. 
Mammalian two-hybrid system used by Suzuki et al. About 3500 mouse cDNAs were 
amplified by PCR and these PCR products (ORF X and ORF Y) mixed with another 
PCR product that carried a cytomegalovirus (CMV) promoter and either a Gal4 DNA-
binding domain (DBD) or a VP16 transcriptional activation domain (AD). Because 
the two PCR products have overlapping sequences, they can be fused into one DNA 
fragment by a secondary PCR reaction using primers at the ends of the individual 
fragments. The final PCR fragments were transfected into tissue culture cells (CHO-
K1) together with a reporter plasmid that carried a luciferase gene (Luc). When the 
encoded proteins interact, the luciferase reporter gene is transcribed and its activity 
can be measured as fluorescence. All 3500 × 3500 protein combinations were tested. 
To speed up the screening procedure, various numbers of baits and preys were co-
transfected (i.e. pooled), and positive signals were later deconvoluted to identify 
interacting proteins. Figure was taken directly from Uetz P. Curr Opin Chem Biol., 6, 
57-62 (Feb 2002). 
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Figure 1-8 Different Y2H suits for distinct cellular compartments where PPI 
occur. Protein X (dark blue puzzle piece, part of bait construct) and protein Y (light blue puzzle piece, 
part of prey construct) directly interact (fitting puzzle pieces), thus inducing reconstitution of split- 
proteins (puzzle pieces of different colors in A, D, E), membrane recruitment (B, C) or protein 
dimerization (F). Protein fusions in bait or prey constructs are shown as solid black lines between 
puzzle pieces. Bait-prey interaction activates further downstream events (arrows) that directly (A) or 
indirectly (B, C, D, F) lead to transcriptional activation, or are independent of transcriptional activation 
(D, E), finally yielding screenable readouts like growth on specific media or color reactions. (A) 
Nuclear Y2H systems all require protein recruitment and bait-prey interaction at nuclear DNA. The 
classic Y2H and RTA Y2H both engage RNA polymerase II (RNA Pol II) transcription either by its 
activation or its inhibition. By contrast, the Pol III Y2H, involves RNA polymerase III (RNA Pol III) 
transcription. (B) Ras signalling based Y2H at the plasma membrane. The SRS Y2H, RRS Y2H, 
and rRRS Y2H are all based on protein recruitment to the plasma membrane via bait-prey interaction 
and subsequent activation of MAPK downstream signalling. While in the SRS and RRS Y2H the prey 
constructs harboring protein Y are anchored at the membrane via myristoylation to analyze interactions 
with cytosolic bait constructs harboring protein X, the rRRS is used to analyze interactions between 
soluble preys containing protein Y and partner X being a membrane protein. (C) G-protein signalling-
based Y2H at the plasma membrane. In the G-protein fusion Y2H, bait X is a membrane or 
membrane-associated protein whose interaction with the prey construct disrupts protein G downstream 
signalling. (D) Split- ubiquitin based Y2H systems involve reconstitution of ubiquitin from two 
domains upon bait-prey interaction. Their subcellular localization depends on the nature of interacting 
proteins X or Y, and on the reporter proteins used. The Split ubiquitin Y2H uses non-transcriptional 
reporting of protein interactions in the cytosol, but can also be used for membrane proteins (not shown). 
The MbY2H is used for interaction analysis with membrane baits and thus occurs at the membrane 
location of protein X, e.g. the plasma membrane. The CytoY2H is used for membrane anchored 
cytosolic baits and occurs close to the ER membrane (E) Split-protein sensor Y2H. The Split-Trp 
Y2H is used to assay cytosolic bait-prey interactions based on reconstitution of an enzyme in 
tryptophan synthesis, allowing for non-transcriptional reporting. (F) ER Y2H system. The SCINEX-P 
Y2H allows bait- prey interaction analysis in the reducing environment of the ER, based on protein 
dimerization in unfolded protein signalling. Figure was taken directly from Brückner A. Int. J. 
Mol. Sci., 10, 2763-2788 (Jun 2009). 
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Table 1-2 Small-molecule modulators of PPIs discovered by Y2H 
 
 
 
 
Table was taken directly from A Hamdi and P Colas. Trends Pharmacol Sci., 33, 109-
118 (Feb 2012). 
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1.4.   RNA-binding motifs and domains 
Interactions between proteins and RNA are essential for every steps in RNA 
metabolism, and are achieved by RNA-binding domains/motifs in RNA binding 
proteins (Cléry and Frédéric, 2012). Table 1-3 lists the common RNA-binding 
domains and their properties such as their topologies, RNA-recognition surfaces, and 
the mechanisms of protein-RNA interactions (Lunde et al., 2007). In this section, we 
review the four most commonly found RNA-binding domains/motifs, namely, zinc 
fingers, RNA recognition motifs (RRM), K homology (KH) domain, and double-
stranded RNA-binding domain (dsRBD).        
1.4.1.   Zinc fingers 
The Zinc finger (ZnF) domain is the second most prevalent domain in the human 
proteome and approximately 3% of human proteins contain at least one ZnF (Burdach 
et al., 2012). So far, at least 20 types of zinc-binding domain have been discovered, of 
which the classical form, originally discovered by Sir Aaron Klug in 1985, is the most 
intensively studied (Font and Mackay, 2010). ZnFs are classified on the basis of the 
amino acids coordinating the zinc ion; for example, two pairs of cysteine and histidine 
(CCHH). The structure of this classical CCHH ZnF domain is composed of a zinc ion 
with 30 amino acids. 5 amino acids provide the linker and the other 25 fold around the 
zinc ion form the domain, the “finger”, in which two pairs of cysteine and histidine 
residues, tetrahedrally coordinate to the zinc ion, and Tyr6 (or Phe6), Phe17 as well as 
Leu23 are the conserved amino acids in this structure (Klug, 2010). The ZnFs locate 
tandemly in a linear, polar fashion to recognise different lengths of specific DNA or 
RNA sequences. Figure 1-9 shows the structure of classical ZnF and the possible 
binding sites of ZnFs.  
 
The capacity of ZnFs to recognise and associate with a variety of RNA or DNA 
sequences is based of variational combination of key amino acids in each similar 
structural ZnF domain (Oteiza, 2012). Moreover, the mechanisms of RNA binding 
differ with different class of ZnFs. The classical ZnF such as TFIIIA binds to two 
RNA loops through the recognition helices of finger 4 and 6, whereas CCCH ZnF 
protein TIS11d binds to AU-rich RNA element (ARE) via hydrogen binding to the 
backbone of TIS11d (Lunde et al., 2007). Apart from the association between ZnFs 
and nucleic acids (DNA and RNA), it has also been shown that ZnF binds to proteins, 
small ligands (lipids) as well as having enzymatic properties (Krishna et al., 2003). 
For instance, Matthews et al., showed that the C-terminal ZnF cluster in Ikaros family 
of transcription factors mediates protein dimerization (Matthews and Sunde, 2002). 
Wagner et al., demonstrated that the zinc finger protein ZNF202 is a transcriptional 
repressor which binds to the regulatory region of many genes involved in lipid 
metabolism via some of the ZnF in ZNF202 (Wagner et al., 2000). In spite of the 
small size of ZnF in comparison with other larger domains, the functions of ZnFs are 
very versatile. Thus, they are involved in replication and repair, transcription and 
translation, metabolism and signaling, cell proliferation and apoptosis (Krishna et al., 
2003). 
1.4.2.   RNA recognition motif 
The RNA recognition motif (RRM), also known as RNA binding domain (RBD) or 
ribonucleoprotein (RNP) domain, is the most prevalent RNA-binding domain in 
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eukaryotes and is the most extensively studied RNA-binding domain/motif (Cléry et 
al., 2008). In general, a RRM contains approximately 90 amino acids with a 
β1α1β2β3α2β4 topology which shapes 4-stranded antiparallel β-sheet buttressed by two 
α helices (Hall, 2012). The RRM binds to single-stranded nucleic acid and two 
consensus sequences on β3 and β1 strands in RRM, ribonucleoprotein 1 (RNP1; 
Lys/Arg-Gly-Phe/Tyr-Gly/Ala-Phe/Tyr-Val/Ile/Leu-X-Phe/Tyr) and RNP2 
(Ile/Val/Leu-Phe/Tyr-Ile/Val/Leu-X-Asn-Leu), where X can be any amino acid, are 
thought to be involved in RNA interactions (Phelan et al., 2012; Maris et al., 2005). In 
fact, how RNA recognition motifs bind RNA depends on the cooperation of multiple 
RRMs and the short (8-11 amino acid) interdomain linker which forms a short helix 
that makes essential contacts to the RNAs (Pérez-Cañadillas and Varani, 2001). A 
mechanism by which two RRM cooperate with each other to bind RNA is illustrated 
in Figure 1-10. 
 
Eukaryotic RRM-containing proteins have been shown to be associated with all post-
transcriptional events: pre-mRNA processing (for example CstF-64 (Cleavage 
stimulation factor 64 kilodalton subunit), LA (La autoantigen-like), or UPF3 proteins), 
splicing (U2B’ (U2 small nuclear ribonucleoprotein B’), U2AF, hnRNPA1 or Y14 
proteins), alternative splicing (hnRNPA1, PTB (Polypyrimdine tract binding protein), 
sex-lethal, SR proteins), mRNA stability (CBP20 (cap-binding protein 20), PABP or 
HuD), RNA editing (ACF), mRNA export (TLS), pre-rRNA complex formation 
(nucleolin), translation regulation and degradation (poly(A)-binding protein, PABP) 
(Maris et al., 2005). These post-transcriptional events are important for maintaining 
normal physiological function. For example, HuD (also known as ELAV-L4 
(embryonic lethal, abnormal vision, Drosophila)-like 4)) has been demonstrated to be 
involved in mRNA stability by its first RRM binding to the ARE within the 3’ 
untranslated region (UTR) of the target transcripts. HuD has been shown to bind and 
stabilize c-fos, c-myc, N-myc, p21, neuroserpin and MARCKS (myristoylated 
alanine-rich protein kinase C substrate), which play a key role in neuronal 
differentiation. Furthermore, HuD has also been shown to bind to GAP-43 (growth 
associated protein 43) to increase its transcript level, which is crucial to the nervous 
system both in response to injury and during spatial learning tasks (Deschênes-Furry 
et al., 2006). Another example of a RRM-containing protein involved in several 
cellular processes is PABP. The RRMs in PABP recognise and associate poly(A) tail 
of mRNA, which is essential for promoting translation initiation and termination, 
recycling of ribosomes and stabilizing mRNA (Mangus et al., 2003).  
 
Of note, RRMs not only bind RNAs but also associate with proteins in some special 
cases. A structural study of the heterodimeric splicing factor U2 snRNP auxiliary 
factor (U2AF) led to the discovery of two RRM-like motifs with specialized 
characteristics for protein recognition (Kielkopf et al., 2004). Several independent 
researchers have confirmed that both the C-terminal U2AF65 and central U2AF35 
protein interaction domains adopt the β1α1β2β3α2β4 RRM-fold topology; however, the 
increasing length of helix A caused by the sequence insertions separates the two RNP-
like motifs (lack of aromatic amino acids in canonical RNP motifs) from three turns 
observed among classical RRMs to five or eight turns for U2AF65 and U2AF35, 
respectively. A hydrophobic pocket between the α-helices and the RNP1- and RNP2-
like motifs is responsible for the short protein ligand recognition (Kielkopf et al., 
2004). 
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1.4.3.   KH domain 
The K homology (KH) domain was first identified in the pre-mRNA-binding protein 
K (heterogeneous nuclear ribonucleoprotein K, hnRNP K) (Siomi et al., 1993). It is 
made up from approximately 70 amino acids, and is found in a wide spectrum of 
proteins in archaea, bacteria and eukaryotes (Valverde et al., 2008). Typically, 
multiple KH domains tend to be found in some RNA-binding proteins and cooperate 
with each other to bind RNA and ssDNA. For example, there are two in fragile X 
mental retardation protein (FMRP) and three in hnRNP K and 14 in vigilin. In some 
proteins, for example, Sam68 or other STAR (Signal Transduction and Activation of 
RNA) proteins, a single KH domain is found to function independently to interact 
with RNA (Lukong and Richard, 2003). Grishin analyzed the spatial structures of KH 
domain of human hnRNP K (type I KH domain) and of ribosomal protein S3 from 
Deinococcus radiodurans (type II KH domain) and discovered that these two KH 
domains are topologically dissimilar with different protein folds. However, they share 
the same minimal KH motif (Grishin, 2001).  
 
Figure 1-11A shows the differences between the type I (eukaryotic) KH domain and 
the type II (prokaryotic) KH domain. The difference is mainly based on β-strand 
arrangements. In the type I KH domain, three β-strands are in the order of β1, β’, and 
β2, in which the β1- and β2-strands are parallel to each other; the β’-strand is 
antiparallel to both. In contrast, in the type II KH domain, three β-strands are in the 
order of β’, β1, and β2, in which the β1- and β2-strands are parallel and adjacent to 
each other; the β’-strand is antiparallel and adjacent to the β1 (Valverde et al., 2008). 
Notably, all canonical KH domains (type I and type II), the link between the α1- and 
α2-helix contains a GxxG loop which is responsible for the DNA/RNA binding 
(Barkan et al., 2007). However, a few KH domains have been found to lack of this 
conserved GxxG loop (degenerate KH domains) and this results in impaired nucleic 
acid binding capability. Furthermore, these degenerate KH domain-containing 
proteins such as human vigilin protein form extensive intra-molecular protein-protein 
contacts (Hollingworth et al., 2012).  
 
The structural study of the type I KH domain has revealed that single strand nucleic 
acid binding is regulated by two regions of the KH domain, namely, the hydrophobic 
cleft generated by two α-helices (α1 and α2) with the intervening GxxG loop and the 
inner surface of the β2-strand with the variable loop (Figure 1-11B, colored green) 
(Sidiqi et al., 2005; Braddock et al., 2002). In comparison with RRMs, the binding 
cleft of KH domains can only accommodate four nucleic acid bases, whereas the 
length of target RNA that associates with RRMs is versatile (Valverde et al., 2008). 
The four nucleic acid bases recognised by the binding cleft vary case by case; for 
example, type I KH3 domain of the transcriptional regulator hnRNP K associates with 
the tetrad 5’-dTCCC ssDNA, Nova-2 KH3 domain binds to the tetranucleotide 
sequence 5’-UCAC of selected stem-loop RNA, and KH3 and KH4 domain in FUSE-
binding protein (FBP) recognise ssDNA 5’-dTTTT and 5’-ATTC, respectively 
(Valverde et al., 2008). In multiple KH domain containing proteins, these KH 
domains often present different affinities and specificities for the nucleic acid 
recognition; for example, in the case of KSRP, the second KH domain in KSRP can 
be defined as an AU-rich recognition domain, whereas the third KH domain in KSRP 
prefers to bind G-rich sequences. Furthermore, in the context of pre-let-7-KSRP 
binding ability, the third KH domain in KSRP shows approximately 50-fold higher 
binding affinity than the one contributed by KH1, KH2, or KH4 (Briata et al., 2012). 
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Further consideration of KH domain will be presented in the discussion section of 
Chapter 4. 
1.4.4.   Double-stranded RBD 
Double-stranded RNAs (dsRNAs) are involved in many cellular processes such as 
gene silencing (Meister and Tuschl, 2004) and innate immune responses against viral 
infection (Fei et al., 2011). The double-stranded RNA binding domain (dsRBD), first 
described in 1992, spans 65-70 amino acids in length with an αβββα topology 
structure. Its main function appears to be to recognise and associate with dsRNA 
(Masliah et al., 2012).  
The association of dsRBD and dsRNA is regulated by the three regions of the dsRBD. 
The first region involves in dsRNA contact is the α1 helix, the second region 
responsible for the contacts is loop 2 where between β1- and β2-strand, and the third 
region for the dsRNA recognition spans from loop 4 (between β3-strand and α2-helix) 
to the α2-helix. The association of dsRNA and dsRBD occurs on one face of the 
dsRNA helix where the region 1 and 2 of the dsRBD interact with the minor groove, 
whereas the region 3 of the dsRBD contacts the major groove (Tian et al., 2004; Ryter 
and Schultz, 1998). Figure 1-12 shows the alignment of dsRBD-containing proteins, 
the positions of the three regions, and the dsRNA-Xlrbpa-2 (dsRNA-dsRBD) 
interaction between the three regions and the major as well as minor grooves of the 
dsRNA. Of note, many protein-RNA bindings are accompanied by a conformational 
change in the RNA, the protein or both and, in some cases, the interactions between 
RNAs and proteins are sequence specific, while the A-form shape of dsRNA remains 
almost the same structure during the association between dsRBD and dsRNA and the 
associations are sequence independent (Tian et al., 2004). Although the classical 
mode of dsRBD-dsRNA interactions was shown to be lacking sequence specificity, 
there are multiple examples where a high degree of specificity exists.  For example, 
the Drosophila Staufen protein has been shown to bind 3’UTR of biciod, oskar and 
prospero mRNAs (Ferrandon et al., 1994; Kim-Ha et al., 1993; Broadus et al., 1998; 
Wagner et al., 2001). As for the paradox of dsRBD-dsRNA sequence-specific 
recognition, Masliah et al., have proposed a binding model that dsRBDs recognise 
their substrates via particular distortion points of the A-form RNA helix caused by 
apical loop structure and some specific amino acid side chains located in α1 helix as 
well as the carbonyl group of the peptide backbone in the loop 2 of dsRBDs make 
contact with the minor grooves of RNA (Masliah et al., 2012). This model has been 
examined with ADAR2- and Aa RNase III-RNA complexes and provides new 
insights on the structural basis of sequence-specific recognition between dsRNAs and 
dsRBDs. 
Here I have reviewed four main RNA binding domains/motifs which have been 
shown to be involved in many cellular processes such as antiviral responses, RNA 
silencing (dsRBD) (Masliah et al., 2012), ARE-directed mRNA decay (KH domain) 
(Gherzi et al., 2004), mRNA stability (RRM) (Maris et al., 2005), and transcriptional 
repression (ZnF) (Wagner et al., 2000). Knowledge of these RNA-binding domains is 
useful for RNA-related research and may shed light on our PARP-14 study. 
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Table 1-3 Common RNA-binding domains and their properties 
 
 
 
 
 
 
Table was taken directly from BM Lunde et al., Nat Rev Mol Cell Biol., 8, 479-490 
(Jun 2007). 
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Figure 1-9 The structure of a zinc finger module. The structure of zinc finger from 
a two-dimensional NMR study (A); Folding scheme for a linear arrangement of 
repeating structural units (“zinc finger modules”), each centered on a tetrahedral 
arrangement of zinc ligands, Cys2 and His2. Gray dots indicate sites of amino acids 
capable of binding DNA (B). Figure was reproduced from A Klug., Annu. Rev. 
Biochem., 79, 213-231 (July 2010). 
(A) 
 
 
(B) 
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Figure 1-10 The canonical topology of RRM (A) Representative canonical RRM 
fold, from the structure of the U1A/RNA complex (PDB code 1URN). The N- and C-
terminal ends of the RRM are indicated. The position and orientation of the RNA are 
represented with a ribbon diagram; how RRMs bind RNA. Figure was reproduced 
from CL Kielkopf et al., Genes Dev., 18, 1513-1526 (Jul 2004). (B) Crystal structure 
of the complex between the Drosophila Sxl protein and a U-rich sequence derived 
from the tra pre-mRNA (RRM1); Crystal structure of the complex between the two 
N-terminal RRMs of human poly(A)-binding protein and poly(A) (RRM2). Figure 
was reproduced from JM Pérez-Cañadillas et al., Curr Opin Struct Biol., 11, 53-58 
(Feb 2001). 
 
 
 
 
(A) 
 
 
 
(B) 
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Figure 1-11 The topologies of type I and type II KH domians (A) Type I and type 
II KH domain folds. Stylized representations of the type I KH domain (eukaryotic) 
and the type II KH domain (prokaryotic). The labeling of second- ary structure 
elements is according to standard KH nomenclature. The dotted line connecting the 
β2-strand and β’-strand represents the variable loop. The white line connecting the 
α1-helix and the α2-helix represents the GXXG loop; how KH domain binds 
RNA/DNA. (B) Type I KH domain; the binding cleft comprises the secondary 
structural elements α1-helix, GXXG loop, α2-helix, β2-strand, and variable loop 
(colored green), and recognizes four nucleotides (cyan sticks). The green dotted line 
represents the location of the variable loop in type II KH domains. Figures was 
reproduced directly from R Valverde et al., FEBS J., 275, 2712-2726 (Jun 2008). 
  
(A) 
 
 
 
(B) 
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Figure 1-12 The alignment of dsRBD proteins (A) Sequence alignment of various 
double-stranded RNA binding domains. Multiple sequence alignment of various 
dsRBD from Homo sapiens, Hs, Drosophila melanogaster, Dm, Saccharomyces 
cerevisiae, Sc, Xenopus leavis, Xl, Arabidopsis thaliana, At and Escherichia coli, Ec 
and Aquifex aeolicus, Aa. The alignment is coloured by amino-acid conservation 
(>40 %) and properties. The sequence consensus (>40 %), the residues conserved for 
the fold and/or dsRNA binding and the canonical secondary structured elements are 
shown below the alignment. The three regions of interaction with dsRNA are also 
indicated. Figure was reproduced from G Masliah et al., Cell. Mol. Life Sci., 70, 
1875-1895 (Jun 2013). (B) How Xlrbpa-2 binds dsRNA. The protein interacts with 
two successive minor grooves and across the intervening major groove on one face of 
the dsRNA helix. Protein 1 is shown as an α-carbon trace in purple. Side chain 
residues interacting with the RNA minor groove in regions 1 and 2 are colored green, 
and side chains interacting with the RNA major groove in region 3 are colored gray. 
Also displayed in gray are the side chains of Y131 and F145, which serve to position 
K167 and K163, respectively. Oxygen atoms are shown in red, nitrogen atoms in blue 
and phosphorus in yellow. Hydrogen bonds are indicated as black lines. Residue 
numbers are those of the full-length Xlrbpa protein. Figure was taken directly from 
JM Ryter and SC Schultz., EMBO J., 17, 7505-7513 (Dec 1998). 
(A) 
 
 
 
(B) 
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1.5.   RNA granules in cytoplasm and their roles in RNA 
turnover 
The composition of messenger ribonucleoproteins (mRNPs) not only reflects their 
nuclear and cytoplasmic histories but also determine their future fates (Anderson and 
Kedersha, 2009). The components of mRNPs determine the formation of different 
types of RNA granule, including stress granules, P body, and exosome complex, and 
influence RNA splicing, RNA export, regulation of translation, subcellular 
localisation, and mRNA turnover (Reineke and Lloyd, 2013). In this section, I review 
the three main types of RNA granule including their compositions, their formation, 
and their functions. 
1.5.1.   Stress granules 
When environmental stresses such as heat shock, oxidative stress, hyperosmolarity, 
viral infection, and UV irradiation are applied to cells, global translation initiation is 
impaired, followed by the generation of non-membranous cytoplasmic foci (0.1-
2.0µm), composed of the assembly of non-translating mRNPs (Anderson and 
Kedersha, 2009). The cytoplasmic foci form under adverse environmental conditions 
(environmental stress) and are therefore named stress granules (SGs). Figure 1-13 
demonstrates how SGs and P-bodies form. Briefly, the formation of SGs starts from 
polysome disassembly caused by translation initiation inhibition, followed by 
disassociation of translating ribosomes from the transcript, thereby forming circular 
polyadenylated mRNPs that can then be aggregated into SGs (Anderson and Kedersha, 
2009; Matsuki et al., 2013). Translation initiation factor (eIF2α)-dependent or eIF2α-
independent signal pathways regulate the translation initiation inhibition, followed by 
SG assembly. Phosphorylation of eIF2α decreases the availability of eIF2α-GTP-
tRNAiMet ternary complex that is indispensible for translation initiation, resulting in 
stalled translation (Kedersha and Anderson, 2007). Translation initiation can also be 
inhibited through a block in eIF4A function; in this case, the phosphorylation of 
eIF2α is not required (Farny et al., 2009). Of note, polysome disassembly can be 
either initiated by deadenylation or by translational silencing, which will then lead 
non-translating mRNPs being directed into P-bodies (see below) or SGs, respectively.  
 
The components of stress granules may contain stalled mRNA, stalled 43S and 48S 
ribosomal preinitiation complexes, polysome-associated proteins such as GTPase-
activating protein SH3 domain-binding protein (G3BP) and its molecular partner 
ubiquitin-specific processing protease 10 (USP10) as well as the translational 
silencers, TIA1 and TIAR (Buchan and Parker, 2009). It is important to be aware of 
the fact that not all SGs are identical in composition, as they vary depending on the 
mode of environmental stress that induce SGs (Balagopal and Parker, 2009). For 
example, SGs induced by heat shock contain heat shock protein 27 (hsp27); however, 
hsp27 is not in the SGs induced by arsenite (Kedersha et al., 2005). Another example 
to demonstrate this phenomenon is virus-induced SGs (V-SGs). Piotrowska and co-
workers have found that Sam68 is one of the components of the V-SGs, whereas it is 
not found in the SGs induced by heat shock (Piotrowska et al., 2010).  
 
Although the components of SGs vary with the stimulus used to elicit their 
aggregation, there are still some core universal components that differentiate SGs 
from P-bodies or other cytoplasmic foci. Anderson and Kedersha group the 
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components of SGs into four classes (Anderson and Kedersha, 2008). The first and 
defining class consists of universal markers for all SGs and contains stalled initiation 
complexes, mRNA transcripts, eukaryotic initiation factor 3 (eIF3), eIF4F 
(comprising eIF4E, eIF4A, and eIF4G), eIF4B, small ribosomal subunits and PABP-1. 
The reliable but not necessarily universal SG components are listed in the second 
class, which includes translational silencing proteins and RNA decay-associated 
proteins. The translational silencing proteins include TIA-1 (T cell internal antigen-1), 
TIAR (TIA-1 related), fragile X mental retardation protein (FMRP), fragile X mental 
retardation-related protein 1 (FXR1), Fas-activated serine/threonine kinase (FAST), 
argonaute proteins, cytoplasmic polyadenylation element-binding protein (CPEB), 
pumillio, smaug, ataxin-2 and RNA-associated protein 55 (Rap55, also called Lsm14), 
tristetraprolin (TTP), butyrate response factor 1 (BRF1), the RNA helicase RCK (also 
named p54), the endonuclease PMR1 (polysome-associated RNase 1) and zipcode 
binding protein 1 (ZBP1). The third class of SG-associated components includes 
RNA-binding proteins that regulate RNA metabolism and overexpression, and 
includes G3BP that nucleates SG assembly. The fourth class of SG components is the 
proteins recruited to SGs by “piggyback” interactions with the core components of 
SGs, for example, SRC3 (steroid coactivator 3) and FBP/KSRP (FUSE-binding 
protein/KH-type splicing regulatory protein). The details of these proteins including 
their known functions, their cellular localisation, and their binding partners are listed 
in Table 1-4. 
 
Buchan and Parker have proposed that the SGs do not primarily function as sites of 
translation repression and in mRNA stabilization but more as sites where the rate of 
biochemical reactions and assembly of initiation complexes can be controlled 
(Buchan and Parker, 2009). Firstly, SG formation is not a prerequisite for inhibition 
of translation initiation (Mokas et al., 2009) and SG disassembly is not required to 
restore translation (Loschi et al., 2009). Secondly, the inhibition of SG formation in 
yeast by mutating the core components of SGs did not impair mRNA stabilization 
(Buchan et al., 2008). Moreover, in Hela cells, (CUG triplet repeat, RNA binding 
protein 1) CUGBP1 is required for stabilizing p21 mRNA in SGs upon bortezomib 
treatment and depletion of CUGBP1 with siRNA has been shown to deter p21 mRNA 
stabilization but to have no effect on SG formation (Gareau et al., 2011). Clearly, the 
causality between the formation of SGs and mRNA stabilization does not exist. In the 
case of p21 mRNA stabilization, Gareau et al., proposed that the possible mechanism 
of the mRNA stabilization would be based on either recruitment or sequestration of 
p21 mRNA by CUGBP1 in SGs where enrich eIF4E and PABP that protect mRNA 
from decapping and deadenylation, respectively. Notably, Poly(A) ribonuclease 
(PARN) are absent in SGs, which prevent CUGBP1 from associating with PARN 
deadenylase to promote deadenylation of the target mRNA. Upon SG disassembly, a 
relatively high concentration of p21 mRNA pool and initiation complexes released 
from SGs become available for rapid translation, thereby providing a transient pulse 
of high p21 expression. It is thus tempting to speculate that the main function of SGs 
is to create cellular compartments where there is protection from decay of mRNPs, 
translation initiation factors, and transcripts that can be translated to maintain cell 
survival when the stress is relieved. 
1.5.2.   Processing bodies 
In 1997, Bashkirov et al., discovered small granular foci in eukaryotic cells, enriched 
with XRN1, DCP2 and its cofactors, which are involved in 5’-to-3’ mRNA-decay; 
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these granular structures were named P-bodies (PBs, processing bodies), DCP bodies 
or mRNA-decay foci because of these components (Bashkirov et al., 1997). Six years 
later, Eystathioy et al., recognised that granular foci (GW bodies) containing 182-kD 
GW182, a RNA binding protein, are identical to PBs and suggested that GW182 plays 
a crucial role in mRNA decay and degradation (Eystathioy et al., 2003). Presently, 
PBs are thought to be distinct cytoplasmic granules, where mRNA can be stored for 
further usage, reversibly repressed in translation, and/or degraded via 5’-to-3’decay. 
Kedersha et al., have proposed a model regarding the substance exchange between 
PBs and SGs. They speculated that SGs act as mRNA triage sites where transcripts 
are sorted for storage/silencing, for re-initiation of translation, and for mRNA decay 
(Figure 1-14A) (Kedersha et al., 2005). Of note, during stress conditions, some PBs 
and SGs are functionally and spatially linked to deliver some TTP- or butyrate 
response factor (BRF)-marked mRNAs from SGs to PBs for decay; however, it 
remains to be determined whether mRNPs can move from SGs to PBs, from PBs to 
SGs or in both directions (Olszewska et al., 2012).  
 
During the last decade, many proteins have been discovered as eukaryotic PB-
associated components, for example, 5’-to-3’ exonuclease (XRN1), Decapping 
enzymes and its cofactors (DCP1/2, Ge-1, Hedls (human enhancer of decapping large 
subunit), Pat1, EDC3 (enhancer of mRNA decapping-3, LSm16), LSm1-7, RAP55 
(LSm 14), RCK/p54), Nonsense-mediated mRNA decay (NMD)-associated proteins 
(SMG (suppressor with a morphogenetic effect on genitalia) 5, SMG7, UPF (up-
frameshift) 1-3), siRNA/miRNA pathway associated proteins (GW182, argonaute 
proteins), translational regulators (eIF4E, eIF4G, eIF4A, eIF2, eIF4E-T, 
CPEB(cytoplasmic polyadenylation element-binding protein)), ARE-mediated mRNA 
decay associated protein (TTP), and deadenylation complex (CCR4-CAF1-NOT 
complex) (Eulalio et al., 2007; Olszewska et al., 2012). It is worth noting that GW182, 
Ge-1, and Hedls harbor Glutamine/Asparagine (G/N)-rich prion-like domains, which 
assemble translational repression mRNPs with cis-elements that recruit PB core 
components such as DCP1/2, Dhh1 (DEAD-box RNA helicase), and Lsm/Pat1 
complex to form multi-assembly-complex mRNPs (Figure 1-14B). These multi-
assembly-complex mRNPs act as PB scaffolds for assembly with other single-
assembly mRNP complexes and aggregation of all these complexes form PBs (Franks 
and Lykke-Andersen, 2008; Fan et al., 2011). Although this PB formation model has 
been proposed for over 5 years, the exact mechanism of PB formation remains to be 
determined (Moser and Fritzler, 2010).  
 
The decay of mRNA is one of the main purposes of PB formation. Three types of 
mRNA decay have been demonstrated to occur in PBs, namely, 5’-to-3’ 
exonucleolytic process by XRN1, NMD by UPF1-3, SMG5, and SMG7 as well as 
ARE-mediated decay by TTP (Jakymiw et al., 2007). Moreover, PBs are also 
involved in siRNA-mediated mRNA silencing/miRNA-mediated mRNA repression 
regulated by GW182 and the Ago family of proteins (Ago1-4) (Jakymiw et al., 2005; 
Liu et al., 2005a; b; Yao et al., 2012). These P-body functions in determining mRNA 
fates are illustrated in Figure 1-15. 
1.5.3.   Exosome complex 
RNA turnover determines the level of transcripts that encode different proteins such 
as cytokines and growth factors (Mukherjee et al., 2002). The decay of mRNA is on 
one side of RNA turnover and it follows three different pathways, namely, 
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deadenylation-dependent mRNA decay, deadenylation-independent mRNA decay, 
and endonuclease-mediated mRNA decay (Figure 1-16A) (Garneau et al., 2007). The 
two ends of eukaryotic mRNAs are the 5’ 7-methylguanosine cap and the 3’ poly(A) 
tail, which interact with cytoplasmic protein complex eIF4F and PABP in order to 
protect the transcripts from exonucleases and promote translation initiation (Kushner, 
2004). In eukaryotic cells, the majority of mRNA decays follow deadenylation-
dependent pathway and the reversible poly(A)-tail shortening of the mRNAs is the 
first step (Parker and Song, 2004). If the mRNAs are still needed for the cell, the 
shortened poly(A)-tails can be readenylated and return to polysomes (Carroll et al., 
2011). If, however, the mRNAs bear incorrect signals and need to be destroyed, either 
5’-to-3’ decay pathway or 3’-to-5’ decay route can lead the mRNAs to decay. For the 
5’-to-3’ decay route, 5’ cap of mRNAs is removed (decapping) by decapping 
enzymes such as DCP1/2, followed by XRN1-mediated decay, whereas, in 3’-to-5’ 
decay pathway, the unprotected 3’ end is attacked by a large exosome complex 
(Cougot et al., 2004). Due to space limitations, deadenylation-independent mRNA 
decay and endonuclease-mediated mRNA decay will not be discussed but these 
subjects have been well reviewed (Garneau et al., 2007).  
 
The exosome complex is the major collection of eukaryotic 3’-to-5’ exonucleases in 
both the nucleus and the cytoplasm, representing a key focus of the RNA-surveillance 
machinery. It is involved in targeting the 3’ ends of nucleus precursors for 3’-to-5’ 
precise trimming as well as playing a role in 3’-to-5’ mRNA degradation (Houseley et 
al., 2006). Apart from precursor processing, the nuclear exosome complexes have also 
been shown to decay aberrant nuclear pre-mRNAs, pre-tRNAs and pre-rRNAs 
(Houseley et al., 2006). The exact composition of eukaryotic exosomes depend on 
their subcellular locations and also seems to differ between organisms (Schmid and 
Jensen, 2008). Nevertheless, all eukaryotic exosome complexes are composed of a 
conserved core associated with nuclear or cytoplasmic specific subunits and pathway-
specific cofactors. The core contains nine subunits forming a ring structure that is 
similar to its counterparts, archaeal exosome and bacterial phosphorolytic nucleases; 
strikingly, notwithstanding the core structural similarity between archaeal and 
eukaryotic exosomes, it has been found that the eukaryotic exosome core is 
catalytically inactive (Lebreton et al., 2008). Table 1-5 lists the main components of 
the eukaryotic exosome complex, including nine core subunits and cofactors. 
Although the core complexes are nucleolytically dead, they are still critical for proper 
exosome function in vivo because ssRNAs are threaded through the central channel of 
the core and interact with two 3’-to-5’ exoribonucleases rRNA-processing (Rrp) 
proteins, Rrp44 (also known as Dis3) and Rrp6 for digestion (Chlebowski et al., 
2013). For cytoplasmic faulty RNA decays, the cytoplasmic exosome complexes 
often cooperate with superkiller (SKI) complex that is essential for exosomal 
degradation of mRNAs under the influence of RNA interference (RNAi) in three 
different ways: NMD for mRNAs with premature termination codons, the non-stop 
decay (NSD) for mRNAs lacking termination codons, and the no-go decay (NGD) for 
mRNAs with ribosomes stalled (Figure 1-16B) (van Hoof et al., 2000; Orban and 
Izaurralde, 2005). Moreover, some AREs in mRNAs interact with exosome 
complexes directly or ARE-binding proteins (AUBPs) which recruit the DExH family 
RNA helicase RHAU and poly(A)-specific ribonuclease (PARN) for rapid 
degradation (Mukherjee et al., 2002; Tran et al., 2004). Because this section is for the 
review of RNA granules in cytoplasm, the review of nuclear exosome complexes is 
not included.  
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Figure 1-13 The formation and dynamic relationship between metazoan RNA 
granules. Polysomal RNA is circularized by interactions between poly(A)-binding protein 1 
(PABP1) and eukaryotic translation initiation factor 4G (eIF4G), which are stabilized by eIF3. 
Polysome disassembly can be initiated by deadenylation (left pathway) or by translational 
silencing (right pathway). Linearized messenger ribonucleoproteins (mRNPs) seem to be 
destined for processing bodies (PBs), whereas circularized mRNPs are directed to stress 
granules (SGs). In the ‘linear’ pathway (left), the deadenylation complex ccR4–NOT1 is 
recruited by destabilizing factors, such as tristetraprolin (TTP), or RNA-induced silencing 
complexes (RiScs), which comprise Argonaute proteins and microRNAs. Breaking the circle 
by the loss of eIF3 and/or deadenylation-induced loss of PABP1 produces a linear transcript. 
This linear mRNA recruits a decapping complex (which consists of decapping protein 1 
(DCP1; DCP1A in humans), DCP2, enhancer of mRNA-decapping protein 3 (EDC3), RcK 
(also known as DDX6) and HEDLS) and a decapping activator complex (PAT1 bound to 
LSM1–7; PAT1 is not shown). Q/N-rich domains in LSM4 and EDC3 promote the 
aggregation of these mRNAs into PBs. In the ‘circular’ pathway (right), transiently stalled 
initiation complexes recruit TIA1 and TIAR (together shown as TIA) as elongating ribosomes 
run off the transcript, converting the polysome into a circular, adenylated mRNP. 
Aggregation of bound TIA1 and TIAR or G3BP–USP10 (G3BP is GTPase-activating protein 
SH3 domain-binding protein and USP10 is ubiquitin-specific processing protease 10) and/or 
modification of ribosomes with O-linked N-acetylglucosamine (GlcNAc) promote the 
assembly of these mRNAs into SGs. It is possible that mRNPs in PBs or SGs can be 
remodelled to nucleate the assembly of other types of RNA granules. Alternatively, selected 
mRNPs might move from one type of granule to another, thus creating transient tethers 
between different granules. Figure was taken directly from P Anderson and N Kedersha., 
Nat. Rev. Mol. Cell Biol., 10, 430-436 (Jun 2009). 
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Table 1-4 Selected SG-associated proteins and their cellular properties 
 
 
 
 
 
 
 
Table was taken directly from P Anderson and N Kedersha., Trends Biochem. Sci., 33, 
141-150 (Mar 2008). 
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Figure 1-14 mRNA sorting model for PBs and SGs (A) Proteins found exclusively 
in SGs are shown in yellow; proteins found in both SGs and PBs are depicted in green; 
and proteins restricted to PBs are shown in blue type; PB formation model. Figure 
was taken directly from N Kedersha et al., J. Cell Biol., 169, 871-884 (Jun 2005).  (B) 
In human cells, Hedls and GW182 contain putative Q/N-rich prion-like domains 
(indicated by red tails), which might promote PB formation in cooperation with or 
independently of Edc3 or Lsm4. It is possible that the assembly of PBs containing a 
heterogeneous pool of mRNPs requires that a subset of PB mRNPs recruit multiple 
assembly complexes, which serve as scaffolds for assembly with mRNPs containing 
single-assembly complexes as indicated by arrows. Alternatively, assembly domains 
may form heterologous inter- actions (e.g., between Hedls and GW182) to assemble 
heterogeneous PBs. Figure was reproduced from TM Franks and J Lykke-Andersen., 
Mol. Cell., 32, 605-615 (Dec 2008). 
 
(A) 
 
 
 
(B) 
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Figure 1-15 The model of P-body functions in mRNA cell cycle in mammals. A 
schematic model of P-body functions in mRNA cell cycle in mammals. (i) Two-step 
deadenylation of pre-mRNAs. First step results in RNPs remodelling that promotes 
the transition of mRNPs into a nontranslatable state. The second step involves two 
ways of further processing of the remodelled mRNPs: one way relies on a decay in 
cytoplasm (5′-3′) or in exosome (3′-5′), whereas another way, on storage or 
degradation (5′-3′ decay) after entering the P-body. (ii) Degradation of aberrant RNA 
(e.g. incorrectly spliced) engages the NMD (nonmediated decay) machinery. (iii) 
Once targeted into P-body, the RNA can be either repressed in translation, degraded 
via the 5′-3′ decay or stored for further usage. miRISC, miRNA-induced silencing 
complex; Ago1, Argonaute protein 1; Rck/p54, DExD/H-box helicase; Dcp, 
decapping protein; EDC3p, enhancer of mRNA decapping; GW182, glycine (G)-
tryptophan (W)-containing bodies; RNP, ribonucleoprotein; UPF1, up-frameshift 1; 
XRN1p, 5′-3′ exonuclease: Fas-activated serine/threonine phosphoprotein. This figure 
was reproduced from M Olszewska et al., Cell Biochem Funct., 30, 177-182 (Apr 
2012). 
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Figure 1-16 Mechanisms of mRNA decay (A) a | Most mRNAs undergo decay by 
the deadenylation dependent pathway. The poly(A) tail is removed by a deadenylase 
activity, shown here as either CCR4–NOT or PARN. Following deadenylation, two 
mechanisms can degrade the mRNA: either decapping followed by 5′→3′ decay or 
3′→5′decay. In the decapping pathway, the Lsm1–7 complex associates with the 3′ 
end of the mRNA transcript and induces decapping by the DCP1–DCP2 complex. 
This leaves the mRNA susceptible to decay by the 5′→3′ exoribonuclease XRN1. 
Alternatively, the deadenylated mRNA can be degraded in the 3′→5′ direction by the 
exosome, with the remaining cap structure being hydrolysed by the scavenger-
decapping enzyme DcpS. b | In Saccharomyces cerevisiae, deadenylationindependent 
pathways require recruitment of the decapping machinery. Here, Rps28B interacts 
with enhancer of decapping-3 (Edc3) to engage the decapping enzyme. Following 
decapping, the mRNA is degraded by Xrn1. c | Endonuclease-mediated mRNA decay 
initiates with internal cleavage of the mRNA, which generates two fragments each 
with one unprotected end. The fragments are degraded by XRN1 and the exosome. 
This figure was reproduced from NL Garneau et al., Nat. Rev. Mol. Cell Biol., 8, 113-
126 (Feb 2007). (B) Map of the exosome's cellular functions and cofactors. This 
figure was reproduced from A Chlebowski et al., Biochim. Biophys. Acta., 1829, 
552-560 (Jun-Jul 2013). 
(A) 
 
  
            
(B) 
 
 
 
 
 
Large and small arrows denote interaction 
and functional involvement, respectively. 
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Table 1-5 Exosome components and cofactors 
 
 
 
 
 
         Exosome components and co-factors* 
 
 
Table was taken directly from M Schmid and TH Jensen. Trends biochem. Sci., 10, 
501-510 (Oct 2008).  
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Chapter 2    Hypothesis and Aims 
 
2.1.   Background to the study 
Atherosclerosis is a dynamic and progressive disorder of arteries, which is initiated by 
endothelial cell (EC) and macrophage dysfunction. During studies on the molecular 
basis of EC and macrophage dysfunction, our laboratory has discovered that PARP-
14 is an inducible protein in these cells, being upregulated by bacterial 
lipopolysaccharide (LPS), proinflammatory cytokines (TNFα, IL-1α, IFNγ), and, in 
the case of EC, by sustained laminar shear stress (LSS) (unpublished data). Moreover, 
using a panel of green fluorescent protein (GFP) fusion proteins, PARP-14 was found 
to localise in focal granules in the cytoplasm, and the region critical for this was 
contained in a fragment consisting of the C-terminal Macro domain and WWE 
domain (unpublished data). Lastly, either PARP-14 siRNA knock-down in human EC 
or peripheral blood-derived macrophages or deficiency of PARP-14 in mouse bone-
marrow-derived macrophages led to an increase in the stability of the 
proinflammatory chemokine IP-10 mRNA following IFNγ or TNFα stimulation 
(unpublished data). Taken together, these observations were consistent with a role in 
regulating RNA turnover. 
 
2.2.   Hypothesis 
Based on the pilot data, we hypothesised that in addition to the role outlined above 
(Section 1.2) that PARP-14 plays as a repressor/coactivator of Stat6-mediated 
transcription; it also functions in the cytoplasm as a regulator of cytokine-driven 
mRNA transcripts.  We propose that this putative function depends critically on 
interactions with other RNA-associated proteins and/or RNA.    
 
2.3.   Aims 
We proposed that the putative cytoplasmic functions of PARP-14 might be clarified if 
the binding partners of PARP-14 are revealed.  The project had three sub-aims, which 
were: 
 
I. To use yeast two hybrid screening to detect potential binding partners of 
PARP-14 (Chapter 3). 
 
II. To use confocal microscopy to observe collocalisation of PARP-14 with main 
components of cytoplasmic RNA granules (Chapter 4). 
 
III. To use Co-IP technique to verify possible protein associations with PARP-14 
(Chapter 5).    
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Chapter 3    Results I: Yeast two-hybrid screening 
 
3.1.   Introduction 
Work in the laboratory has suggested that PARP-14 may play a role in regulating 
macrophage and endothelial activation via regulating mRNA transcripts. The present 
work set out to explore intracellular binding partners of PARP-14 using yeast two-
hybrid (Y2H) screening. The precise origins of the work described in the thesis derive 
from an unpublished experiment performed by Dr. Michael Johns, and illustrated in 
Figure 3.1. Full-length PARP-14 as well as a number of PARP-14 domain constructs 
were fused with GFP and transfected into Hela cells. Cytoplasmic fluorescent 
granules were observed with full-length PARP-14-GFP, Macro1-Macro2-Macro3-
WWE-GFP and Macro3-WWE-GFP, whereas a diffuse pattern was observed when 
the cells were transfected with N-terminal PARP-14-GFP, Macro3-GFP, WWE-GFP, 
WWE-PARP-GFP, PARP-GFP or GFP alone. The minimal construct that formed 
granules therefore stretched from the Macro3 to the WWE domain. It was, therefore, 
decided to perform a Y2H screen to identify proteins interacting with this region.  An 
introduction to Y2H is given in Chapter 1.3 above.  
3.2.   Methods and materials 
The components of yeast two-hybrid screening were bought from Clontech-Takara 
Bio Europe, France. The details of the yeast two-hybrid components can be found in 
the sections of the list of components in MatchmakerTM Gold Yeast Two-Hybrid 
System User Manual and YeastmakerTM Yeast Transformation System 2 User Manual. 
(http://www.clontech.com/GB/Products/Protein_Interactions_and_Profiling/Yeast_T
wo-Hybrid/Matchmaker_Gold_Yeast_Two-Hybrid_System?sitex=10030:22372:US). 
Of note, all the experiments relating to yeast two-hybrid screening were only 
performed once.   
3.2.1.   Western blotting 
The equipment for gel electrophoresis was bought from Invitrogen. The reagents for 
SDS-PAGE performed in this chapter were NuPAGE® 4-12% Bis-Tris Gel 
(NP0321PK2) with MES Running Buffer (NP0002) and NuPAGE® transfer buffer 
(NP0006) from Invitrogen. Immobilon-PSQ Membrane, PVDF, 0.2µm (ISEQ00010) 
from Merck Millipore was used as a transfer membrane during the transfer process of 
Western blotting. After the transfer process, the membrane was blocked by incubating 
in 5% skimmed milk with PBS for 1 hour (hr) at room temperature, followed by 
primary antibody incubation overnight at 4°C. Blots were then washed three times, 
each for 10 minutes, and then incubated with secondary antibody for 1 hr at room 
temperature. After the antibody incubations, the membrane was washed three times as 
before. The target proteins were then visualised using Amersham ECL Western 
blotting detection reagents (RPN2106, GE Healthcare), Kodak BioMax light 
Chemiluminescence film (Z370398-50EA, Sigma-Aldrich), and Kodak X-OMAT 
film processor. 
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3.2.2.   Control mating experiment 
A control mating was performed to establish the procedure of Y2H. Using the 
Yeastmaker Yeast Transformation System 2 (Clontech-Takara Bio Europe, France), I 
performed transformations and generated Y2HGold with the plasmids pGBKT7-53 
and pGBKT7-Lam and Y187 with the plasmid pGBADT7-T. Y2HGold (pGBKT-53 
and pGBKT7-Lam) and Y187 were then cultured on SD/-Trp and SD/-Leu for 3 days, 
respectively. After 3 days culture, Y2HGold (pGBKT7-53) was mated with Y187 as a 
positive control mating and Y2HGold (pGBKT7-Lam) was mated with Y187 as a 
negative mating. The mated yeasts were then plated on 100mm single (drop-out Trp 
or Leu) drop-out (SDO) agar plates, double (drop-out both Trp and Leu) drop-out 
(DDO) agar plates, and double drop-out agar plates with X-α-Gal (5-Bromo-4-chloro-
3-indolyl-α-D-galactopyranoside) and AbA (Aureobasidin A), and cultured at 30°C 
for 3 days. 
3.2.3.   Cloning and testing bait for autoactivation and toxicity 
3.2.3.1.   Generation of a bait clone 
Since PARP-14 is a large protein with several domains, I decided to narrow the aims 
of the Y2H by using as bait the stretch of cDNA encoding Macro-3 and the WWE 
domain, which had been found to be sufficient for localization of a GFP-fusion 
protein to cytoplasmic granules (see Figure 3.1). The details of primers and PCR 
conditions for generating the bait clone can be found in the sections of generate a bait 
clone in MatchmakerTM Gold Yeast Two-Hybrid System User Manual. Briefly, the 
forward and reverse primers were 5’-C ATG GAG GCC GAA TTC 111 222 333 444 
555 666 777 888 and 5’-GC AGG TCG ACG GAT CC LLL NNN NNN NNN NNN 
NNN NNN NNN, respectively (of note, 111 stands for the first codon of the bait and 
LLL stands for reverse complement of last codon of the bait). The bait was amplified 
by the primers at 37°C for 15 minutes, then at 80°C for 15 minutes in a PCR thermal 
cycler. The PCR product of the cDNA fragment encoding the Macro-3 + WWE 
together with a c-myc tag was ligated into pGBKT7 vector to create the bait plasmid 
DNA for the study. The DNA was then transformed into Y2HGold yeast cells. The 
transformed yeast cells were plated on YPDA agar plates to form the bait clone. Of 
note, the bate clone contains AUR1-C gene, controlled by M1 promoter, which 
encodes the enzyme inositol phosphoryl ceramide synthase. The expression of AUR1-
C confers strong resistance to the otherwise highly toxic drug Aureobasidin A.    
3.2.3.2.   Detection of bait expression 
The urea/SDS method was adopted to extract the yeast protein of interest. Briefly, the 
frozen transformed yeast cells were broken with vigorously vortex and 60°C pre-
warm cracking buffer with glass beads; then aqueous-insoluble proteins in the 
transformed yeast cells were solubilized by using urea/SDS cracking buffer. The 
supernatant was collected and was analyzed by western blotting. Of note, the cracking 
buffer contains 8M urea, 5% w/v SDS, 40mM Tris-HCl (pH6.8), 0.1mM EDTA, and 
0.4mg/ml Bromophenol blue.   
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3.2.3.3.   Autoactivation test and toxicity test 
Overnight cultures (5ml) of a bait clone and a Y2HGold clone with pGBKT7-p53 
(positive control) were diluted and then 100 µl of a 1/10 and 1/100 dilution culture 
were spread onto SD/-Trp (Single drop-out of Trp, SDO) agar plates, SDO/X-α-Gal 
agar plates, and SDO/X-α-Gal/AbA agar plates. These plates were then culture at 
30°C for 3 days. The positive control clone from the control mating was also applied 
and was plated on a DDO/ X-α-Gal/AbA agar plate as comparison. 
3.2.4.   Two-hybrid library screening using yeast mating 
3.2.4.1.   DDO/X/A 
The bait yeasts were mated with Y187 yeasts pre-transformed with normalized 
universal human cDNA library (Clontech) for 10 hours in 2x YPDA liquid medium 
with 50µg/mL kanamycin and then the mated culture was plated on 150mm DDO/ X-
α-Gal/AbA agar plates. These plates were cultured at 30°C for 4-6 days. 
3.2.4.2.   QDO/X/A 
Following 4-6 days culture on 150mm DDO/ X-α-Gal/AbA agar plates, the blue yeast 
colonies were patched onto QDO/X-α-Gal/AbA agar plates (Quadri-drop-out (QDO) 
agar plate which drop out Ade, His, Leu, and Trp). These plates were cultured at 30°C 
for 4-8 days. 
3.2.5.   Rescue and sequencing of the prey plasmids 
3.2.5.1.   Rescue and isolation of library plasmid responsible for 
activation of reporters 
After 4-8 days culture on QDO/X-α-Gal agar plates, blue yeast patches were 
scratched away from the plates and re-streaked on DDO/ X-α-Gal agar plates for 4-6 
times to ensure that activators could be isolated. 
3.2.5.2.   Sequence 
When approximately 90% of the colonies on DDO/ X-α-Gal agar plates were blue, 
one blue yeast colony was sampled for sequencing. We adopted Matchmaker AD LD-
Insert Screening Amplimer Set (630433, Clontech) to prepare and amplify cDNA 
from the blue yeast colony, followed by using T7 sequencing primer for sequencing. 
The sequencing was done by the genomics laboratory at Clinical Science Centre 
(Hammersmith Campus, Imperial College London). 
3.2.6.   Hela cell transfection and confocal microscopy 
Hela cells were co-transfected with Macro-3+WWE-GFP and Cox11-DDK with 
Lipofectamine® 2000 transfection reagent for 8 hr, followed by 4% PFA 
(Paraformaldehyde) fixation in PBS, 0.5% TritonTM X-100/PBS permeabilization, and 
then incubating with anti-DDK (clone 4C5) antibody (TA150022, DyLight 550 
conjugated, 1:1000) and TO-PRO®-3 Iodide (1:1000) in 3% human serum albumin 
(HSA) for 1 hr at RT (room temperature). After the antibody incubation, washed three 
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times with PBS and then the samples were ready for the observation by confocal 
microscopy. Of note, TO-PRO®-3 Iodide, a carbocyanine monomer nucleic acid stain 
with far-red fluorescence similar to Alexa Fluor® 647 or Cy®5 dyes, was used to stain 
the nucleus in this thesis. A Zeiss LSM510 confocal microscope with 63x Plan-
Apo/1.4 NA Oil with DIC capability was used for assessing colocalization of Cox-11-
DDK with Macro-3+WWE-GFP (Chapter 3), PARP-14-GFP fusion proteins (Chapter 
4) or immunostained PARP-14 (Chapter 4) with components of RNA granules. 
Before using the confocal microscope, LSM510, a software that control the 
microscope, was used for switching on the lasers, adjusting brightfield Köhler 
illumination, setting up image scanning mode and configurations. In this chapter, all 
the images were taken under multi track mode in order to avoid each fluorophore 
crosstalk. Following adjusting the settings of the microscope, we used scan function 
to find the cells, followed by adopting “Fast XY scan” in actual focus plane and then 
using “Single” to start a scan with all configured scan control options. Once an image 
was taken, the criteria used for colocalization were that the colocalization could be 
observed in more than a single cell in the image and the colocalization size and shape 
between two proteins were almost identical. More details of Hela cell 
culture/transfection can be found in 4.2.3 and 4.2.4.    
3.3.   Results 
3.3.1.   Control experiment 
Theoretically, if a yeast cell harbours the plasmids of Gal4 DNA-BD fused with 
murine p53 (pGBKT7-p53) and Gal4 AD fused with SV40 large T antigen 
(pGADT7-T), the yeast cell will survive on a DDO/X-α-Gal/AbA agar plate and the 
MEL1 and AUR1-C reporter genes will be triggered. Practically, if a yeast harbors 
both plasmids and it is cultured on a DDO agar plate or on a DDO/X-α-Gal/AbA agar 
plate, similar number of colonies will result, although fewer colonies may be 
observed on the DDO/X-α-Gal/AbA agar plate due to the greater selection pressure. 
On the other hand, if a yeast cell harbours the plasmids of Gal4 DNA-BD fused with 
lamin (pGBKT7-Lam) and pGADT7-T, the yeast cell will survive on a DDO agar 
plate but will not survive on a DDO/X-α-Gal/AbA agar plate. Table 3-1 shows that 
the number of positive control mating on DDO agar plate is similar to the number of 
blue positive clones on DDO/X-α-Gal/AbA agar plate. In contrast, the negative 
control mating only survived on the DDO agar plate. These results indicated that the 
positive control yeast and the negative control yeast had been transformed correctly 
and that the reporter genes of MEL1 and AUR1-C had been triggered in the positive 
control mating. 
3.3.2.   Demonstration of expression of the bait (Macro-3 + WWE) 
If the bait protein (Gal4 DNA BD fused to Macro-3 + WWE, Figure3-2A) is 
expressed in Y2HGold, the molecular weight (M.W.) of the protein should be 
approximately 65 kDa. As shown in Figure 3-2B, a 62 kDa protein was detected with 
c-Myc antibody (dilution ratio, 1:200) and the M.W. of the positive control (Y2HGold 
[pGBKT7-p53]) was detected correctly (57kDa), which suggested the bait protein was 
expressed correctly. 
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3.3.3.   The result of autoactivation and toxicity testing 
Lack of activation of the reporter genes without the presence of prey and lack of 
toxicity of the bait protein need to be investigated before the experimental mating 
experiment. Theoretically, if the expression of the bait protein is not toxic to yeast, the 
number of bait colonies should be similar to the number of positive colonies 
(Y2HGold [pGBKT7-p53]). In addition, the colour of the bait colonies on SDO/X-α-
Gal should be white and no bait colony should grow on SDO/X-α-Gal/AbA without 
the presence of prey. As shown in Table 3-2, expression of the bait protein was not 
toxic to yeasts and there was no autoactivation effect of prey on reporter gene 
expression. 
3.3.4.   Modification of the mating experiment 
According to the Clontech Y2H manual, the mating time suggested is 20-24 hours. 
However, we found the suitable time frame is shorter. Briefly, a small scale mating 
experiment was performed and the mating efficiency (percentage of diploids, the 
calculation formula can be found in MatchmakerTM Gold Yeast Two-Hybrid System 
User Manual) as well as the number of clones were evaluated. Figure 3-3 shows that 
the mating efficiency and the number of colonies reached the highest values when the 
mating time decreased to 8-10 hours. However, in the figure, the mating efficiency 
would have decreased approximately 50% if the mating time had been fixed to 20-24 
hours. Moreover, when the mating time was 10 hours, according to the fitting curve, 
the mating efficiency reached the highest value and the number of clones was in a 
plateau state. Thus, 10 hours was used as the mating time in the following experiment. 
3.3.5.   The macro-3 + WWE mating result 
Following 10 hours mating and 4-6 days culture on DDO/X-α-Gal/AbA agar plates, 
12.88 million yeast clones were screened and the mating efficiency reached 7.27%. 
Among these 12.88 million colonies, 92 yeast clones on DDO/X-α-Gal/AbA agar 
plates showed blue colour and therefore potential expression of proteins interacting 
with Macro-3 + WWE. After low stringency selection on DDO/X-α-Gal/AbA agar 
plates, these 92 candidates were then selected with high stringency agar plates 
(QDO/X-α-Gal/AbA agar plates). Due to higher selection pressure on QDO/X-α-
Gal/AbA agar plates, 81 colonies out of 92 candidates were further screened out.   
Thus, the potential candidates were further reduced to 11 colonies. 
3.3.6.   The sequence analysis of the hits 
NCBI databases including BLAST and PubMed were used to align each hit sequence 
and to search their possible functions. The results were listed in Table 3-3. 
Sequencing of the 11 clones gave 5 potential hits that can be categorized into two 
separate groups. Among these five potential hits, three out of five were protein hits. 
These two groups will be discussed in the following sections.     
3.3.6.1.   Possible traditional protein-protein interactions 
Only three hits were of coding sequences, consistent with traditional protein-protein 
interactions. The identities of these three hits were cytochrome c oxidase subunit 11 
(Cox11), gap junction protein, epsilon 1, 23kDa (Cx23), and hCG1983077.  
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Cytochrome c oxidase (Cox) complex has 13 different subunits and they has been 
implicated in the stabilization of the mitochondrial membrane potential (Li et al., 
2006). Dysfunctional Cox in cells results in impairing mitochondrial membrane 
potential, which, in turn, decreases the level of ATP, followed by leading cells to 
apoptosis (Li et al., 2006). The region of Cox11 putatively interacting with PARP-14 
Macro-3 + WWE was part of the most conserved domain, CtaG_Cox11. We adopted 
a confocal technique as a preliminary test to identify the possibility of the interaction. 
Theoretically, Cox11 should colocalise with Macro-3 + WWE if the interaction is 
genuine. We purchased a DDK-tagged ORF clone of Homo sapiens Cox11 
(RC203238, Origene) and co-transfected this with Macro-3 + WWE-GFP into Hela 
cells with Lipofectamine® 2000 (11668-027, Invitrogen) for 8 hours. Localisation of 
the two proteins was then visualized under confocal microscopy. Figure 3-4 shows 
that no colocalization was observed. As this reduced the chance that the interaction 
was relevant, we decided not to pursue further work on Cox11.     
 
A recent research paper has shown that overexpression of mouse Cx23 in Hela cells 
leads to ATP release (Sonntag et al., 2009) and ATP seems to be required for 
downstream events in apoptosis (Green and Reed, 1998). However, judging from the 
NCBI protein database, Cx23 has no confirmed existence as a protein in human and 
no commercially available antibody exists. We therefore decided not to investigate 
this hit further.   
 
hCG1983077 was another protein hit. The function of this protein is not clear and the 
existence of this protein has not confirmed yet. We therefore decided not to 
investigate this hit further.  
 
3.3.6.2.   Possible protein-RNA interactions 
In the case of two hits, the regions of the prey cloned by the Y2H were 3’UTR rather 
than coding sequences. The identities of these were protein kinase, cAMP-dependent, 
regulatory, type I, alpha (PRKAR1A) and transmembrane emp24 protein transport 
domain containing 7 (TMED7). Table 3-3 shows the repeatability of these five hits in 
the eleven-hit pool.  There was high repeatability of the protein-RNA binding (4 times 
for TMED7). Although unusual, it is tempting to speculate that these hits are genuine. 
This is discussed further below.  
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                      Data provided by Dr. Michael Johns 
 
 
 
Figure 3-1 Cellular distribution of PARP-14-GFP and GFP tagged truncated 
PARP-14 domains. GFP fusion constructs were transfected into Hela cells for 8 
hours, followed by 4% PFA fixation and observation with Zeiss LSM510 confocal 
microscope. TO-PRO®-3 Iodide was used for nuclear staining. Full-length PARP-14-
GFP (Full-length-GFP), M1-3-WWE-GFP, M3-WWE-GFP formed cytoplasmic 
granules, whereas PARP-GFP, WWE-GFP, M3-GFP, GFP alone, WWE+PARP-GFP, 
and N-terminal PARP-14-GFP (N-terminal-GFP) exhibited a diffuse distribution. The 
non-transfected Hela cells acted as a negative control. 
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Table 3-1 Control mating experiment. 
 
 
 
 
 DDO DDO/X/A 
Yeast Dilution ratio 1/10 1/100 1/1000 1/10 1/100 1/1000 
Number of Positive 
control colonies 
51 2* 1 42# 1 0 
Number of Negative 
control colonies 
1** 0** NA NA NA NA 
 
 
*: A few tiny colonies around a large colony.  
**: Many tiny colonies. 
#: 33 colonies are blue and 8 colonies are white. 
 
NA: Not applicable 
 
Y2HGold [pGBKT7-p53] mated with Y187 [pGBADT7- T] as positive control 
mating and Y2HGold [pGBKT7-Lam] mated with Y187 [pGBADT7-T] as negative 
control mating. The positive control mating and negative control mating were then 
streaked onto DDO agar plates and DDO/X/A agar plates with the dilution ratio of 
1/10, 1/100, and 1/1000. These agar plates were then cultured at 30°C for 3 days. 
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Figure 3-2 The detection of the bait (Macro-3 + WWE) expression with western 
blot analysis. The transformed Y2HGold [pGBKT7-Macro-3 + WWE] (A) and 
Y2HGold [pGBKT7- p53] (positive control) were lysed with cracking buffer 
(Clontech) and the cell lysate was electrophoresed and the proteins were then 
transferred to a blot. The blot was probed with c-Myc antibody (dilution ratio was 
1:200). The theoretical M.W. of Y2HGold [pGBKT7-Macro3/WWE] and Y2HGold 
[pGBKT7-p53] are 65 KDa and 57 KDa, respectively (B).  
 
 
(A) 
 
(B) 
 
 
M3/WWE    Positive 
                    Control 
188 
 
 
98 
 
 
62 
 
49 
 
 
38 
 
 
28 
 
 
57kDa 
65kDa 
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Table 3-2 Autoactivation and toxicity test for the bait protein expression. 
 
 
 
 
 pGBKT7-BD-P53 
1/100 
pGBKT7-BD-M3/WWE 
1/100 
SDO 1489 (White) 1277 (white) 
SDO/X  1514 (white) 
SDO/X/A N/A 
 
 
Y2HGold [pGBKT7- Macro3/WWE] was spread onto SDO, SDO/X, and SDO/X/A 
agar plates and Y2HGold [pGBKT7-p53] was spread onto SDO agar plate with the 
dilution ratio of 1/100. These plates were cultured at 30°C for 3 days. 
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Figure 3-3 The mating time adjustment. Y2HGold [pGBKT7-Macro-3 + WWE] 
was mated with Y187 with normalized human cDNA library. The OD600 was 
measured at 4 hours, 5 hours, 8 hours, 17 hours, 19 hours, 21 hours, and 24 hours 
after the mating experiments started. The number of screened colonies (A) and the 
mating efficiency (B) were calculated.  
 
 
 
(A) 
 
(B) 
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Table 3-3 The re-occurrence of the five hits.  
 
 
 
 
The name of the 
hits 
The region of the 
sequence 
Number 
of 
colonies 
Function 
Cox11 Coding region  
(35 a.a.-149 a.a) 
1 Cox11 may be an important 
docking motif for Cox1 or a 
Cox1-associated protein. 
Cox11 is important in the 
assembly of cytochrome c 
oxidase (CoO). 
Cx23 Coding region  
(133 a.a.-146 a.a.) 
4 Cx23 causes enhanced ATP 
release from HeLa cells 
hCG1983077 Coding region 
 (7 a.a.-16 a.a.) 
1 Unclear 
PRKAR1A 3’ UTR 
(2659 b.p.-3646b.p.) 
1 Involved in the activation of 
PKA 
TMED7 3’ UTR 
(2156b.p.-2727b.p.) 
4 bringing cargo forward from 
the ER 
 
 
In the sequence analysis and the blast results, it showed that some of the hits 
repeatedly occurred and the repeatability of the five hits were recorded. Of note, a.a. 
represents amino acid.  
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(A)                                                                      (B) 
 
 
 
 
(C)                                                                      (D) 
 
 
Figure 3-4 The colocalization of Macro-3+WWE-GFP and Cox11-DDK. 
Cotransfection of Macro-3 +WWE-GFP and Cox11-DDK (A); Cox11-DDK 
transfection only (B); Macro-3 +WWE-GFP transfection only (C); Mock transfection 
(D). TO-PRO®-3 Iodide was used for nuclear staining. The scale bar indicates the 
length of 10 µm in these images. These images represent three independent 
experiments (n=3).  
  
  
Nucleus 
Macro-3 + WWE-GFP 
Merge 
Cox11-DDK Cox11-DDK 
Nucleus 
Nucleus 
Merge 
Macro-3 + WWE-GFP 
Merge Merge Nucleus 
Macro-3 + WWE-GFP 
Macro-3 + WWE-GFP Cox11-DDK Cox11-DDK 
Nucleus Nucleus 
Merge Merge 
10 µm 
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3.4.   Summary and discussion 
3.4.1.   The optimization of the mating experiment 
When the mating of Y2HGold [pGBKT7-Macro-3 + WWE] with the normalized 
human cDNA library was for 20-24 hours, the mated yeast cells hardly survived on 
QDO/X-α-Gal/AbA agar plates, which implied the condition of mating yeast cells 
may not be sufficient to overcome the selection pressure. By performing an 
optimization of mating time experiment, we found that the mating efficiency at 10 
hours was twice that at 20-24 hours. The mating time was therefore decreased to 10 
hours in order to maximise detection of protein-protein interactions with active yeast 
cells. 
3.4.2.   The outcome 
3.4.2.1.   Protein-protein interactions 
Only three hits were of coding sequences (Cox11, Cx23 and hCG1983077). In the 
case of Cox11, we failed to show colocalisation with Macro-3 + WWE-GFP in Hela 
cells using confocal microscopy which did not encourage further work.  Furthermore, 
neither Cx23 nor hCG1983077 have confirmed existences as proteins in the human 
protein database. It remains possible that any one of these three hits could truly reflect 
an interaction with the bait. However we decided not to pursue them during the thesis 
work as to do so would have been too risky in the light of the time available for the 
project.   
 
It is of course possible, and even likely, that the Y2H screen failed to detect genuine 
protein binding partners of Macro-3 + WWE. There are many possible reasons for 
false negative results in Y2H screening, and these will be discussed in 6.1.1. 
3.4.2.2.   Possible RNA-protein interactions 
In traditional Y2H screening, Gal4 BD fused to bait protein must interact with Gal4 
fused to prey and the interaction between bait and prey brings binding domain and 
activation domain of Gal4 into proximity to trigger the downstream reporter genes. 
However, if 3’UTR of PRKAR1A or TMED7 can replace the function of activation 
domain in Gal4, the downstream reporter genes may still be activated. Saha et al., 
have indicated a set of RNA molecules that can act as transcription activators and 
they further propose possible loop structures in the RNA molecules which are 
responsible for this activation (Saha et al., 2003). Our bioinformatic analysis using 
RNAfold (a web-based server) (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi) 
showed the 3’UTR of PRKAR1A and TMED7 have similar loop structures, with 70-
80% similarity to proposed RNA transcription activators (data not shown). Whilst it is 
possible therefore that these hits were real, a deeper analysis of the mechanisms 
involved was felt to be beyond the remit of the project and we decided not to pursue 
them. 
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Chapter 4    Results II: Observations on 
cytoplasmic granules using confocal microscopy  
 
4.1.   Introduction 
As shown in Figure 3.1, the Macro-3 + WWE-GFP fusion protein localised to 
cytoplasmic granules in Hela cells, whereas Macro-3-GFP and WWE-GFP each had a 
diffuse distribution. We had initially interpreted the diffuse distribution of the Macro-
3-GFP and WWE-GFP constructs as due to their relatively small size giving them 
access throughout the cell. Following the negative results of the Y2H screen, we 
decided to investigate the sequence between the Macro-3 and WWE domains to see if 
a previously unrecognised structure could be identified that might account for 
cytoplasmic granular localisation of the Macro3 to WWE fragment.  
4.2.    Methods and materials 
4.2.1.   Cell activation stimuli 
Sodium arsenite and Lipopolysaccharide (LPS, from Escherichia coli 055:B5) were 
purchased from Sigma Aldrich. 
4.2.2.   Generation of PARP-14 constructs 
Invitrogen pENTRTM Directional TOPO Cloning Kits (K2400-20) and Vivid 
ColorsTM pcDNATM6.2/C-EmGFP-DEST (V355-20, Invitrogen) were used in the 
cloning work of this chapter. The various constructs studied are shown in Figure 4.1.   
Full-length PARP-14 in pENTR directional TOPO vector was provided by Dr. 
Michael Johns. This was used as a template and the primers in Table 4-1 were 
adopted to produce blunt-end PCR products, followed by TOPO® cloning into the 
pENTRTM TOPO® vector and transformation into One Shot® TOP10 E coli (C404050, 
Invitrogen). The transformed TOP 10 E coli (transformants) were cultured on 
kanamycin agar plates at 37°C overnight, after which 5 colonies were picked and 
cultured overnight in 100µg/mL kanamycin LB Broth (L7275-500TAB, Sigma-
Aldrich). After overnight culture in LB Broth, plasmid DNA was isolated from the 
transformants using a QIAprep Spin Miniprep Kit (27104, QIAGEN). Following 
isolation, plasmids were sequenced by using M13 Forward (-20) and M13 Reverse 
primers in the cloning kit. Once the correct sequence had been confirmed, a LR 
recombination reaction was performed using a Gateway® LR Clonase® II Enzyme mix 
(11791-020, Invitrogen) to produce the GFP construct. 
 
Macro-3 (M3)-WWEΔKH3-GFP and M1-3-WWEΔKH3-GFP were cloned by using a 
similar strategy (ΔKH3 represents KH3 deletion). M3 in pENTRTM TOPO® vector 
acted as a template. The primers in Table 4-1 were used to produce M3-WWEΔKH3 
(this PCR product contains the Macro3 domain followed by the first five amino acid 
of WWE domain but without the KH3 domain). We then used AvaI to digest M3-
WWE in pENTRTM TOPO® vector, followed by ligation of the PCR product and the 
digested vector to obtain M3-WWEΔKH3, again in pENTRTM TOPO® vector.  The 
approach was essentially the same to create M1-3-WWEΔKH3-GFP, except that M1-
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3 in pENTRTM TOPO® vector acted as the template. Once we had obtained these two 
constructs in the pENTRTM TOPO® vector, the LR recombination reaction was used 
to obtain M3-WWEΔKH3-GFP and M1-3-WWEΔKH3-GFP. 
 
KH1-GFP and KH2-GFP were provided by Dr. Michael Johns and the tyrosine 
mutated KH3-GFP constructs were generated by Mr. Niall Burke. 
4.2.3.   Hela and macrophage cell culture 
Hela cells were cultured in DMEM medium (12491-023, Invitrogen) with 10% fetal 
bovine serum (FBS, IBV-SER, InnovativeTM research) and 1% L-glutamine at 37°C 
and 5% CO2. When the cultured cells reached 90% confluence, they were passaged at 
8×104 cells/mL per well onto transparent cover slips (one cover slip per well) in a 24-
well plate (3524, Corning) and cultured overnight at 37°C and 5% CO2. Mouse bone 
marrow macrophages were provided by Dr. Michael Johns and Dr. M. Bilal Iqbal and 
passaged in a similar way. 
4.2.4.   Transfecting GFP construct 
Following overnight incubation on cover slips, cells were transfected with GFP 
constructs using Lipofectamine® 2000 transfection reagent (11668-027, Invitrogen). 
Basically, 0.8µg plasmid DNA was diluted with 25µL Opti-MEM® I Reduced Serum 
Medium (Opti-MEM) in Eppendorf A (the optimal dilution ratio having been 
previously determined) and 1.91µL Lipofectamine® 2000 transfection reagent was 
diluted with 25µL Opti-MEM in Eppendorf B. Following incubation for 5 min at 
room temperature, the contents of Eppendorf A and B were mixed and then incubated 
for another 20 min at room temperature to generate plasmid DNA-Lipofectamine 
complexes. During the 20 minutes incubation, the culture medium was removed from 
the 24-well plate and the plate was washed with PBS (Phosphate-Buffered Saline, 
10010-015, Invitrogen) three times, followed by addition of 450µL DMEM (with 1% 
L-glutamine but without FBS) per well. DNA-Lipofectamine complexes (50µL/well) 
were then added mixed gently. Cells were then incubated at 37°C in 5% CO2 for 3 
hours, after which 250µL medium per well was removed and replaced with 250µL 
DMEM medium with 20% FBS and 1% L-glutamine for culturing over another 5 
hours. After a total culture of 8 hours, the cells were ready for 500µM sodium arsenite 
treatment for 30 minutes or 1 µg/mL LPS treatment for 8 hours. Following treatment, 
the medium was removed from wells and the cells were washed three times with PBS, 
followed by addition of 4% paraformaldehyde (PFA; P6148-500G, Sigma-Aldrich) 
for cell fixation. 
4.2.5.   Antibodies 
Rabbit polyclonal PARP-14 antibody was provided by Dr. Michael Johns. It was 
generated by immunization of a rabbit with a peptide sequence 
(DKRNNGDPSDKNPKAED) between Macro2 and Macro3 domain, and was affinity 
purified on the immunizing peptide linked to sepharose. Other antibodies used in the 
study are listed in Table 4.2. 
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4.2.6.   Immunostaining 
Fixed cells were permeabilized with 0.5% TritonTM X-100 (T8787-100ML, Sigma 
Aldrich) in PBS for 15 min at room temperature, after which they were washed three 
times with PBS. They were then incubated overnight with primary antibodies in 3% 
human serum albumin (HSA) at 4°C. Cells were then washed three times with PBS 
and incubated with appropriate Alexa Fluor® -labelled anti-IgG and TO-PRO®-3 
Iodide (642/661) (T3605, Molecular ProbesTM, Invitrogen) (both at 1:1000 dilution) at 
room temperature for 1 hour. After further washing three times with PBS, cells were 
ready for observation by using confocal microscopy. 
4.2.7.   Confocal microscopy 
The confocal microscopy has been introduced in section 3.2.6.  
4.2.8.   Identification of lysosomes 
Lysosomes were identified using the CellLight® reagent (C10597, Invitrogen). The 
reagent is a modified baculovirus expressing a fusion construct of Lamp1 and red 
fluorescent protein (RFP). By using endocytotic entry and endosomal escape, the 
fusion construct moves to the nucleus where only Lamp1 peptide with RFP is 
expressed. Following the RFP fusion protein expression, the fusion protein targets 
cytosolic lysosomes, as the expressed Lamp1-RFP is one of the core components of 
lysosome. Hence, the lysosomes can be positioned. 
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Table 4-1 The primers used in the cloning work 
 
 
PCR product for 
TOPO® reaction 
Primer 
M3-KH3 CACCATGGGTGTGTATGAAATGAAGATTGGC 
CAATCGAACTCTCTTGATCATCGC 
KH3-WWE CACCATGGGCCAGCTTTCTTCCCAACAGTCTGTG 
CTTCATATCACTCCAGTGTGCAGG 
M3-WWE CACCATGGGTGTGTATGAAATGAAGATTGGC 
CTTCATATCACTCCAGTGTGCAGG 
KH3 CACCATGGGCCAGCTTTCTTCCCAACAGTCTGTG 
CAATCGAACTCTCTTGATCATCGC 
WWE CACCATGGCCAAAGAACAGGAATCCCGGGCA 
CTTCATATCACTCCAGTGTGCAGG 
Macro3 CACCATGGGTGTGTATGAAATGAAGATTGGC 
AGTCCCTTCTCTTTTCTTCATGTTG 
M3-WWEΔKH3 GTAAAACGACGGCCAGTCTTAAGCTCGGGCCCCAAA 
TAATGATTTTATTTTGACTGATAGTGACCTGTTCGTTGCA 
CGCGCATGTCCCCGGGATTCCTGTTCTTTGGCAGCTCCA 
GCTGCAGTCCCTTCTCTTTTCTTCAT 
M1-3 CACCATGGTCTTGGCCCCTGGCGT 
AGTCCCTTCTCTTTTCTTCATGTTG 
M1-3-KH3 CACCATGGTCTTGGCCCCTGGCGT 
CAATCGAACTCTCTTGATCATCGC 
M1-3-WWE CACCATGGTCTTGGCCCCTGGCGT 
CTTCATATCACTCCAGTGTGCAGG 
M1-3-WWEΔKH3 GTAAAACGACGGCCAGTCTTAAGCTCGGGCCCCAAA 
TAATGATTTTATTTTGACTGATAGTGACCTGTTCGTTGCA 
CGCGCATGTCCCCGGGATTCCTGTTCTTTGGCAGCTCCA 
GCTGCAGTCCCTTCTCTTTTCTTCAT 
 
 
Apart from Macro3-WWE and Macro1-Macro3-WWE, full-length PARP-14 in 
pENTR directional TOPO vector was used as a template in PCR cloning work. 
Macro3-KH3-WWE was used as a template for generating Macro3-WWE and 
Macro1-Macro3-KH3-WWE was adopted for producing Macro1-Macro3-WWE. The 
PCR reaction setting for the PCR cloning work was 95°C for 1 minute, followed by 
30 cycles of 94°C (30 seconds), 58°C (30seconds), and 72°C (90 seconds).  
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Figure 4-1 The diagram shows the GFP constructs that were made from the 
primers used in Table 4-1 and were used in this thesis. We used the primers listed 
in Table 4-1 to generate corresponding RCR products for TOPO® reactions, followed 
by LR reactions to transfer genes from Gateway® entry clones to the destination 
vector with GFP. From the diagram, the relative positions of different PARP-14 
domains are shown. Of note, in the following confocal images, we used M to 
represent Macro domain, followed by number1, number2, and number3 to represent 
Macro1, Macro2, and Macro3, respectively. We also used KH3Δ to represent KH3 
domain deletion in the GFP constructs. 
  
KH3 GFP 
WWE GFP 
Macro3 GFP 
Macro3 KH3 GFP 
Macro3 WWE GFP 
KH3 WWE GFP 
Macro3 KH3 WWE GFP 
Macro1 Macro2 Macro3 GFP 
Macro1 Macro2 Macro3 KH3 
M3-KH3-GFP 
 
KH3-WWE-GFP 
 
M3-WWE-GFP 
 
KH3-GFP 
 
WWE-GFP 
 
Macro3-GFP 
 
M3-WWEΔKH3-GFP 
 
M1-3-GFP 
 
M1-3-KH3-GFP 
 
M1-3-WWE-GFP 
 
M1-3-WWEΔKH3-GFP 
 
 
KH1-GFP 
 
KH2-GFP 
GFP 
Macro1 Macro2 Macro3 KH3 WWE GFP 
Macro1 Macro2 Macro3 WWE GFP 
KH1 GFP 
KH2 GFP 
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Table 4-2 Antibodies used for immunostaining and Co-IP, Alexa Fluor® -labelled 
secondary antibodies, and control IgG. 
 
Antibody for 
Immunofluorescence 
staining 
The species 
in which the 
antibody 
was raised 
Company Cat Number Dilution 
ratio 
eIF3η (N-20) Goat Santa Cruz sc-16377 1:100 
TTP (N-18) Goat Santa Cruz sc-8458 1:100 
TIA-1 (C-20) Goat Santa Cruz sc-1751 1:100 
EIF2C2/Ago2 Mouse Abnova H00027161-M01 1:50 
DCP1A Mouse Abnova H00055802-M06 1:25 
GW182 (4B6) Mouse Santa Cruz sc-56314 1:200 
LC3 Mouse NanoTools 0231-100/LC3-5F10 1:50 
Lamp1 (C-20) Goat Santa Cruz sc-8098 1:100 
hDcp1a (D-13) Goat Santa Cruz sc-22574 1:100 
GW182 (C-19) Goat Santa Cruz sc-47034 1:100 
EXOSC2 Rabbit proteintech 14805-1-AP 1:100 
Antibody for Co-IP     
eIF3η (N-20) Goat Santa Cruz sc-16377 1:100 
(WB) 
TTP Mouse Kennedy 
Institute of 
Rheumatolo
gy, Oxford, 
UK 
N/A 1:2000 
(WB) 
GFP(FL) Rabbit Santa Cruz sc-8334 N/A(used 
for 
capturing 
KH3-
GFP) 
GFP(B-2) Mouse Santa Cruz sc-9996 1:100 
(WB) 
Alexa Fluor® anti-
IgG 
    
Alexa Fluor®555 
Donkey Anti-Goat 
IgG 
Donkey Invitrogen A21432 1:1000 
Alexa Fluor®546 
Goat Anti-Mouse 
IgG 
Goat Invitrogen A11003 1:1000 
Alexa Fluor®488 
Donkey Anti-Rabbit 
IgG 
Donkey Invitrogen A21206 1:1000 
Control IgG     
Normal Rabbit IgG NA Santa Cruz sc-2027 N/A 
Normal Goat IgG NA Santa Cruz sc-2028 N/A 
  
WB stands for western blotting.  
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4.3.   Results 
4.3.1.   The region between the Macro-3 and WWE domains contains a 
KH domain 
Conserved domains in proteins are thought to be mediate protein interactions, nucleic 
acid binding, enzyme activity, and other important cellular processes (Malek and Haft, 
2001). To look more closely at the region between the Macro-3 and WWE domains, 
we used a web based domain and protein fold recognition server developed by Dr. 
Lawrence A Kelley at Imperial College London, designated PHYRE (Protein 
Homology/analogy Recognition Engine). This revealed that the predicted secondary 
structure of this region is highly homologous to the structure of the second and the 
third KH domains in the KSRP protein. The predicted structure (N- to C-terminal) of 
this region is αβ1α1α2β2β’α’, which is almost identical to a canonical KH domain 
(β1α1α2β2β’α’) (see Figure 4-2A). An important exception, however, is the absence of 
a normally-conserved GxxG loop between the α1 and α2 helices (Figure 4-2B), which 
is thought to be usually required for KH domain binding to RNA (Hollingworth et al., 
2012). Furthermore, we also used PHYRE to analyze the corresponding region in 
Mus musculus and Bos Taurus, and found that the topology of the degenerate KH 
domain in Homo sapiens is highly conserved (Figure 4-2C). Figure 4-2C shows that 
the topology of the degenerate KH domain in Homo sapiens (αβ1α1α2β2β’α’, α helix is 
in red and β strand is in Blue) is almost identical to those of the corresponding regions 
of these species. Therefore, we hypothesized that this degenerate KH domain might 
be involved in granule localization. 
4.3.2.   PARP-14 has three degenerate KH domains 
Further inspection of the PARP-14 domain structure revealed that in addition to the 
KH domain between Macro-3 and WWE, there are two further previously 
unrecognised KH domains between the RRM domain and the Macro-1 domain.  
These were designated KH1 and KH2 and the KH domain between Macro-3 and 
WWE was designated KH3. 
4.3.3.   KH3 localises to cytoplasmic granules 
To test whether KH3 localises to cytoplasmic granules, we cloned several GFP fusion 
constructs with and without KH3, transfected them into Hela cells, and observed their 
distribution by confocal microscopy.  We found that any construct with the KH3 
domain formed granules, whereas the constructs without KH3 exhibited diffuse 
patterns. For example, KH3-GFP, KH3-WWE-GFP, M3-KH3-GFP, and M1-3-KH3-
GFP demonstrated granular patterns. On the other hand, M3-WWEΔKH3-GFP, M1-
3-WWEΔKH3-GFP, and M1-3-GFP showed diffuse patterns (Figure 4-3). From this 
we concluded that KH3 is sufficient for granule localization, and is necessary for the   
granule localization of the Macro-1 to WWE fragment. 
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(B) 
 
 
 
 
Continued… 
 
The rectangle area is the region where 
GxxG is missing and the green arrow 
indicates the potential phosphorylation 
site (Tyr)    
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Figure 4-2 The predicted structure of conserved degenerate KH domain between 
the Macro-3 and WWE domains of PARP-14. We used the PHYRE server to 
predict the 3-D structure of the degenerate KH domain. The 3-D diagram coloured by 
rainbow (the rainbow colours indicates the direction from C-terminal (red) to N-
terminal (blue)) revealed with high confidence the structure of a degenerate KH 
domain, which is highly homologous to the structure of the second and the third KH 
domains in KSRP (A); From the PHYRE analysis, the topology of the degenerate KH 
domain is αβ1α1α2β2β’α’ and the software also demonstrated the confidence score of 
the secondary structure in rainbow colours (from 0 to 9) and the disorder region of the 
structure (B); Again using PHYRE, we found that the secondary structure of the 
degenerate KH domain in human is conserved in Mus musculus and Bos Taurus. The 
red regions represent α helix and the blue regions stand for β strand (C). 
 
 
 
 
 
The secondary structure of KH3 in Homo sapiens 
The secondary structure of KH3 in Mus musculus 
The secondary structure of KH3 in Bos taurus 
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Figure 4-3 The PARP-14 KH3 domain localises to granules. GFP-tagged truncated 
PARP-14 with and without KH3 were transfected into Hela cells. KH3-GFP, KH3-
WWE-GFP, M3-KH3-GFP, and M1-3-KH3-GFP displayed granular patterns, 
whereas M1-3-GFP, M3-WWEΔKH3-GFP, and M1-3-WWEΔKH3-GFP 
demonstrated a diffuse distribution. In all cases, GFP is in green and the nucleus 
staining by TO-PRO®-3 Iodide (642/661) is in purple. These observations show that 
the KH3 domain plays a pivotal role in granule localisation of Macro1 to WWE 
fragment. ΔKH3 stands for KH3 deletion; M1-3 represents the region from Macro1 to 
Macro3 and M3-WWEΔKH3-GFP represents the region from Macro3 to WWE with 
KH3 is deleted. The scale bars indicate the length of 10 µm in these images. All 
images are representative of three independent experiments (n=3). 
 
KH3-GFP 
 
KH3-WWE-GFP 
 
M3-KH3-GFP 
 
M1-3-GFP 
 
M1-3-KH3-GFP 
 
M3-WWEΔKH3-GFP 
 
M1-3-WWEΔKH3-GFP 
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4.3.4.   KH3 preferentially localises to cytoplasmic granules compared 
to KH1 and KH2 
We next directly compared the relative capacities of KH1-GFP, KH2-GFP and KH3-
GFP to localise to cytoplasmic granules. To ensure that observed differences in 
distribution of the three constructs was not a function of amount of transfected DNA, 
a range of plasmid doses (0.2μg to 1.8μg) was used for transfection of Hela cells. 
Compared to KH3, KH1-GFP and KH2-GFP showed diffuse distributions as each of 
the DNA doses (Figure 4-4). These observations therefore suggest that KH3 has a 
specific capacity to localise in granules and this is not shared by KH1 and KH2. 
Based on this dose-response experiment, 0.8μg KH3-GFP was judged to be optimal 
for further transfection experiments. 
4.3.5.   Importance of 1457Tyr for KH3 function   
From the amino acid sequence of the KH3 in PARP-14, we found that a potential 
phosphorylation site (1457Tyr) is situated in the position between two α-helixes 
normally occupied in KH domains by the conserved GxxG loop which recognises 
RNA (Figure 4.2B). As protein-protein interactions are commonly regulated by 
phosphorylation, we tested the effect of mutating the KH3 domain with non-
phosphorylatable (alanine, A) or pseudo-phosphorylated  (aspartate, D) amino acid at 
this tyrosine residue. Following transfection into Hela cells, the nonphosphorylation 
KH3 1457YA-GFP showed normal localization to granules (Figure 4-5). In contrast, 
transfection of the phosphomimetic 1457YD mutant led to cell death (Figure 4-5). Of 
note, after 4 hours transfection of the phosphomimetic 1457YD mutant, a dramatic 
drop in cell density occurred with the presence of a lot of cell debris.  However, cell 
death was not formally measured in this study. The possible reason of this 
observation could be based on the phosphomimetic 1457YD mutant was unstable. 
Whilst this observation suggests that the 1457Y residue is functional, time 
considerations prevented us studying it further. 
4.3.6.   Immunostaining of cells transfected with KH3-GFP to identify 
the nature of the granules 
We next used a panel of antibodies to try to define the nature of the granules to which 
the KH3-GFP construct localises. Experiments were performed with unstimulated 
cells, and also with cell stimulated with sodium arsenite to stimulate stress granule 
(SG) formation. In a preliminary experiment, the dose of sodium arsenite was titrated, 
and SGs identified after 30 min by immunostaining with anti-eIF3η. As shown in 
Figure 4-6, SGs were observed at concentrations of sodium arsenite of 250µM or 
above. With 500µM sodium arsenite stimulation, distinct SGs could be observed in 
almost every cell. Distinct SGs could be no longer be distinguished when the 
concentration of sodium arsenite was 1000µM (Figure 4-6). We concluded that 
sodium arsenite should be used at a concentration of 500µM in further experiments.  
In addition to sodium arsenite, LPS (1 µg/ml) was used as a canonical 
proinflammatory stimulus that activates NFκB-mediated gene transcription. For 
example, increases in IL-8 and TNF-α steady-state mRNA expression are induced in 
an NF-κB-dependent manner when Hela cells are treated with LPS (Chang et al., 
2006). 
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Figure 4-4 Specificity of KH3 localisation to cytoplasmic granules. The cellular 
distributions of KH1-GFP, KH2-GFP and KH3-GFP in Hela cells were compared.  
The three KH domains were overexpressed separately in Hela cells with different 
amounts of plasmid DNA used in transfections (0.2µg-1.8µg). The distribution 
patterns were observed with Zeiss LSM510 confocal microscope with 40x Plan-
Neo/1.3 NA Oil lens. KH3-GFP displayed a granular pattern from 0.2µg plasmid to 
1.8µg plasmid, whereas KH1 or KH2 exhibited diffuse patterns at all concentrations 
of plasmid DNA transfected. The scale bar indicates the length of 10 µm in these 
images. All images are representative of three independent experiments (n=3). 
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Figure 4-5 The effect of 1457Tyr phosphorylation on granule formation. Hela 
cells were transfected with phosphomimetic mutant of 1457Tyr-GFP (PARP-14 1457 
YD, YD stands for changing 1457Tyr to 1457Asp) and with dephosphorylated mutant 
of 1457Tyr-GFP (PARP-14 1457YA, YA stands for changing 1457Tyr to 1457Ala). 
After 3 hours transfection, PARP-14 1457YA still formed granules, whereas PARP-
14 1457YD did not form any granules and the cells began to die of the mutant 
transfection. The scale bar indicates the length of 10 µm in these images. All images 
are representative of three independent experiments (n=3). 
  PARP-14 1457 YA mutation PARP-14 1457 YD mutation 
10 µm  
 99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6 Dose-response of SG formation in HeLa cells exposed to sodium 
arsenite. The cells were treated with different arsenite concentrations for 30 minutes, 
after which they were fixed with 4% paraformaldehyde and immunostained for eIF3η. 
A confocal microscope was used to visualize SGs. Distinct SGs could be observed 
following 250µM and 500µM sodium arsenite exposure. Notably, distinct SGs could 
be observed in almost every single cell exposed to 500µM sodium arsenite. Distinct 
SGs were hard to visualize in cells following 1000µM sodium arsenite exposure. All 
images are representative of three independent experiments (n=3). 
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4.3.6.1.   Distribution of KH3-GFP in unstimulated Hela cells  
Unstimulated Hela cells were fixed with 4% PFA 8 hr after transfection, after which 
they were immunostained with the panel of antibodies against cytoplasmic markers 
(see Table 4.2).  As shown in Figure 4.7, KH3-GFP granules colocalised with 
EXOSC2 (a core component of the exosome complex) and tristetraprolin (TTP, a 
reliable SG component which also exists in PB), whereas the granules did not 
colocalise with eukaryotic initiation factor 3η (eIF3η, a defining core component of 
SG), argonaute2 (Ago2, a reliable SG component and also presents in PB and in 
polysomes), T cell intracellular antigen (TIA, a reliable SG component which also 
exists in PB), GW182 (a defining core component of PB), DCP1A (a core component 
of PB), Lamp1 (a component of lysosome and autolysosome), and LC3 (a component 
of autophagosome). Of note, Ago2 and GW182 were undetectable in unstimulated 
cells and eIF3η staining was weak and did not show a completely granular pattern. 
The signals for TTP, TIA, and Lamp1 were also weak but did show granular patterns 
(Figure 4-7). Overall, these observations suggest that KH3-GFP localises with the 
exosome complex in transfected but otherwise unstimulated cells. 
4.3.6.2.   Distribution of KH3-GFP in sodium arsenite-stressed cells 
To examine the localization of KH3-GFP in sodium arsenite-stressed cells, the KH3-
GFP plasmids were transfected into Hela cells for 8 hr, followed by 30 min 
stimulation with 500 µM sodium arsenite. Cells were then fixed and immunostained 
as in 4.3.6.1 above. Under oxidative stress, KH3-GFP colocalised with eIF3η, Ago2, 
TTP, TIA, and EXOSC2 (Figure 4-8). Anderson et al., classified eIF3 as a defining 
SG component and TTP, TIA, as well as Ago2 have also been categorized as reliable 
SG markers (Anderson and Kedersha, 2008). In Figure 4-8, most of the KH3-GFP 
granules completely colocalised with these SG markers but KH3-GFP did not 
colocalise with P-body makers (GW182 and DCP1A), the lysosome marker (Lamp1) 
or the autophagosome marker (LC3). Notably, under arsenite stress, the signals for 
eIF3η, Ago2, TTP, and TIA were stronger and more granular in comparison to 
unstimulated cells using the same confocal microscope settings. Moreover, most of 
the KH3-GFP granules colocalised with the identical sizes and shapes of these SG 
marker proteins in the cytoplasm, indicating that the space in cytoplasm occupied by 
these KH3-GFP granules was close to the location where these SG marker proteins 
were positioned. These observations suggest that KH3-GFP localises to SGs under 
oxidative stress.  
4.3.6.3.   Distribution of KH3-GFP in LPS-stimulated cells 
Hela cells were transfected with KH3-GFP for 8 hours, after which they were 
stimulated with LPS (1 µg/ml) for another 8 hr. The concentration of LPS and the 
duration for LPS stimulation were determined by Dr. Yu Liu’s work (unpublished 
Data; Briefly, this condition is the best condition for observing cytoplasm granules in 
Hela cells). Cells were then fixed with 4% PFA and then immunostained as above. 
Following LPS stimulation, KH3-GFP colocalised with TTP, TIA, EXOSC2, Lamp1, 
and LC3, whereas no colocalization was observed with eIF3η, Ago2, GW182, 
DCP1A, suggesting that KH3-GFP localises with molecules involved in exosome-
mediated RNA degradation and the autophagy pathway (Figure 4-9). Of note, the 
sizes of TTP granules under LPS stimulation were much bigger than they were in the 
absence of stimulation or in arsenite-stressed cells. As TTP is known to be induced by 
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LPS, this acts as evidence for LPS-mediated Hela cell activation (Jalonen et al., 2005; 
Chen et al., 2006). 
4.3.6.4.   Summary 
In summary, KH3-GFP granules can be classified as SGs under oxidative stress and, 
with LPS stimulation, KH3-GFP may incorporate into granules involved in exosome-
mediated RNA degradation and the autophagy pathway possibly related to the 
regulation of LPS-stimulated mRNA. Table 4-3 summarises the results of KH3-GFP 
colocalization. 
 
 
 
  
 102 
 
Continued…        
 
KH3-GFP eIF3η 
Nucleus Merge  
KH3-GFP 
Nucleus Merge 
Ago2 
 
TTP KH3-GFP 
Nucleus Merge  
KH3-GFP 
Nucleus Merge 
TIA 
  
KH3-GFP KH3-GFP 
Nucleus Nucleus Merge Merge 
DCP1A GW182 
 103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                     10 µm 
 
 
 
 
 
 
 
 
Figure 4-7 Colocalisation of KH3-GFP under unstimulated conditions. Hela cells 
were transfected with KH3-GFP for 8 hr, followed by 4% PFA fixation and 
immunostaining for 9 different core components of RNA granules. KH3-GFP 
granules colocalised with TTP and EXOSC2 but did not colocalise with eIF3η, Ago2, 
TIA, GW182, DCP1A, Lamp1, and LC3, suggesting that KH3-GFP localizes with 
molecules involved in exsosome-mediated RNA decay. The scale bar indicates the 
length of 10 µm in these images. All images are representative of three independent 
experiments (n=3). 
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Figure 4-8 The colocalisation of KH3-GFP following exposure to sodium arsenite. 
Hela cells were transfected with KH3-GFP for 8 hr and then stimulated with 500µM 
sodium arsenite for another 30 min, followed by 4% PFA fixation and 
immunostaining for 9 different core components of RNA granules. KH3-GFP 
granules colocalised with eIF3η, Ago2, TTP, TIA and EXOSC2 but did not colocalise 
with GW182, DCP1A, Lamp1, and LC3, suggesting that KH3-GFP colocalises with 
SGs in sodium arsenite stimulated cells. The scale bar indicates the length of 10 µm in 
these images. All images are representative of three independent experiments (n=3). 
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Figure 4-9 The colocalisation of KH3-GFP under LPS stimulation. Hela cells 
were transfected with KH3-GFP for 8 hr and then stimulated with 1 µg/mL LPS for 
another 8 hr, followed by 4% PFA fixation and immunostaining for 9 different core 
components of RNA granules. KH3-GFP granules colocalised with TTP, TIA, 
EXOSC2, Lamp1, and LC3 but did not colocalise with eIF3η, Ago2, GW182, 
DCP1A, suggesting that KH3-GFP colocalises with molecules involved in exsosome-
mediated RMA degradation and the autophagy pathway in LPS-stimulated cells. The 
scale bar indicates the length of 10 µm in these images. All images are representative 
of three independent experiments (n=3). 
 
  
 
KH3-GFP 
KH3-GFP 
KH3-GFP 
Nucleus 
Nucleus 
Nucleus 
LC3 
Merge 
Merge Merge 
Lamp1 EXOSC2 
 108 
 
 
 
 
Table 4-3 Summary of the colocalisation outcomes of KH3-GFP with different 
RNA granule components. 
 
 
 
 
 
 Non-stimulated Arsenite 
stimulated 
LPS stimulated 
eIF3η No co-localisation Co-localisation No co-localisation 
Ago2 No co-localisation Co-localisation No co-localisation 
TTP Co-localisation Co-localisation Co-localisation 
TIA No co-localisation Co-localisation Co-localisation 
GW182 No co-localisation No co-localisation No co-localisation 
DCP1A No co-localisation No co-localisation No co-localisation 
EXOSC2 Co-localisation Co-localisation Co-localisation 
Lamp1 No co-localisation No co-localisation Co-localisation 
LC3 No co-localisation No co-localisation Co-localisation 
 
 
eIF3η, a defining core component of SG; Ago2, a reliable SG component and it also 
presents in PB and in polysomes; TTP, a reliable SG component and it also exists in 
PB; TIA, a reliable SG component and it also exists in PB; GW182, a defining core 
component of PB; DCP1A, a core component of PB; Lamp1, a component of 
lysosome and autolysosome, EXOSC2, a core component of exosome complex and 
LC3, a component of autophagosome. 
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4.3.7.   Does PARP-14-GFP localise in the same way as KH3-GFP?    
The results so far have demonstrated that KH3-GFP localises to SGs under arsenite 
stress but with exosome-mediated RNA degradation and autophagy pathways 
following LPS stimulation. The next question to ask was whether KH3-GFP is 
representative of the cytoplasmic distribution of full-length PARP-14. We therefore 
transfected full-length PARP-14-GFP plasmid DNA into Hela cells, and studied its 
distribution in unstimulated Hela cells and in Hela cells stimulated with sodium 
arsenite or LPS, using the same experimental conditions as used for KH3-GFP in the 
previous section. 
4.3.7.1.   PARP-14 localisation in unstimulated Hela cells 
Judging from the number of cells expressing GFP, the transfection efficiency of full-
length PARP-14-GFP was very low, presumably due to the large size of the construct 
(6.135 kb encoding a fusion protein of ~225KDa). In comparison with KH3-GFP or 
M3-WWE-GFP, the highest transfection efficiency of full-length PARP-14-GFP was 
33.3%, whereas the highest transfection efficiency of KH3-GFP and that of M3-
WWE-GFP were 83.3% and 50%, respectively. As shown in Figure 4-10, the few 
cells that were successfully transfected with full-length PARP-14-GFP showed 
cytoplasmic granules. However there was no convincing colocalization with the panel 
of granule markers. Full-length PARP-14 GFP therefore differed from KH3-GFP in 
not colocalising with EXOSC2 and TTP. 
4.3.7.2.   PARP-14 localisation in sodium arsenite-stimulated Hela cells 
Following sodium arsenite stimulation, full-length PARP-14-GFP colocalised with 
eIF3η, Ago2, TTP, but not with TIA, GW182, DCP1A, EXOSC2, Lamp1, and LC3 
(Figure 4-11). Thus full-length PARP-14-GFP granules colocalised with a defining 
SG core component (eIF3η) and two other reliable SG markers (Ago2 and TTP) but 
did not colocalise with P-body markers (GW182 and DCP1A), lysosome marker 
(Lamp1), exosome complex marker (EXOSC2), and autophagosome marker (LC3).  
Granules identified by PARP-14-GFP had almost identical size and shape to those 
identified by SG markers, which increased the reliability of these colocalization 
results. The results with full-length PARP-14-GFP were broadly similar to those with 
KH3-GFP with the exception that full-length PARP-14-GFP granules did not 
colocalise with TIA or, as with unstimulated cells, with EXOSC2. 
4.3.7.3.   PARP-14 localisation in LPS-stimulated Hela cells 
Following LPS stimulation of Hela cells, full-length PARP-14-GFP colocalised with 
TTP, TIA, and EXOSC2, and did not colocalise with eIF3η, Ago2, GW182, DCP1A, 
Lamp1, and LC3 (Figure 4-12). Broadly this was similar to KH3-GFP. However 
while KH3-GFP granules colocalised with Lamp1 and LC3, this was not the case for 
full-length PARP-14-GFP. We also observed similarities in the size of KH3-GFP 
positive granules and the full-length PARP-14 positive granules. Thus, compared to 
the granules in unstimulated cells or sodium arsenite stimulated cells, the size of the 
granules was much bigger and they tended to aggregate with each other in the 
cytoplasm. 
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4.3.7.4.   Summary 
In summary, these observations indicate that full-length PARP-14-GFP localises with 
SGs under oxidative stress and exosome-mediated RNA degradation following LPS 
stimulation. The similarities between PARP-14-GFP and KH3-GFP were much 
greater than the differences, suggesting that the distribution of KH3-GFP is to a large 
extent mimicking that of full-length PARP-14. 
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Figure 4-10 The colocalisation of full-length PARP-14-GFP with cytoplasmic 
antigens in unstimulated Hela cells. Hela cells were transfected with full-length 
PARP-14-GFP for 8 hr, followed by 4% PFA fixation and immunostaining for 9 
different core components of RNA granules. Full-length PARP-14-GFP granules did 
not colocalise with any core component of RNA granules, suggesting that full-length 
PARP-14-GFP granules are not SG, PB, exosome complex, lysosome, or 
autophagosomes. The scale bar indicates the length of 10 µm in these images. All 
images are representative of three independent experiments (n=3). 
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Figure 4-11 Colocalisation of full-length PARP-14-GFP with cytoplasmic 
antigens in sodium arsenite Hela treated cells. Hela cells were transfected with full-
length PARP-14-GFP for 8 hr and then stimulated with 500µM sodium arsenite for 
another 30 min, followed by 4% PFA fixation and immunostaining for 9 different 
core components of RNA granules. Full-length PARP-14-GFP granules colocalised 
with eIF3η, Ago2, TTP but did not colocalise with GW182, DCP1A, EXOSC2, 
Lamp1, and LC3, suggesting that KH3-GFP granules can be classified as SGs under 
arsenite stress as the granules colocalized with a defining core component (eIF3η) and 
two reliable SG markers (Ago2 and TTP). The scale bars indicate the length of 10 µm 
in these images. All images are representative of three independent experiments (n=3). 
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Figure 4-12 Colocalisation of full-length PARP-14-GFP with cytoplasmic 
antigens in LPS-activated Hela cells. Hela cells were transfected with full-length 
PARP-14-GFP for 8 hr and then stimulated with 1 µg/mL LPS stimulation for another 
8 hr, followed by 4% PFA fixation and immunostaining for 9 different core 
components of RNA granules. KH3-GFP granules colocalised with TTP, TIA, 
EXOSC2 but did not colocalise with eIF3η, Ago2, GW182, DCP1A Lamp1, and LC3, 
suggesting that KH3-GFP granules were involved in exsosome-mediated RMA 
degradation. The scale bar indicates the length of 10 µm in these images. All images 
are representative of three independent experiments (n=3). 
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Table 4-4 Summary of the colocalisation outcomes of full-length PARP-14-GFP 
with different RNA granule components. 
 
 
 
 
 Non-stimulated Arsenite 
stimulated 
LPS stimulated 
eIF3η No co-localisation Co-localisation No co-localisation 
Ago2 No co-localisation Co-localisation No co-localisation 
TTP No co-localisation Co-localisation Co-localisation 
TIA No co-localisation No co-localisation Co-localisation 
GW182 No co-localisation No co-localisation No co-localisation 
DCP1A No co-localisation No co-localisation No co-localisation 
EXOSC2 No co-localisation No co-localisation Co-localisation 
Lamp1 No co-localisation No co-localisation No co-localisation 
LC3 No co-localisation No co-localisation No co-localisation 
 
 
eIF3η, a defining core component of SG; Ago2, a reliable SG component and it also 
presents in PB and in polysomes; TTP, a reliable SG component and it also exists in 
PB; TIA, a reliable SG component and it also exists in PB; GW182, a defining core 
component of PB; DCP1A, a core component of PB; Lamp1, a component of 
lysosome and autolysosome, EXOSC2, a core component of exosome complex and 
LC3, a component of autophagosome. 
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4.3.8.   Do the results with KH3-GFP and full-length PARP-14-GFP 
reflect the distribution of endogenous PARP-14? 
So far, we have demonstrated that both KH3-GFP and PARP-14-GFP localise into 
SGs in arsenite stressed cells and exosome complexes following LPS-induced 
activation. These observations are therefore consistent with KH3 being a critical 
domain for PARP-14 localization into either type of granule. We therefore went on to 
check whether the localization of these GFP fusion proteins reflected that of 
endogenous PARP-14. Because the level of endogenous PARP-14 in Hela cells is low 
(unpublished data), I decided to use mouse bone marrow-derived macrophages to 
study the localisation patterns under arsenite or LPS stimulation.     
4.3.8.1.   Establishing conditions for dual immunostaining 
Before we performed dual immunostaining for endogenous PARP-14 and RNA 
granule components, we performed a control experiment to validate the 
immunostaining protocol. Specifically, we needed to ensure that there was no species 
cross-reaction between secondary antibodies as well as no signal breakthrough under 
confocal microscopy. We tested different combinations of Alexa Fluor® anti-IgGs, 
isotype control IgGs, polyclonal rabbit PARP-14 antibody, and cytoplasmic antigen 
antibodies (eIF3η, Ago2, TTP, etc.) and used them as negative controls (Figure 4-13). 
The details of all the negative controls and observation samples are listed in Table 4-5. 
From these control stainings, there were no inappropriate antibody signals present 
apart from some nuclear staining. Thus, there was no cross-reaction among antibodies 
and control isotype IgGs and no signal breakthrough under the confocal microscope. 
We therefore proceeded to using these antibodies and isotype control IgGs in dual 
immunostaining. 
4.3.8.2.   Colocalisation of endogenous PARP-14 and cytoplasmic 
antigens in unstimulated macrophages 
Mouse bone marrow-derived macrophages were fixed with 4% PFA and then 
permeabilized with 0.5% TritonTM X-100, followed by incubating overnight with 
rabbit polyclonal PARP-14 antibody and one of the panel of antibodies to cytoplasmic 
antigens in 3% mouse serum albumin at 4°C. The cells were then washed three times 
with PBS and incubated with Alexa Fluor®555 donkey anti-goat IgG and Alexa 
Fluor®488 donkey anti-rabbit IgG at RT for 1 hour. The cells were then washed three 
times and inspected using the confocal microscope. The staining pattern of 
endogenous PARP-14 was granular, which was similar to that of PARP-14-GFP and 
that of KH3-GFP. Apart from a DCP1A cytoplasmic signal, none of the other 
antibodies against cytoplasmic granule components gave positive staining, consistent 
with the cells not being under stress or inflammatory activation. As for DCP1A, this 
could be detected in more than half of the macrophages; however, the positions of 
DCP1A granules in the cytoplasm were different from the positions of endogenous 
PARP-14 granules. In summary, no colocalization between endogenous PARP-14 and 
the RNA granule components was observed in unstimulated macrophages (Figure 4-
14). 
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4.3.8.3.   Colocalisation of endogenous PARP-14 and cytoplasmic 
antigens in sodium arsenite-stressed macrophages 
Mouse bone marrow-derived macrophages were stimulated with sodium arsenite for 
30 min, and dual immunostained as above. The granules stained by antibodies against 
eIF3η and Ago2 colocalised with granules stained by anti-PARP-14, with 
colocalizations detectable in more than one cell and almost identical size/shape of the 
colocalised granules. Apart from eIF3η and Ago2, no colocalization was observed 
with the other cytoplasmic antigen such as GW182, DCP1A, Lamp1, etc.  In 
summary, we found that endogenous PARP-14 colocalised with eIF3η and Ago2 but 
did not colocalise with TTP, TIA, GW182, DCP1A, EXOSC2, and Lamp1 (Figure 4-
15). Because endogenous PARP-14 colocalised with a defining core component of 
SG (eIF3η) and one reliable SG markers (Ago2), endogenous PARP-14 can be 
classified as present in SG under oxidative stress induced by sodium arsenite. The 
cytoplasmic distribution of endogenous PARP-14 in macrophages under arsenite 
stress was therefore identical to that of full-length PARP-14 in arsenite-stressed Hela 
cells.      
4.3.8.4.   Colocalisation of endogenous PARP-14 and cytoplasmic 
antigens in LPS-activated macrophages 
Mouse bone marrow-derived macrophages were stimulated with LPS for 8 hr, 
followed by fixation and dual immunostaining. No cytoplasmic staining of eIF3η, 
GW182 or Lamp1 was observed (Figure 4-16). The cytoplasmic staining of Ago2 
colocalised with the staining of endogenous PARP-14 in one cell; however, this 
phenomenon could only be observed in this single cell and did not therefore meet our 
criteria for colocalization. As for TTP, TIA, and EXOSC2, endogenous PARP-14 did 
not colocalise with these antigens with the similar size/shape in multiple cells. In 
summary, endogenous PARP-14 did not colocalise with eIF3η, Ago2, TTP, TIA, 
GW182, DCP1A, EXOSC2 and Lamp1. In addition, endogenous PARP-14 did not 
form the big aggregates seen with PARP-14-GFP and KH3-GFP in LPS-stimulated 
Hela cells. This suggests that these large aggregates in PARP-14-GFP and KH3-GFP 
cells were related to overexpression.               
4.3.8.5.   Summary 
Endogenous PARP-14 appears to localise to SG under oxidative stress induced by 
sodium arsenite. Because mouse bone marrow-derived macrophages are different 
from Hela cells regarding different cell type and species, it limits the comparison 
between the results obtained from macrophages and those obtained from Hela cells. 
Table 4-6 lists the results of endogenous PARP-14 colocalization.  
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Table 4-5 The list of the antibodies and control IgGs used in the double 
immunostaining.  
 
 
 
 
Control Condition 
donkey anti goat/donkey anti rabbit Stimulated with Arsenite 
rabbit IgG-donkey anti rabbit  Stimulated with Arsenite  
goat IgG-donkey anti goat Stimulated with Arsenite  
PARP-14 antibody/ goat IgG-donkey anti 
Goat 
Stimulated with Arsenite  
Target protein / rabbit IgG-donkey anti rabbit  Stimulated with Arsenite  
goat IgG-donkey anti goat / rabbit IgG-donkey 
anti rabbit  
Stimulated with Arsenite  
Observation  
Target protein-donkey anti goat / PARP-14 
antibody-donkey anti rabbit   
Stimulated with Arsenite, LPS, and Non-
stimulated 
 
 
This table lists all the antibodies/control IgGs combinations for the control experiment 
and their experimental conditions used in the double immunostaining. The wild type 
mouse bone marrow macrophages used for the control experiment were stimulated 
with arsenite for 30 minutes before the immunostaining.  
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Figure 4-13 Negative controls for the dual immunostaining of endogenous 
PARP-14 and a specific RNA granule component such as eIF3η, Ago2, and TTP, 
etc. Mouse bone marrow macrophages were stimulated with arsenite for 30 minutes 
and then the cells were fixed with 4% PFA and were permeabilized with 0.5% 
TritonTM X-100, followed by performing the negative controls of the dual staining to 
ensure no signal breakthrough and no cross-reactions among antibodies, isotype 
control IgGs and Alexa Fluor® IgGs. The negative controls include Alexa Fluor® 
IgGs only, Isotype control IgGs and Alexa Fluor® IgG, polyclonal rabbit PARP-14 
antibody and Goat IgG / Donkey anti Goat IgG, isotype controls and Rabbit IgG / 
Donkey anti Rabbit with a target protein (eIF3η, Ago2, TTP, etc.). Apart from 
nucleus signal, no signal can be observed with the confocal microscope settings. 
These settings were used in the following dual immunostaining experiment. The scale 
bar indicates the length of 10 µm in these images. All images are representative of 
three independent experiments (n=3). 
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Figure 4-14 Colocalisation of endogenous PARP-14 with cytoplasmic antigens in 
unstimulated macrophages. Mouse bone marrow macrophages were fixed with 4% 
PFA and were permeabilized with 0.5% TritonTM X-100, followed by performing the 
dual immunostaining according to the standard protocol as described in 4.3.8. 
Endogenous PARP-14 granules did not colocalise with any core component of RNA 
granules, suggesting that endogenous PARP-14 granules are not SG, PB, exosome 
complex, lysosome, or autophagosome. The scale bar indicates the length of 10 µm in 
these images. All images are representative of three independent experiments (n=3). 
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Figure 4-15 Colocalisation of endogenous PARP-14 with cytoplasmic antigens in 
sodium arsenite-treated cells. Mouse bone marrow macrophages were fixed with 
4% PFA and were permeabilized with 0.5% TritonTM X-100, followed by performing 
the dual immunostaining according to the standard protocol as described in 4.3.8. 
Endogenous PARP-14 granules colocalised with eIF3η, Ago2, and TTP but did not 
colocalise with TIA, GW182, DCP1A, EXOSC2, and Lamp1, suggesting that 
endogenous PARP-14 granules can be regarded as SGs under oxidative stress induced 
by sodium arsenite. The scale bar indicates the length of 10 µm in these images. All 
images are representative of three independent experiments (n=3). 
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Figure 4-16 Colocalisation of endogenous PARP-14 with cytoplasmic antigens in 
LPS treated macrophages. Mouse bone marrow macrophages were fixed with 4% 
PFA and were permeabilized with 0.5% TritonTM X-100, followed by performing the 
double immunostaining according to the standard protocol as described in 4.3.8. 
Endogenous PARP-14 granules colocalised with TTP, TIA, and EXOSC2 but did not 
colocalise with eIF3η, Ago2, GW182, DCP1A, and Lamp1, suggesting that 
endogenous PARP-14 granules could be involved in exsosome-mediated RNA 
degradation. The scale bar indicates the length of 10 µm in these images. All images 
are representative of three independent experiments (n=3). 
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Table 4-6 Summary of the colocalisation outcomes of endogenous PARP-14 with 
different RNA granule components. 
 
 
 
 
 Non-stimulated Arsenite 
stimulated 
LPS stimulated 
eIF3η No co-localisation Co-localisation No co-localisation 
Ago2 No co-localisation Co-localisation No co-localisation 
TTP No co-localisation No co-localisation No co-localisation 
TIA No co-localisation No co-localisation No co-localisation 
GW182 No co-localisation No co-localisation No co-localisation 
DCP1A No co-localisation No co-localisation No co-localisation 
EXOSC2 No co-localisation No co-localisation No co-localisation 
Lamp1 No co-localisation No co-localisation No co-localisation 
 
 
eIF3η, a defining core component of SG; Ago2, a reliable SG component and it also 
presents in PB and in polysomes; TTP, a reliable SG component and it also exists in 
PB; TIA, a reliable SG component and it also exists in PB; GW182, a defining core 
component of PB; DCP1A, a core component of PB; Lamp1, a component of 
lysosome and autolysosome, EXOSC2, a core component of exosome complex and 
LC3, a component of autophagosome. 
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4.3.9.   Distribution of M3-KH3-WWE-GFP 
In Figure 3-1, we demonstrated that M3-KH3-WWE-GFP localises to granules in 
Hela cells. In view of the small number of hits in the Y2H screening using M3-KH3-
WWE (Chapter 3), we decided to check the colocalization pattern of this construct 
tagged with GFP and to compare this with the previous results using KH3-GFP and 
full-length PARP-14-GFP. 
4.3.9.1.   No colocalisation of M3-KH3-WWE-GFP with cytoplasmic 
antigens in unstimulated Hela cells  
M3-KH3-WWE-GFP plasmid DNA was transfected into Hela cells for 8 hours and 
the cells were then fixed with 4% PFA and immunostained as in previous experiments. 
No colocalization between M3-KH3-WWE-GFP and the RNA granule components 
was observed (Figure 4-17).      
4.3.9.2.   Colocalisation of M3-KH3-WWE-GFP with cytoplasmic 
antigens in sodium arsenite-treated Hela cells 
Following sodium arsenite treatment, M3-KH3-WWE-GFP only colocalised with 
Lamp1 and did not colocalise with eIF3η, Ago2, TTP, TIA, GW182, DCP1A, 
EXOSC2, and LC3 (Figure 4-18).      
4.3.9.3.   Colocalisation of M3-KH3-WWE-GFP with cytoplasmic 
antigens in LPS-treated Hela cells 
Following LPS stimulation, we found that M3-KH3-WWE-GFP granules colocalised 
with TTP, TIA, EXOSC2, and Lamp1 but not with eIF3η, Ago2, GW182, DCP1A, 
and LC3 (Figure 4-19). As with KH3-GFP and full-length PARP14-GFP, M3-WWE-
GFP granules formed larger aggregates under LPS stimulation.        
4.3.9.4.   Lysosome colocalisation 
The colocalization of M3-KH3-WWE-GFP with endogenous Lamp-1 but not with SG 
components suggested that it might preferentially localise in lysosomes. To test this 
further, we used a proprietary lysosome marker, CellLight®. The details of the 
CellLight® reagent, which is based on Lamp1, can be found in 4.2.8. Initially, we 
demonstrated that mock transfection of Hela cells did not lead to any signal and 
transfection with Macro3-KH3-WWE-GFP or the CellLight® reagent alone led only 
to green or red signals respectively (Figure 4-20A). Secondly, we transfected Macro3-
KH3-WWE-GFP and 10 to 50 CellLight® baculovirus particles per cell (PPC) and 
found that the Macro3-KH3-WWE-GFP GFP construct colocalised with the 
baculovirus particles. This strongly suggests that Macro3-KH3-WWE-GFP 
colocalised with lysosome and supports the results from direct staining of endogenous 
Lamp-1 (Figure 4-20B). 
4.3.9.5.   Summary 
Table 4-7 lists the results of M3-WWE-GFP colocalization. M3-KH3-WWE-GFP did 
not colocalise with any RNA granule components in unstimulated cells but 
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colocalised with lysosome and exosome-mediated RNA decay components following 
arsenite or LPS exposure. 
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Figure 4-17 No colocalisation of M3-WWE-GFP with cytoplasmic antigens in 
unstimulated Hela cells. Hela cells were transfected with M3-WWE-GFP for 8 hr, 
followed by 4% PFA fixation and immunostaining for 9 different core components of 
RNA granules. M3-WWE-GFP granules did not colocalise with any core component 
of RNA granules, suggesting that M3-WWE-GFP granules are not SG, PB, exosome 
complex, lysosome, or autophagosome. The scale bar indicates the length of 10 µm in 
these images. All images are representative of three independent experiments (n=3). 
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Figure 4-18 Colocalisation of M3-WWE-GFP with cytoplasmic antigens in 
sodium-arsenite stimulated Hela cells. Hela cells were transfected with M3-WWE-
KH3-GFP for 8 hr and then stimulated with 500µM sodium arsenite for another 30 
minutes, followed by 4% PFA fixation and immunostaining for 9 different core 
components of RNA granules. M3-WWE-GFP granules only colocalised with Lamp1 
but did not colocalise with eIF3η, Ago2, TTP, TIA, GW182, DCP1A, EXOSC2, and 
LC3. The lysosome colocalization suggested the possibility of protein misfolding 
when M3-WWE-GFP was overexpressed in Hela cells. The scale bars indicate the 
length of 10 µm in these images. All images are representative of three independent 
experiments (n=3). 
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Figure 4-19 Colocalisation of M3-WWE-GFP with cytoplasmic antigens in LPS-
treated Hela cells. Hela cells were transfected with M3-WWE-GFP for 8 hr and then 
stimulated with 1 µg/mL for another 8 hr, followed by 4% PFA fixation and 
immunostaining for 9 different core components of RNA granules. M3-WWE-GFP 
granules colocalised with TTP, TIA, EXOSC2, and Lamp1 but did not colocalise with 
eIF3η, Ago2, GW182, and DCP1A. The scale bar indicates the length of 10 µm in 
these images. All images are representative of three independent experiments (n=3). 
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Table 4-7 Summary of the colocalisation outcomes of M3-WWE-GFP with 
different RNA granule components. 
 
 
 
 
 
 
 
eIF3η, a defining core component of SG; Ago2, a reliable SG component and it also 
presents in PB and in polysomes; TTP, a reliable SG component and it also exists in 
PB; TIA, a reliable SG component and it also exists in PB; GW182, a defining core 
component of PB; DCP1A, a core component of PB; Lamp1, a component of 
lysosome and autolysosome, EXOSC2, a core component of exosome complex and 
LC3, a component of autophagosome. 
 
 
 
 
 
 Non-stimulated Arsenite 
stimulated 
LPS stimulated 
eIF3η No co-localisation No co-localisation No co-localisation 
Ago2 No co-localisation No co-localisation No co-localisation 
TTP No co-localisation No co-localisation Co-localisation 
TIA No co-localisation No co-localisation Co-localisation 
GW182 No co-localisation No co-localisation No co-localisation 
DCP1A No co-localisation No co-localisation No co-localisation 
EXOSC2 No co-localisation No co-localisation Co-localisation 
Lamp1 No co-localisation Co-localisation Co-localisation 
LC3 No co-localisation No co-localisation No co-localisation 
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Figure 4-20 CellLight® reagent was used to verify the colocalisation between 
Macro3-WWE-GFP and lysosome under arsenite stress. We transfected 
CellLight® reagent (From 10PPC to 50 PPC) into Hela cells for 24 hours before 
Macro3-WWE-GFP was transfected into the cell. Firstly, only Macro3-WWE-GFP or 
the CellLight® reagent was transfected into Hell cells to ensure that breakthrough 
signals do not exist (A); Secondly, we transfected the CellLight® reagent for 24 hr, 
followed by Macro3-WWE-GFP transfection and 30 min arsenite stimulation. The 
colocalisation between Macro3-KH3-WWE-GFP and lysosome was observed from 
10 PPC to 50 PPC (B). The scale bar indicates the length of 10 µm in these images. 
All images are representative of three independent experiments (n=3). 
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4.3.10.   Which domain in Macro3-KH3-WWE contributes to the 
colocalisation with lysosomes? 
Although the localization of Macro3-KH3-WWE-GFP in lysosomes may be simply 
due to suboptimal folding or processing of the fusion protein, another possibility is 
that it is due to a more specific function of PARP-14.  Thus, WWE domains have 
been linked to ubiquitination (Zweifel et al., 2005) and mono-ubiquitinated proteins 
may be degraded by lysosomes (Marques et al., 2004). We transfected CellLight® 
reagent into Hela cells for lysosome detection, together with KH3-WWE-GFP or M3-
KH3-GFP and looked for colocalization in arsenite-stressed cells using confocal 
microscope. We found that KH3-WWE-GFP rather than M3-KH3-GFP colocalised 
with lysosomes (Figure 4-21). As KH3-GFP localised in arsenite-stressed cells to SG, 
and WWE-GFP has a diffuse distribution, this raises the possibility that the 
combination of KH3+WWE localises specifically to lysosomes. However, the 
alternative possibility that both Macro-3-KH3-WWE and KH3-WWE localise to 
lysosomes because of suboptimal folding cannot be excluded. 
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Figure 4-21 Macro3-KH3-GFP or KH3-WWE-GFP was transfected into Hela 
cells with 20 PPC CellLight® reagent. The CellLight® reagent was transfected into 
Hela cells 24 hr before GFP constructs were transfected into the cells. The 
colocalization was then observed with Zeiss LSM510 confocal microscope. KH3-
WWE-GFP colocalised with lysosome-RFP but M3-KH3-GFP did not colocalise with 
lysosome-RFP, indicating WWE domain rather than Macro3 domain contributes to 
lysosome colocalization. The scale bar indicates the length of 10 µm in these images. 
All images are representative of three independent experiments (n=3). 
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4.4.   Summary and discussion 
4.4.1.   KH3 is the minimal domain in PARP-14 that mimics the 
cytoplasmic localisation of PARP-14 
In this chapter, I have described a previously unrecognised KH domain situated 
between the Macro-3 and WWE domains of PARP-14. This was designated KH3, as 
there are also two novel KH domains (KH1 and KH2) at the N terminal between the 
RRM and Macro 1 domain. I found that KH3-GFP but not KH1-GFP or KH2-GFP 
localises in the cytoplasm in a very similar way to PARP-14-GFP. A technical 
proviso to this conclusion is that the distribution of KH3-GFP (and indeed other GFP 
fusion proteins) might have been influenced by the GFP tag, and verification is 
needed using antibody staining once an antibody to KH3 is available. Furthermore, 
the observations on full-length PARP-14-GFP need to be qualified by the relatively 
poor transfection efficiency of this large construct. Nevertheless, the observation that 
KH3-GFP and full length PARP-14-GFP showed a similar distribution to endogenous 
PARP-14 stained by a polyclonal antibody adds support to the overall conclusion.  A 
further experiment that needs to be performed to establish that KH3 is critical for 
PARP-14 cytoplasmic localization is to show that a full-length PARP-14-GFP 
construct with a KH3 deletion fails to localise to granules. 
4.4.2.   Possible phosphorylation of KH3-GFP 
There is already evidence that protein phosphorylation is vital for SG 
formation/assembly. Thus, G3BP, one of the nucleation proteins in SG assembly, 
becomes partially dephosphorylated at Ser149 during SG formation and a Ser149 
G3BP phosphomimetic mutant can no longer trigger SG assembly (Tourrière et al., 
2003). By analogy, it is possible that PARP-14 phosphorylation may also be involved 
in regulating its distribution and entry into SG.  We found that KH3 has a potentially 
phosphorylatable tyrosine at position 1457, which is situated at the site of the missing 
RNA-binding GXXG motif between the α1- and α2-helix. Furthermore, We found 
that mutation of Y1457 to alanine (i.e. non-phosphorylatable) had no effect on KH3-
GFP cytoplasmic localization, whereas mutation to aspartate (i.e. phosphomimetic) 
led to cell death. Once the interactions of KH3 with other proteins and/or RNA are 
better clarified, it will be possible to determine whether this observation truly reflects 
a role of Y1457 in KH3 function or whether the cell death we observed is non-
specific. 
4.4.3.   Cytoplasmic localisation pattern of PARP-14 
The nature of the cytoplasmic granules to which PARP-14 localises was investigated 
using a panel of antibodies. We aimed to screen for colocalisation with markers of 
well-recognised cytoplasmic granules, including the exosome complex, SG and 
lysosomes. Furthermore, our approach was to expose cells with arsenite to induce SG, 
or stimulate with LPS to induce an RNA transcriptional response relevant to 
inflammatory cell activation. Taken together, these experiments using confocal 
microscopy have allowed us to draw conclusions about the distribution and possible 
function of PARP-14 in the cytoplasm that will be discussed in more detail in Chapter 
6. A limitation of the approach is that there may be other cytoplasmic 
organelles/bodies to which PARP-14 localises but which would not be identified 
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without other antibodies, and that forms of cell stimulation other than arsenite and 
LPS may affect PARP-14 distribution differently. As for LPS stimulation, the lack of 
control (Hela cells transfected with either KH3-GFP or PARP-14-GFP for 16 hours) 
is a major limitation to interpreting the results with LPS.  
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Chapter 5    Results III: Biochemical evidence for 
KH3 interaction with RNA 
 
5.1.   Chapter introduction 
In chapter 4, we demonstrated that three KH domains are predicted to exist in the 
PARP-14 structure, and that the one between the Macro-3 and WWE domains 
localises within the cell in a manner similar to full-length PARP-14. Furthermore, 
PARP14 localises to SG and endosomal complexes, depending on the culture 
conditions. This chapter describes experiments in which the association of PARP-14 
with RNA and RNA-binding proteins was further explored. 
 
5.2.   Methods and materials 
5.2.1.   Materials 
5.2.1.1.   Antibodies for Co-IP experiments 
The antibodies used for Co-IP are listed in Table 4-2.  
5.2.1.2.   Co-IP beads 
Dynabeads coated with Protein G (10004D, Invitrogen) were used to pull down 
immune-complexes prior to SDS-PAGE.  
5.2.1.3.   Co-IP lysis buffer 
The Co-IP lysis buffer contained 0.5% TritonTM X-100, 20mM Tris (pH=7.5), 
150mM NaCl (S3014-500G, Sigma-Aldrich), PMSF (phenylmethanesulfonyl fluoride, 
1:100) (93482-50ML-F, Sigma-Aldrich), protease inhibitor cocktail (1:100) (P8340-
1ML, Sigma-Aldrich) and molecular biology grade water (W4502, Sigma-Aldrich). 
5.2.1.4.   Co-IP wash buffer 
The wash buffer contained 0.1% TritonTM X-100, 20mM Tris (pH=7.5), 150mM 
NaCl, PMSF (1:100), protease inhibitor cocktail (1:100) and molecular biology grade 
water. 
5.2.2.   Western blotting 
The western blotting equipment and reagents were as same as used in chapter 3. We 
used a stripping buffer (21059, Thermo Scientific) for stripping and re-probing blots.    
5.2.3.   Fluorescence in situ Hybridization (FISH) 
The procedures for Hela cell culture and KH3-GFP transfection were the same as in 
4.2.3 and 4.2.4. The fixed cells were permeabilized with 0.5% TritonTM X-100 at 
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37°C for 15 minutes. The control cell sample was then treated with 0.2 µg/mL RNase 
A (19101, QIAGEN) at 37°C for 1 hour, followed by culturing both control and 
observation samples with hybridization mixture (1mL mixture contains 100µl 20x 
SSC Buffer (S6639-1L, Sigma-Aldrich), 100µl t-RNA from Baker’s yeast 
(10109495001, Roche), 100mg dextran sulphate (D8906, Sigma-Aldrich), 250µl 
formamide (F9037, Sigma-Aldrich), 550µl molecular biology grade water (W4502-1L, 
Sigma-Aldrich), 1nM Biotinylated Oligo(dT) Probe (Z5261, Promega)) at 42°C 
overnight. After overnight culture, the samples were washed with 2x SSC Buffer 
twice and 0.5x SSC Buffer once at 42°C, followed by 4% PFA fixation. The samples 
were then washed three times with PBS and then labeled with Streptavidin, Alexa 
Fluor® 555 conjugate (S-21381, Molecular ProbesTM, Invitrogen) and TO-PRO®-3 
Iodide (642/661) for 1 hour at room temperature. After the final PBS wash, the 
samples were viewed by confocal microscopy. 
5.2.4.   Co-immunoprecipitation (Co-IP) 
Hela cells were transfected with KH3-GFP and then stimulated with sodium arsenite 
for 30 minutes. The cells were then lysed at 4°C for 15 minutes with the Co-IP lysis 
buffer. In some samples, RNase A (19101, QIAGEN) was added to the Co-IP lysis 
buffer at a final concentration of 5µg/mL. After 15 minutes, the lysates were 
centrifuged at 4°C with 17,000 rpm for 10 minutes to remove the cell debris. Protein 
concentrations of the supernatants from the lysates were measured with an absorbance 
assay (OD 280nm). The supernatants with or without RNase A were transferred into 
two separate pre-chilled Eppendorf tubes, after which 5 mg total protein was 
withdrawn and split into two other pre-chilled Eppendorf tubes. The GFP antibody 
(5µg) (sc-8334) was then added to one and the rabbit isotype control IgG (5µg) (sc-
2027, Santa Cruz) to the other. The tubes were rotated on a wheel at room 
temperature for 10 minutes and then 50µL Dynabeads coated with Protein G were 
added into each, followed by further rotation on the wheel for another 10 minutes at 
room temperature. The beads were then isolated with DynaMagTM-96 Side Skirted 
(12027, Invitrogen) and washed with the ice-cold wash buffer three times. The KH3-
GFP complexes were then eluted by boiling the beads in NuPAGE® LDS Sample 
Buffer (4X) (NP0007, Invitrogen) at 100°C for 5 minutes. The complexes were 
analyzed by using NuPAGE® Novex® 4-12% Bis-Tris Gel (NP0335BOX), Western 
blotting and immunodetection according to standard protocols. 
5.3.   Results 
5.3.1.   Can RNA be detected in KH3 granules? 
Having shown that the cytoplasmic distribution of KH3-GFP acts as a surrogate for 
PARP-14, we next used FISH to determine whether granules identified by KH3-GFP 
contain mRNAs. Hela cells were transfected with KH3-GFP, and left unstimulated or 
treated with sodium arsenite or LPS as in chapter 4. The cells were then fixed and 
permeabilized with 4% PFA and 0.5% TritonTM X-100, respectively. A biotinylated 
Oligo(dT) probe was then added to cells and hybridization to mRNA visualized using 
Alexa Fluor® 555-conjugated streptavidin and confocal microscopy. Figure 5-1 
illustrates that KH3-GFP colocalised with foci of mRNA, and that this colocalization 
was abolished by pretreatment of cells with RNase A. This association of KH3-GFP 
with RNA provides further evidence that the putative granules with which KH3-GFP 
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associates are indeed SG and exosome complexes, depending on the nature of the 
culture conditions. 
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Figure 5-1 Granules identified by KH3-GFP contain mRNA. Hela cells were 
transfected with KH3-GFP and then left unstimulated or treated with sodium arsenite 
or LPS. FISH was then used to determine whether granules containing KH3-GFP also 
contain mRNA. The figure shows that KH3-GFP colocalized with polyA mRNA. 
This colocalisation was abolished by pretreatment with RNase A, supporting the 
conclusion that KH3-GFP granules are RNA granules. The scale bar indicates the 
length of 10 µm in these images. All images are representative of three independent 
experiments (n=3). 
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5.3.2.   Can KH3-GFP Co-IP with RNA-binding proteins 
In a complementary approach, we used Co-IP to determine whether the KH3-GFP 
probe can be used to pull-down eIF3η and TTP. These were chosen as representative 
RNA granule components that had been shown to colocalise with KH3-GFP in 
chapter 4. 
5.3.2.1.   Co-IP of eIF3η with KH3-GFP  
Hela cells were transfected with KH3-GFP for 8 hours, treated with sodium arsenite 
for 30 min and lysed with lysis buffer. Anti-GFP antibody was then used to pull-down 
KH3-GFP together with associated complexes. Immunoprecipitated proteins were 
then identified by immunoblotting. As shown in Figure 5.2, eIF3η was present in the 
input lysate and also in the material immunoprecipitated by anti-GFP. However eIF3η 
was not detected in the immunoprecipitate from the lysate pretreated with RNase A.  
As a control, the same blot was stripped with the stripping buffer and re-probed with 
anti-GFP. This showed a clear KH3-GFP signal in the immunoprecipitate that was not 
affected by RNase A. Taken together, these observations establish that KH3-GFP 
physically associates with eIF3η but that this association requires RNA or RNA acts 
as a bridge.  
5.3.2.2.   Co-IP of TTP with KH3-GFP 
We preformed the same Co-IP protocol as described in 5.3.2.1 but probed the blot for 
TTP rather than eIF3η. As shown in Figure 5-3, similar results were obtained, with 
TTP co-IP with KH3-GFP being abolished by RNase A. Of note, the anti-TTP 
antibody identified as a single band in the input but two bands in the material pulled 
down with KH3-GFP. 
 
 
 
  
 152 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2 Detecting an association between KH3-GFP and eIF3η using Co-IP. 
Hela cells were transfected with KH3-GFP for 8 hours and then stimulated with 
sodium arsenite for 30 minutes. The cells were then lysed with Co-IP lysis buffer with 
or without RNaseA. The lysates were centrifuged to remove the cell debris and the 
supernatants were cultured with GFP antibody or isotype IgG control, followed by 
Dynabeads binding, bead washing, and protein elution. The elution samples were then 
analyzed using a NuPAGE® Novex® 4-12% Bis-Tris Gel and immunoblotting (IB). 
The result showed that eIF3η was pulled down in association with KH3-GFP, but that 
this was abolished by RNaseA treatment. This indicates that the connection between 
eIF3η and KH3-GFP is RNA dependent. The Co-IP experiments were repeated three 
times (n=3).  
      
 
 
 
 
 
 
                       
 
 
                       
 
IP: KH3-GFP 
Input       Anti-GFP      Rabbit IgG       Anti-GFP      Rabbit IgG 
eIF3η, 110kDa 
IB: eIF3η 
KH3-GFP 
IB: GFP 
Without RNaseA                   With RNaseA 
50kDa 
 
40kDa 
 153 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-3 Detecting an association between KH3-GFP and TTP using Co-IP. 
Hela cells were transfected with KH3-GFP for 8 hours and then stimulated with 
sodium arsenite for 30 minutes. The cells were then lysed with Co-IP lysis buffer with 
or without RNaseA. The lysates were centrifuged to remove the cell debris and the 
supernatants were cultured with GFP antibody or isotype IgG control, followed by 
Dynabeads binding, bead washing, and protein elution. The elution samples were then 
analyzed using a NuPAGE® Novex® 4-12% Bis-Tris Gel and immunoblotting (IB). 
The result showed that TTP was pulled down in association with KH3-GFP, but that 
this was abolished by RNaseA treatment. This indicates that the connection between 
TTP and KH3-GFP is RNA dependent. The Co-IP experiments were repeated three 
times (n=3).  
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5.4.   Summary and discussion 
This chapter provides two further pieces of evidence supporting the view that PARP-
14 localises in ribonucleoprotein complexes. First, the KH3-GFP fusion protein, 
which acts as a surrogate for full-length PARP-14, colocalised with granules that 
stained positively with a FISH probe against the poly-A tails of mRNAs. This was not 
seen in sections treated with RNase A, supporting the specificity of the FISH probe. 
This result therefore establishes the PARP-14 positive granules in unstimulated Hela 
cells and in Hela cells stimulated with arsenite or LPS as sites of ribonucleoprotein 
accumulation. Of note, in the Co-IP experiments, the lack of control (without arsenite 
stimulation) limits interpretation of the results.  
 
Secondly, KH3-GFP co-immunoprecipitated with two RNA-associated proteins, 
eIF3η and TTP.  In both instances the co-IP was abolished by RNase A, indicating 
that RNA is required for successful co-IP. This will be discussed further in Chapter 6.       
In the case of TTP, it is interesting that the anti-TTP antibody recognised two bands 
in the material pulled down with KH3-GFP. From a literature review, Sheflin and the 
co-workers demonstrated that multiple bands ranging from 37-55kDa were recognised 
after TTP pull-down from Jurkat cells and that these represented phosphorylated TTP 
isoforms (Sheflin et al., 2004). It is possible therefore that the two bands we identified 
represent two differentially phosphorylated TTP isoforms. It is well known that TTP 
phosphorylation via p38 mitogen-activated protein kinase (MAPK)-activated kinase 
MK2 reduces the ability of TTP to recruit deadenylases to target mRNAs and that this 
impairs TTP target mRNA degradation (Clement et al., 2011). As SGs are thought to 
contain mRNA that is translationally stalled but are not the places for RNA decay, it 
would not be surprising if TTP in the pull-down aggregates is in an inactive 
phosphorylated form. Further analytical work, for example using phospho-specific 
antibodies or mass spectrometry, is needed to establish this point. 
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Chapter 6    Discussion 
 
6.1.   Summary of the achievements of the study 
At the onset of the study, we knew from the work of Boothby et al., (Goenka et al., 
2007) that PARP-14 has a nuclear role as a coactivator of Stat-6-mediated DNA 
transcription. Our study has revealed a separate role for PARP-14 as a cytoplasmic 
protein interacting with ribonucleoproteins in SGs. Furthermore, the study has 
identified a previously unrecognised KH domain that may be involved in the 
localization of PARP-14 into cytoplasmic granules.  
6.1.1.   Results of the Y2H screen 
Although we have not yet shown that the KH3 domain in PARP-14 interacts directly 
with another protein(s), the demonstration that it is able to localise to cytoplasmic 
granules suggests that this is probably the case. It also remains possible that the M3 
and WWE domains may independently interact with other proteins. Given these 
considerations, the failure to obtain more hits using the Y2H screen in Chapter 3 is 
probably a false negative result. Whether or not the hits we did obtain are false 
positives remains unclear, as we made a strategic decision not to follow them up. 
Given that PARP-14 is an RNA-interacting protein (this thesis and unpublished data), 
the hits representing RNA 3’UTR rather than coding regions is particularly interesting 
and worthy of further work.     
 
According to the literature, Y2H screening may give false negative results due to 
incomplete screening of the many possible protein-protein interactions, biophysical, 
biochemical, and steric properties of the fusion proteins (bait and/or prey); incorrect 
processing or folding of mammalian proteins in yeast; as well the absence of 
important cofactors in yeast (Zhang et al., 2013; Braun et al., 2013). Of these, the 
following are particular considerations in our case: (i) incomplete screening, as 
previous work has shown that <30% of PPIs could be discovered by two large-scale 
independent Y2H screens with the same method and known PPIs could be found in 
both Y2H screens in only 12.5% (Ito et al., 2001). From this estimation, a single Y2H 
screen may not be enough to cover the complete proteome; (ii) our subsequent 
observation in Chapter 4 that the M3-KH3-WWE-GFP fusion protein localises to 
lysosomes in Hela cells to a greater extent than do KH3-GFP or full length PARP-14-
GFP suggests that the M3-KH3-WWE construct may not fold or be processed 
optimally. Although we demonstrated by western blotting that the bait was expressed 
in yeasts, it is possible that suboptimal folding might have reduced the chances of 
obtaining genuine hits; (iii) it is possible that any interactions between M3, KH3 or 
WWE domains with other proteins may require other cofactors, such as other proteins 
in the RNA-protein complex or RNA itself, to achieve sufficient affinity for detection 
in the screen. 
 
Given that M3-KH3-WWE-GFP and WWE-GFP colocalised with a lysosome marker, 
Lamp1, under cellular stress, we believe either bait misfolding or, possibly, specific 
interactions between the bait and lysosomal components are likely to explain the low 
number of hits in our experiment. In the case of misfolding, Kubota indicated that 
misfolded proteins are toxic to cells and, in the cytosol, the macroautophagy-
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lysosome serves as a quality control mechanism to monitor protein folding and to 
eliminate misfolded species (Kubota, 2009). Furthermore, Kubota also indicated that 
misfolded monomer could associate with each other to form soluble aggregates, 
which increases cellular stress. The stress can trigger the interaction between 
molecular chaperones such as HSP70/HSC70 and misfolded proteins, followed by 
ubiquitination and macroautophagy-lysosome degradation (Kubota, 2009). 
6.1.2.    Discovery of a KH domain between Macro-3 and WWE 
Our choice of bait in the Y2H screen was based on the minimal GFP-fusion protein 
(M3 to WWE) that we had found at that time to form granules in the cytoplasm of 
Hela cells (Figure 3-1). The failure of the Y2H screen to give more hits prompted us 
to take another look for previously unrecognised domains in PARP-14, using the 
PHYRE bioinformatics programme developed at Imperial College. This revealed 
three novel KH domains, with KH1 and KH2 at the N-terminus and KH3 situated in a 
critical region for this study between the M3 and WWE domains. Interestingly, none 
of these three KH domains have the GxxG motif that is thought to mediate binding of 
KH domains to RNA, and it therefore seems possible that these KH domains may be 
primarily involved in protein-protein interactions. It should be noted that PARP-14 
has an RRM domain at the N-terminus, and other work in the laboratory using a solid 
phase binding assay has demonstrated that this can bind directly to CXCL10 mRNA 
3’UTR, whereas KH3-GFP does not (Dr. Michael Johns, personal communication). 
The RRM domain may therefore be primarily responsible for PARP-14 binding RNA, 
with the KH domains enabling the formation of RNA-associated protein complexes. 
6.1.3.   The KH3 domain localises with RNA-associated proteins 
Using a KH3-GFP fusion protein, the study demonstrated that KH3 localises in 
cytoplasmic granules in Hela cells in the absence of cell stimulation. We further 
found that KH3 localised under oxidative stress induced by sodium arsenite with 
eIF3η, Ago2, TTP, and TIA, which are core SG components.  Moreover, following 
cell activation by LPS, KH3 was shown to localise with TTP, TIA, and EXOSC2, 
components of the exosome complex. The latter is reminiscent of the third KH 
domain of KSRP which recruits TTP to ARE-containing RNAs for exosome-
mediated RNA degradation (Linker et al., 2005; Houseley et al., 2006; Gherzi et al., 
2004).  Although this raises the question of whether the isolated PARP-14 KH3-GFP 
fusion protein is behaving non-specifically in the assay, the observation that PARP-14 
KH1-GFP and KH2-GFP failed to show the same granular distribution as KH3-GFP 
provides support that the same results cannot be obtained with any KH domain. 
6.1.4.   KH3 interacts with proteins in a RNA-dependent manner 
A FISH experiment described in Chapter 5 confirmed that the granules identified with 
KH3-GFP contain mRNA. Subsequently, Co-IP experiments were performed which 
established that the KH3 domain physically associates with eIF3η and TTP in sodium 
arsenite-treated Hela cells. Furthermore, in both cases the association is RNA 
dependent, as it was prevented by RNase A (Figure 5-2 and Figure 5-3). It is therefore 
likely that mRNA provides a bridge linking these two proteins with KH3-GFP. One 
possible explanation is KH3-GFP forms a ternary complex with TTP and/or eIF3η, 
and that the strength of the direct protein-protein interaction in the absence of mRNA 
is insufficient to allow successful Co-IP. Alternatively, there may be no direct contact 
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between KH3-TTP and KH3-eIF3η, with KH3-GFP binding to one or more of the 
many other proteins in the ribonucleoprotein complex. 
 
6.1.5.   KH3 mimics the cytoplasmic distribution of PARP-14   
Comparisons between the cytoplasmic distributions of KH3-GFP and full-length 
PARP-14 in Hela cells showed that with minor exceptions the two fusion proteins 
localised in a similar fashion. Furthermore, immunostaining of mouse macrophages 
showed that experiments with the two fusion proteins predicted the localization of 
endogenous PARP-14 in mouse macrophages. It is therefore reasonable to speculate 
that the KH3 domain is instrumental for PARP-14 localization into RNA-containing 
granules. This hypothesis is supported by the experiment shown in Figure 4-4 using 
the PARP-14 fragments with and without the KH3 domain, but for completeness this 
might be repeated with the full length PARP-14 with the KH3 domain deleted or be 
repeated with mutations that present its localisation. 
6.1.6.   Localisation of KH3-GFP and PARP-14-GFP in unstimulated 
cells 
Under resting conditions, KH3-GFP colocalised with TTP and EXOSC2. The 
behavior of KH3-GFP was different from that of endogenous PARP-14 or that of GFP 
tagged PARP-14. This could be caused by overexpressed KH3-GFP. It is possible that 
lipofectamine-based KH3-GFP transfection activates Hela cells through the high 
expression of KH3-GFP, resulting in KH3-GFP and TTP being recruited to ARE 
containing RNAs, followed by exosome-mediated RNA decay. On the other hand, 
low transfection efficiency of lipofectamine-based PARP-14-GFP may not be enough 
to activate Hela cells, so that full-length PARP-14-GFP granules did not colocalise 
with TTP and EXOSC2. 
 
We noticed that the eIF3η signal under resting conditions was weak and not fully 
granular. Stress granules, P-body, and autophagosome/autolysosome are protective 
mechanisms to help cells to survive under adverse environments such as oxidative 
stress, heat shock, hypoxia, and viral infection (Matsuki et al., 2013; Levine, 2007; 
Thomas et al., 2011). Therefore, without an adverse environment, the stress 
mechanisms are not initiated, resulting in the eIF3η signal being weak and not fully 
granular. This explanation for the weak non-granular staining pattern of eIF3η also 
can be applied to explain the undetectable/weak signals for Ago2, TTP, TIA, and 
Lamp1.  Of note, PB can be observed under non-stimulated cells in the late S and G2 
phases of the cell cycles (Chan and Fritzler, 2013). This may explain why the DCP1A 
signal was still detectable although GW182 and Ago2 were undetectable. 
6.1.7.   PARP-14 localises in SGs in sodium arsenite treated cells 
Under oxidative stress, colocalizations with eIF3η and Ago2 were seen with KH3-
GFP, full-length PARP-14-GFP, and endogenous PARP-14. These are all defining 
and core components of SG. Therefore, there is no doubt that under arsenite-induced 
oxidative stress, PARP-14 positive granules and KH3-GFP positive granules can be 
classified as SG.  Whilst the study was underway, a paper was published indicating 
that several PARP proteins including PARP-5a, PARP-12, PARP-13, PARP-15 and 
probably PARP-14 colocalised in SGs. Moreover, forced expression of these PARPs 
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resulted in the de novo nucleation of SGs (Leung et al., 2012).  Our work using KH3-
GFP and full length PARP-14-GFP are entirely consistent with the work of Leung et 
al., and provides support for PARP-14 and other PARP proteins being instrumental in 
integrating SG function.  It is possible that the KH3 domain associates with other KH 
domains to form a higher-order structure to act as a scaffold which could be a 
platform to associate RNA/protein complexes under oxidative stress (Nakel et al., 
2010). A more speculative possibility is that PARP-14 circularizes by direct protein-
protein interactions between KH3 and KH1 or KH2 domains. 
6.1.8.   PARP-14-GFP localises in exosomes in LPS-treated cells 
We used LPS as a stimulus to contrast with that of arsenite stress and to gain insight 
into the distribution of PARP-14-GFP following inflammatory activation.  It should 
be noted that there have been reports that Hela cells respond poorly to LPS (Wyllie et 
al., 2000; Hetherington et al., 1999). However Chang et al have found that IL-8 and 
TNF-α mRNAs were induced by LPS in Hela cells (Chang et al., 2006). In the present 
study, the response of Hela to LPS was clearly shown by the upregulated confocal 
staining of TTP, which is known to be regulated by LPS (Brooks et al., 2004). 
 
The distribution of the KH3 domain and full length PARP-14-GFP in LPS activated 
cells was different to that in unstimulated or sodium arsenite-treated cells, with 
colocalization with EXOSC2 and TTP. This shows that PARP-14-GFP is not SG 
specific, but instead may accompany mRNA in a more general way. It is already 
known that KSRP, which has four KH domains, is involved in recruiting TTP and 
ARE-containing RNAs to the exosome complex for mRNA decay (Linker et al., 2005; 
Houseley et al., 2006), and PARP-14-GFP may contribute to this process.  In support 
of this possibility, other work in the laboratory has shown that PARP-14 is required 
for TTP-mediated decay of Tissue Factor mRNA (Dr. M. Bilal Iqbal, personal 
communication). 
 
We also noticed that KH3-GFP localised with autophagy markers under LPS 
stimulation, whereas, under the same condition, full-length PARP-14-GFP did not 
colocalise with these markers. We speculate that highly forced expression of KH3-
GFP under LPS stimulation triggers Hela cell activation that drives autophagy process 
to eliminate the expression of KH3-GFP. The full-length PARP-14-GFP expression in 
Hela cells under the influence of LPS was low in comparison with the expression of 
KH3-GFP and possibly the expression of PARP-14-GFP itself probably was not 
enough to trigger autophagy process. 
6.2.   Limitations of the study 
6.2.1.   Confocal microscopy and image analysis 
The main limitation of confocal microscopy is that the image can only offer the 
information that two proteins are close to each other in space. However, without more 
biochemical evidence, it does not establish that two proteins that colocalise physically 
link with each other. Another issue that needs to be considered is how colocalization 
is judged. We used the naked eye to decide whether colocalization occurred. We 
believe this was a robust approach, as colocalization was only accepted if it was 
present in more than one cell and in more than one place in a single cell. A refinement 
would have been to adopt a pixel diagram function on our existing confocal 
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microscope or to use commercially available image analysis programs such as image 
J or Definiens Developer XD. However, in the interests of time and the large number 
of images involved, it was decided not to adopt computerized image analysis. 
6.2.2.   Low transfection efficiency of PARP-14-GFP                 
The transfection efficiency of full-length PARP-14-GFP was low, presumably 
because of the relatively large size of the cDNA construct. The low transfection 
efficiency increased the difficulty of confocal image analysis, as it was sometimes 
hard to find cells that met the requirement for judging colocalization. However the 
similarity in distribution of full-length PARP-14-GFP in Hela and endogenous PARP-
14 in macrophages suggests that this did not lead to erroneous conclusions.   
6.3.   Future investigations 
6.3.1.   Crystal structure of KH3 
So far the existence of the three KH domains in PARP-14 is based bioinformatic 
analysis of the PARP-14 amino acid sequence.  Ultimately, these domains should be 
crystallized to establish that they do actually form in the predicted way.  Once a 
crystal structure is available, it will be possible to identify residues most likely to 
interact with other proteins and also to verify the location of the tyrosine at position 
1457, which may be a site for post-translational modification and interactions with 
other proteins or possible RNA.      
6.3.2.   PARP-14 protein binding partners 
We used Co-IP to examine whether KH3-GFP physically associates with TTP and 
eIF3η. The Co-IP results indicated that the associations were RNA-dependent, 
suggesting that the associations between these proteins were indirect. Further 
investigation is needed to identify direct KH3 binding partners.  One possibility 
would be to repeat the Y2H screen using KH3 as the bait rather than the Macro-3 + 
WWE construct. If suboptimal protein folding of the previous bait was responsible for 
the failure of the initial screen, this may be rectified with a smaller and simpler bait. 
Another approach to identify PARP-14 binding partners would be adopting mass 
spectrometry. We have demonstrated that we could pull-down KH3-GFP complex 
with protein-RNA aggregates and we can therefore obtain a list of proteins that exist 
in complex with KH3-GFP including TTP and eIF3η with mass spectrometry. 
However this would not establish which proteins directly bind to KH3. DiMaggio and 
the coworkers proposed a mathematical algorithm (integer linear optimization also 
known as integer linear programming or ILP) for De Novo peptide identification via 
tandem mass spectrometry to address peptides that physically linked to the target 
protein (DiMaggio and Floudas, 2007). IPL and tandem mass spectrometry would be 
another way to address the issue of PARP-14 binding partners.       
 
6.3.3.   The function of PARP-14 in relation to RNA 
Now that we have established that PARP-14 localises with RNA in SG, it will be 
important to determine if and how PARP-14 regulates mRNA processing. Two 
separate projects are currently underway in the laboratory that have utilized PARP-14 
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knockout mice and which give insight into this. First, as mentioned above, PARP-14 
interacts with TTP and contributes to Tissue Factor mRNA decay (Dr. M. Bilal Iqbal, 
personal communication). Secondly, PARP-14 binds the mRNA for the chemokine 
CXCL10 and is involved in regulating its translation into protein (Dr. Michael Johns, 
personal communication). Considering that PARP-14 also functions as a coactivator 
of Stat-6-mediated gene transcription, it is therefore likely that PARP-14 has 
pleiotropic effects in regulating nucleic acid function. 
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